Effectiveness of miniscrew-supported maxillary molar distalization according to temporary anchorage device features and appliance design: systematic review and meta-analysis

Chiara Ceratti^a; Marco Serafin^b; Massimo Del Fabbro^c; Alberto Caprioglio^d

ABSTRACT

Objectives: To evaluate the effectiveness of distalizing maxillary first molars (U6) by temporary anchorage devices (TADs) according to their location (palatal, buccal, and zygomatic), their number, and appliance design.

Materials and Methods: An electronic search of maxillary molar distalization with TADs was done through April 2023. After study selection, data extraction, and risk-of-bias assessment, meta-analyses were performed for the extent of distalization, distal tipping, and vertical movement of U6 using the generic inverse variance and random-effects model. The significance level was set at 0.05.

Results: Forty studies met the inclusion criteria: 4 randomized controlled trials (RCTs), 13 prospective studies, and 23 retrospective studies (total of 1182 patients). Distalization of the U6 was not significantly greater (P = .64) by palatal (3.74 mm) and zygomatic (3.68 mm) than by buccal (3.23 mm) TADs. Distal tipping was significantly higher (P < .001) in nonrigid (9.84°) than in rigid (1.97°) appliances. Vertical movement was mostly intrusive and higher but not significantly different (P = .28) in zygomatic anchorage (-1.16 mm).

Conclusions: Distalization of U6 with TADs can be an effective and stable treatment procedure, especially when performed with rigid palatal appliances. However, further RCTs or prospective cohort studies are strongly recommended to provide more clinical evidence. (*Angle Orthod*. 2024;94:107–121.)

KEY WORDS: Class II malocclusion; Molar distalization; Orthodontic miniscrew; Systematic review

INTRODUCTION

Maxillary molar distalization is the most frequently performed treatment for correcting Class II malocclusion and achieving Class I molar and canine relationships without extractions.¹ However, finding appropriate anchorage to avoid side effects is fundamental. Anchorage is crucial for the successful treatment of Class II malocclusion,² as instability of anchor teeth can result in unfavorable occlusal relationships and an unsatisfactory outcome.³

Extraoral appliances (e.g., headgear) and intraoral options (e.g., Nance button) are commonly used to reinforce anchorage. However, extraoral traction poses compliance challenges, while intraoral methods often result in anchorage loss.⁴ To address this, intraoral distalization devices have been used and supported by skeletal anchorage. Dental implants have emerged as a stable solution for orthodontic purposes, benefiting from their osteointegration capabilities⁵; implants have demonstrated resilience against forces and remain stable following orthodontic loading over time.⁶

Although implants offer clear advantages in preserving anchorage, their invasive insertion and removal techniques hinder widespread adoption in daily practice. To address this limitation, temporary anchorage devices (TADs), including mini-implants,⁷ miniscrews,⁸ and onplants,⁹ have emerged as promising alternatives. Miniscrews especially utilize less-invasive methods

^a Private Practice, Milan, Italy.

^b PhD Student in Translational Medicine, Department of Biomedical Sciences for Health, University of Milan, Milan, Italy.

^c Professor, Coordinator of PhD in Clinical Research, Department of Biomedical, Surgical, and Dental Sciences, University of Milan, Milan, Italy.

^d Associate Professor, School of Orthodontics, Department of Biomedical, Surgical, and Dental Sciences, University of Milan, Milan, Italy.

Corresponding author: Dr Marco Serafin, Department of Biomedical Sciences for Health, Via Mangiagalli 31, Milan 20133, Italy

⁽e-mail: marco.serafin@unimi.it)

Accepted: August 2023. Submitted: May 2023.

Published online: October 24, 2023

 $[\]ensuremath{\textcircled{\sc 0}}$ 2024 by The EH Angle Education and Research Foundation, Inc.

 Table 1.
 Eligibility and Inclusion Criteria^a

Inclusion Criteria	Exclusion Criteria
P (population): patients with Class II malocclusion who received distalization treatment of the maxillary molars	Case reports or case series, editorials, personal opinions, and narrative reviews
I (intervention): distalization of U6 with TADs	No sample or an insufficient sample (fewer than 5 patients)
C (comparison): between pre- and posttreatment	Distalization without the use of TAD
O (outcomes): assessment of distalization (mm), distal tipping (°), and vertical displacement movements (mm)	Nonhuman subjects, non-English written
S (study design): RCTs and nonrandomized prospective or retrospective clinical studies that included at least pre- and posttreatment measurements	Non-Class II malocclusion

^a U6 indicates maxillary first molars; TAD, temporary anchorage device; RCT, randomized controlled trials.

than conventional implants and hold great potential for providing stable skeletal anchorage, particularly for posterior tooth distalization.¹⁰

TAD-supported appliances can be placed buccally in interdental spaces, palatally¹¹ in the retromolar region,¹² or even in the zygomatic area.¹³ The varied bone characteristics in these regions require smaller implants, particularly in length, while ensuring stability to withstand orthodontic forces. Factors such as ease of insertion, active treatment and removal, reliable wire fixation, and ease of handling are crucial for successful implant application in orthodontics.¹⁴

Recent reviews have examined the use of TAD-supported appliances for nonextraction treatment of Class II malocclusion and highlighted their advantages.^{15–18} All of the reviews agreed regarding the advantages provided by TADs, but to date, no systematic reviews have evaluated and compared the overall efficacy of molar distalization performed with different TAD-supported appliances categorized by the location of placement, rigidity of the appliance, and number of TADs used. It is interesting and important to evaluate which types of anchorage and appliance can be used more effectively and efficiently for different malocclusions. Clinically, this information may affect the choice of appliance, depending on specific side effects in terms of changes in molar tipping, vertical movement, or inclination of the occlusal plane. The studies included in this review were stratified based on the location of placement and rigidity of the device used. Therefore, it was possible to evaluate various dental effects and propose a new, different analysis from previous systematic reviews. Therefore, this systematic review and meta-analysis aimed to evaluate the treatment effects of TAD-supported maxillary molar distalization in Class II malocclusion, considering the amount of distalization, tipping, and vertical movement of the maxillary first molars (U6).

MATERIALS AND METHODS

Protocol and Registration

This review followed the PRISMA standards of quality for reporting systematic reviews and meta-analyses.¹⁹ The protocol was registered in PROSPERO (CRD420 22333115).

Inclusion Criteria and Search Strategy

An electronic search of PubMed and MEDLINE, Google Scholar, and the Cochrane Oral Health trial registry was conducted from January 2011 to April 2023. Studies with the following characteristics were selected: studies on human subjects, studies published in English, sample size mentioned (at least five patients); prospective and retrospective studies, and random clinical trials (RCTs) that included descriptions of the distalization appliance. Table 1 describes the inclusion and exclusion criteria.

The search strategy included the following terms: Maxillary_molar_distalization_AND_Class_II_AND_ skeletal anchorage AND miniscrew OR mini-implants AND_(y_10[Filter"]). (((("maxilla"[MeSH_Terms]_OR"_ "maxilla"[All_Fields]_OR_"maxillary"[All_Fields]_OR_ "maxillaries" [All Fields] OR "maxillaris" [All Fields]) AND_("molar"[MeSH_Terms]_OR_"molar"[All_Fields]_ OR_"molars"[All_Fields]_OR_"molars"[All_Fields])_ AND ("distal" [All Fields] OR "distalization" [All Fields]_OR_"distalize"[All_Fields]_OR_"distalized" [All Fields] OR "distalizer"[All Fields] OR "distalizers" [All_Fields]_OR_"distalizes"[All_Fields]_OR_"distalizing" [AllFields]_OR_"distally"[All_Fields]_OR_"distals" [All_Fields])_AND_(""class"[All_Fields]_OR_"classe" [All_Fields]_OR_"classed"[All_Fields]_OR_"classes" [All_Fields])_AND_"II"[All_Fields])_AND_(("skeletal"[All_ Fields]_OR_"skeletals"[All_Fields])_AND_("anchorage" [All_Fields]_OR_"anchorages"[All_Fields]))_AND_ ("miniscrew" [All_Fields]_OR_"miniscrews" [All_Fields]))_ OR_"mini-implants"[All Fields])_AND_((y_10[Filter])_ AND (humans[Filter])).

Manual searches were performed using reference lists in full-text articles deemed appropriate for inclusion in the study and other relevant systematic reviews. Two authors conducted the search for studies to be included independently, and differences were resolved by discussion and consensus with a third, trained researcher. Data were finally extracted according to the PICOS questions and categorized.

Assessment of Study Quality

The quality of the included studies was assessed independently by two independent researchers. The Joanna Briggs Institute (JBI) checklist was used for randomized trials (7 guestions) and nonrandomized cohort studies (11 questions).²⁰

Data Collection and Analysis

The study design, sample size, age, type of appliance, location of placement, number of miniscrews, and material used for measurements were obtained. The means and standard deviations (SDs) of distalization, distal tipping, and vertical movement of the U6 were calculated. All data were extracted into an Excel spreadsheet by one author and reviewed by another author to confirm accuracy. Studies whose mean was more than double the mean of the subgroups were excluded from the meta-analysis after testing them by analysis of variance.

Meta-analysis was performed using Review Manager software (RevMan version 5.4; The Cochrane Collaboration, 2020) with a generic inverse variance approach. The random-effects method was used because the studies included in the analysis had a high degree of heterogeneity and were quite diverse in terms of the entity of the forces applied. Heterogeneity was first assessed from a clinical perspective based on the position of the TADs, their number, and the rigidity of the distalization system. The significance level was set at 0.05. For meta-analysis, the standard error (SE) value of the SD of the individual results was also calculated.

RESULTS

Study Selection and Trial Flow

The database search identified 805 studies, and after the removal of duplicates, titles and abstracts were independently evaluated for inclusion. After the study selection, the percentage of agreement between reviewers reached a Cohen's kappa coefficient value of 0.93. A third author was consulted for resolution of the disagreements to obtain the final list of included studies. Ultimately, 40 studies met the inclusion criteria for qualitative and quantitative analyses (Figure 1).

Characteristics of the Studies

The studies included in this review were published between January 2011 and April 2023: 4 RCTs, 13 prospective studies, and 23 retrospective studies.

Distalization groups included 1182 patients. Studies were divided into palatal, $^{21-47}$ buccal, $^{10,28,32,48-52}$ and zygomatic $^{53-59}$ according to the position of TADs. For studies with palatal TADs, a distinction was made between rigid^{21-23,25,26,28,29,38,47} and

Records removed before screening Duplicate records removed Records identified from (n = 578) Records (n = 90) databases (n = 805) del Records <u>screened</u> (n = 137) Records excluded (n = 97) Screel dies included in review (n = 40)

Figure 1. PRISMA flow diagram of the study selection process.

nonrigid^{21,30,35} appliances and between 2-TADsupported^{21-23,25,26,28-30,35,38,47} and 3-TAD-supported^{24,27,31–34,36,37,39–46} appliances. The characteristics of the 40 studies included in the qualitative analysis are summarized in Table 2.

Risk of Bias

The JBI checklist was used. In the analysis of retrospective and prospective cohort studies, 10 studies were classified as "low" risk, 17 studies as "moderate," 7 studies as "serious," and 2 studies as "critical." The risk of bias (ROB) in the included RCTs was "serious" in two studies and "moderate" in the other two. Tables 3 and 4 show the summary of ROB for nonrandomized and RCT studies, respectively.

Quantitative Analysis

U6 distalization with palatal anchorage ranged from 1.65 mm³² to 5.4 mm,⁴⁴ with tipping values ranging from $0.1^{\circ ^{38,47}}$ to $11.24^{\circ .^{30}}$ Most studies reported U6 intrusion $(-0.04 \text{ mm}^{43} \text{ to } -2.6 \text{ mm}^{46})$, while some reported extrusion (0.2 mm²⁸ to 1.6 mm³⁹).

Using buccal TADs, U6 distalization ranged from 1.29 mm⁴⁸ to 5.05 mm,²⁸ with tipping ranging from $0.6^{\circ 51}$ to 7.2°.³² Vertical movement varied from intrusion of -1.4 mm⁴⁸ to extrusion of 1.3 mm.¹⁰

U6 distalization with zygomatic anchorage ranged from 2.93 mm⁵⁴ to 5.31 mm.⁵⁵ Distal tipping varied from 1.21°54 to 11.29°.59 Vertical movement ranged from -3.7 mm^{56} (intrusion) to 0.6 mm⁵⁸ (extrusion).

Devices with 2 TADs had a distalization range of 2.3 mm^{26} to 5.3 mm^{38} while the distalization range of devices with 3 TADs ranged from 1.65 mm³⁶ to 5.4 mm.⁴⁴ Distal tipping for devices with 2 TADs was $0.1^{\circ 38}$ to $11.24^{\circ 30}$, and for devices with 3 TADs, it was 0.28°41 to 5.09°.46 Vertical movement values for the 2-TAD-supported subgroup ranged from -1 mm^{22,28} (intrusion) to 0.7 mm²³ (extrusion), and the values for




Table 2. Qualitative and Quantitative Analyses of the 40 Included Studies^a

	Type of	Sample	Age, Y	ears	Measuring	
Study	Study	Size	Mean	SD	Material	Appliance Design
Nur et al., ⁵³ 2012	PS	15	15.87	1.09	Ceph	Zygoma gear
Sar et al., ²¹ 2013	PS	14	14.8	3.6	Ceph	MISDS
,		14	14.5	1.5		BAPA
Bechtold et al., ⁴⁸ 2013	RCT	12	23.58	6.92	Ceph	Miniscrew between 2P and 1M
		13	22.92	7.1	oopn	Miniscrews between 1P and 2P and between
		10	22.32	7.1		2P and 1M
Suzuki and Suzuki, ²² 2013	PS	20	23.2	4.7	Ceph	2 miniscrews in the midpalatal suture (iPanda)
El-Dawlatly et al., ⁵⁴ 2014	RCT	10	N/A	N/A	CBCT	IZC screw
23 2014	RCT	18	11.5	1.7	Ceph	Distal screw
ozzani et al., ²³ 2014 ariani et al., ¹⁰ 2014						MGBM system
ook et al., ²⁴ 2014	RS	30	13.3	2.3	Ceph	5
DOK et al., 2014	RS	20	22.9	N/A	CBCT	MPAP
aprioglio et al., ²⁵ 2015	RS	19	11.3	1.9	Ceph	Distal screw
iresmaeili et al., ²⁶ 2015	PS	26	19.8	6.3	3D cast CBCT	Palatal miniscrews between 2P and 1M
a'aed et al., ²⁷ 2015	RS	24	12.42	1.69	Ceph	MPAP
ozzani et al., ²⁸ 2016	RS	29	12.3	1.5	Ceph	MGBM system
,		24	11.3	1.2		Distal screw
uran et al., ²⁹ 2016	PS	21	13.6	N/A	3D cast	Miniscrew-supported hyrax screw
ilkis et al., ⁵⁵ 2016	PS					
		21	15.68	2.18	Ceph	Zygoma gear
li et al., ⁴⁹ 2016	RS	17	26.4	10.8	3D cast	Miniscrew between 2P and 1M
ambiano et al., ³⁰ 2017	PS	18	14	1.08	Ceph	BAPA
ark et al., ³¹ 2017	RS	22	24.7	7.77	Ceph	MCPP
e et al., ³² 2018	RS	22	21.9	6.6	Ceph	MCCP
		18	24.2	6.8		Interradicular miniscrew
/u et al., ⁵⁶ 2018 o et al., ³³ 2018 ark et al., ³⁴ 2018	RS	20	23	5	CBCT	IZC screw
a = 1, 2010	RS	20	22.4	6.3	Ceph	MCPP
$\frac{34}{2010}$						
ark et al., 2018	RS	17	21.5	3.99	CBCT	MCPP exo group
		16	22.9	3.99		MCPP nonexo group
rcalı and Yüksel, ³⁵ 2018	PS	20	14.05	2.4	Ceph	ВАРА
ee et al., ³⁶ 2019	RS	20	12.5	1.2	Ceph	MCPP
hoaib et al., ³⁷ 2019	RS	23	20.1	N/A	Ceph	MCPP
hahani et al., ⁵⁷ 2019	PS	6	>18	N/A	Ceph	IZC screw + passive self-ligating
		6	>18	N/A		IZC screw + clear aligner
assetta et al., ³⁸ 2019	RCT	10	13.1	N/A	3D cast	Distal screw
	HOT	10	15.1	IN/A	Ceph	Distal screw
bdelhady et al., ⁵⁰	PS	11	12.4	N/A	Ceph	Miniscrew between 2P and 1M
2020						
echtold et al., ⁵¹ 2020	RS	19	24.9	5.0	Ceph	Miniscrew between 2P and 1M
faifi et al., ³⁹ 2020	RS	21	11.7	1.3	Ceph	MCPP
hou et al., ⁴⁰ 2021	RS	20	12.9	1.0	CBCT	MCPP
ung et al.,41 2021	RS	20	12.1	1.1	Ceph	MCPP hyperdivergent
	10				Cepii	,, °
42 000 1	50	20	12.3	1.5		MCPP hypodivergent
ark et al., ⁴² 2021 ark et al., ⁴³ 2021	RS	284	N/A	N/A	3D cast	MCPP
ark et al.,43 2021	RS	15	13.2	1.32	CBCT	MCPP
		12	12.0	1.24		MCPP
naikh et al., ⁵⁸ 2021	PS	10	N/A	N/A	Ceph	IZC screw between 1M and 2M + interradicu- lar miniscrew
ong et al., ⁵² 2022	RS	39	24.5	5.38	Ceph Dental cast	Miniscrews between 2P and 1M or between 1M and 2M
lfawaz et al., ⁴⁴ 2022	RS	25	22.5	7.2	Ceph	MCPP
im at al 452022	RS	30	25.1	_	CBCT	MCPP
m et al., ⁴⁵ 2022 m et al., ⁴⁶ 2022						
	RS	24	19.0	7.9	Ceph 3D model	MCPP
ltieri et al.,47 2022	PS	22	13.2	1.7	Ceph 3D model	Distal screw
osa et al., ⁵⁹ 2023	DO.	05	10.0	15		17C aprove
osa et al., 2023	PS	25	13.6	1.5	Ceph	IZC screw
					3D model	

^a Data extracted for quantitative analysis included the means of T0-T1 changes and standard deviations, description of the TAD site, and type of device: palatal (subsets according to numbers [#] of TADs between rigid and nonrigid devices), buccal, and zygomatic. TAD indicates temporary anchorage device; SD, standard deviation; PS, prospective study; RS, retrospective study; RCT, randomized controlled trial; N/A, not applicable; P, palatal; B, buccal; Z, zygomatic; R, rigid device; NR, nonrigid device; MISDS, miniscrew implant-supported distalization system; BAPA, bone-anchored pendulum appliance; IZC, infrazygomatic crest; MGBM system, Maino-Giannelly-Bednar-Mura system; MPAP, modified palatal anchorage plate; MCPP, modified C-palatal plate; 1M, first molar; 2M, second molar; 1P, first premolar; 2P, second premolar; CBCT, Cone Beam Computed Tomography; and Ceph, cephalometry.

Table 2. Extended

# of Site Appliance TADs Uppe Mean SD Mean SD Z - - 4.36 2.15 3.3 2.31 P 2 R 2.81 2.7 1.65 7.29 B - - 1.29 0.66 3.19 4.61 - 2.91 0.96 1.55 1.32 P 2 R 4.5 1.5 1.8 4.0 Z - - 2.93 0.7 1.21 0.89 P 2 R 4.5 1.5 1.8 4.0 Z - - 2.93 0.7 1.21 0.89 P 2 R 4.5 1.5 1.8 4.0 Z - - 2.93 0.7 1.21 0.89 P 2 R 4.7 1.6 2.8 2.2 B - - 3.3 1.8	Mean 0.5 N/A	SD 0.46
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		0.46
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	N/A	
2 NR 2.93 1.74 9.0 6.74 B - - 1.29 0.66 3.19 4.61 - 2.91 0.96 1.55 1.32 P 2 R 4.5 1.5 1.8 4.0 Z - - 2.93 0.7 1.21 0.89 P 2 R 4.7 1.6 2.8 2.2 B - - 4.6 0.3 9.75 0.75 P 3 - 3.3 1.8 3.42 5.79 P 2 R 4.2 1.4 3.2 3.0 P 2 R 2.3 1.1 0.6 4.3 P 3 - 3.06 0.54 1.53 0.98 B - - 5.5 1.8 10.3 2.9 P 2 R 4.1 1.57 11.02 5.32		N/A
B - - 1.29 0.66 3.19 4.61 - - 2.91 0.96 1.55 1.32 P 2 R 4.5 1.5 1.8 4.0 Z - - 2.93 0.7 1.21 0.89 P 2 R 4.7 1.6 2.8 2.2 B - - 4.6 0.3 9.75 0.75 P 3 - 3.3 1.8 3.42 5.79 P 2 R 4.2 1.4 3.2 3.0 P 2 R 2.3 1.1 0.6 4.3 P 3 - 3.06 0.54 1.53 0.98 B - - 5.5 1.8 10.3 2.9 P 2 R 4.1 1.57 11.02 5.32 Z - - 2.04 1.41 <	N/A	N/A
- 2.91 0.96 1.55 1.32 P 2 R 4.5 1.5 1.8 4.0 Z - - 2.93 0.7 1.21 0.89 P 2 R 4.7 1.6 2.8 2.2 B - - 4.6 0.3 9.75 0.75 P 3 - 3.3 1.8 3.42 5.79 P 2 R 4.2 1.4 3.2 3.0 P 2 R 2.3 1.1 0.6 4.3 P 3 - 5.5 1.8 10.3 2.9 P 2 R 3.2 0.7 3.0 1.5 S - - 5.5 1.8 10.3 2.9 P 2 R 4.1 1.57 11.02 5.32 Z - - 5.31 2.46 6.39 5	-0.84	1.09
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	-1.4	0.99
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	-1.0	0.8
P 2 R 4.7 1.6 2.8 2.2 B - 4.6 0.3 9.75 0.75 P 3 - 3.3 1.8 3.42 5.79 P 2 R 4.2 1.4 3.2 3.0 P 2 R 4.2 1.4 3.2 3.0 P 2 R 2.3 1.1 0.6 4.3 P 3 - 3.06 0.54 1.53 0.98 B - - 5.5 1.8 10.3 2.9 P 2 R 3.2 0.7 3.0 1.5 P 2 R 3.2 0.7 3.0 1.5 P 2 R 4.1 1.57 11.02 5.32 Z - - 2.04 1.41 4.59 7.97 P 2 NR 3.45 1.54<		
B - - 4.6 0.3 9.75 0.75 P 3 - 3.3 1.8 3.42 5.79 P 2 R 4.2 1.4 3.2 3.0 P 2 R 2.3 1.1 0.6 4.3 P 2 R 2.3 1.1 0.6 4.3 P 3 - 3.06 0.54 1.53 0.98 B - - 5.5 1.8 10.3 2.9 P 2 R 3.2 0.7 3.0 1.5 P 2 R 3.2 0.7 3.0 1.5 P 2 R 4.1 1.57 11.02 5.32 Z - - 5.31 2.46 6.39 5.39 B - - 4.22 2.0 3.85 3.11 P 3 - 4.22 2.0<	-1.57	1.18
P 3 - 3.3 1.8 3.42 5.79 P 2 R 4.2 1.4 3.2 3.0 P 2 R 2.3 1.1 0.6 4.3 P 2 R 2.3 1.1 0.6 4.3 P 3 - 3.06 0.54 1.53 0.98 B - - 5.5 1.8 10.3 2.9 P 2 R 3.2 0.7 3.0 1.5 P 2 R 4.1 1.57 11.02 5.32 Z - - 5.31 2.46 6.39 5.39 B - - 2.04 1.41 4.59 7.97 P 2 NR 3.45 1.54 11.24 3.44 P 3 - 4.22 2.0 3.85 3.11 P 3 - 2.0 <	0.7	1.9
P 2 R 4.2 1.4 3.2 3.0 P 2 R 2.3 1.1 0.6 4.3 P 3 - 3.06 0.54 1.53 0.98 B - - 5.5 1.8 10.3 2.9 P 2 R 3.2 0.7 3.0 1.5 P 2 R 4.1 1.57 11.02 5.32 Z - - 5.31 2.46 6.39 5.39 B - - 2.04 1.41 4.59 7.97 P 2 NR 3.45 1.54 11.24 3.44 P 3 - 4.22 2.0 3.85 3.11 P 3 - 2.0 1.25 2.0 4.20 B - 2.0 1.26 7.2 5.22 Z - 2.0 1.26 7.2	1.3	0.9
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	-1.75	1.35
P 3 - 3.06 0.54 1.53 0.98 B - - 5.5 1.8 10.3 2.9 P 2 R 3.2 0.7 3.0 1.5 P 2 R 4.1 1.57 11.02 5.32 Z - - 5.31 2.46 6.39 5.39 B - - 2.04 1.41 4.59 7.97 P 2 NR 3.45 1.54 11.24 3.44 P 3 - 4.22 2.0 3.85 3.11 P 3 - 4.2 2.0 3.85 3.11 P 3 - 2.0 1.26 7.2 5.22 Z - - 3.1 1.0 N/A N/A P 3 - 3.97 0.67 2.93 1.90	0.3	0.8
B - - 5.5 1.8 10.3 2.9 P 2 R 3.2 0.7 3.0 1.5 P 2 R 4.1 1.57 11.02 5.32 Z - - 5.31 2.46 6.39 5.39 B - - 2.04 1.41 4.59 7.97 P 2 NR 3.45 1.54 11.24 3.44 P 3 - 4.22 2.0 3.85 3.11 P 3 - 4.2 2.0 4.20 4.20 B - 2.0 1.26 7.2 5.22 Z - - 3.1 1.0 N/A P 3 - 3.97 0.67 2.93 1.90	-0.53	0.56
P 2 R 3.2 0.7 3.0 1.5 P 2 R 4.1 1.57 11.02 5.32 Z - - 5.31 2.46 6.39 5.39 B - - 2.04 1.41 4.59 7.97 P 2 NR 3.45 1.54 11.24 3.44 P 3 - 4.22 2.0 3.85 3.11 P 3 - 4.2 2.0 3.85 3.11 P 3 - 2.0 1.26 7.2 5.22 Z - 3.1 1.0 N/A N/A P 3 - 3.97 0.67 2.93 1.90	-1.66	0.55
P 2 R 4.1 1.57 11.02 5.32 Z - 5.31 2.46 6.39 5.39 B - - 2.04 1.41 4.59 7.97 P 2 NR 3.45 1.54 11.24 3.44 P 3 - 4.22 2.0 3.85 3.11 P 3 - 4.2 1.25 2.0 4.20 B - 2.0 1.26 7.2 5.22 Z - 3.1 1.0 N/A N/A P 3 - 3.97 0.67 2.93 1.90	-1.0	0.3
Z - - 5.31 2.46 6.39 5.39 B - - 2.04 1.41 4.59 7.97 P 2 NR 3.45 1.54 11.24 3.44 P 3 - 4.22 2.0 3.85 3.11 P 3 - 2.0 1.25 2.0 4.20 B - 2.0 1.26 7.2 5.22 Z - 3.1 1.0 N/A N/A P 3 - 3.97 0.67 2.93 1.90	0.2	0.3
B - - 2.04 1.41 4.59 7.97 P 2 NR 3.45 1.54 11.24 3.44 P 3 - 4.22 2.0 3.85 3.11 P 3 - 4.22 1.25 2.0 4.20 B - 2.0 1.26 7.2 5.22 Z - - 3.1 1.0 N/A P 3 - 3.97 0.67 2.93 1.90	-0.59	0.5
B - - 2.04 1.41 4.59 7.97 P 2 NR 3.45 1.54 11.24 3.44 P 3 - 4.22 2.0 3.85 3.11 P 3 - 4.22 1.25 2.0 4.20 B - 2.0 1.26 7.2 5.22 Z - - 3.1 1.0 N/A P 3 - 3.97 0.67 2.93 1.90	-0.76	2.85
P 2 NR 3.45 1.54 11.24 3.44 P 3 - 4.22 2.0 3.85 3.11 P 3 - 4.22 1.25 2.0 4.20 B - 2.0 1.26 7.2 5.22 Z - - 3.11 1.0 N/A N/A P 3 - 3.97 0.67 2.93 1.90	-0.11	1.39
P 3 - 4.22 2.0 3.85 3.11 P 3 - 4.2 1.25 2.0 4.20 B - 2.0 1.26 7.2 5.22 Z - 3.1 1.0 N/A N/A P 3 - 3.97 0.67 2.93 1.90	-0.74	0.868
P 3 - 4.2 1.25 2.0 4.20 B - 2.0 1.26 7.2 5.22 Z - - 3.1 1.0 N/A N/A P 3 - 3.97 0.67 2.93 1.90	-2.53	1.40
B - 2.0 1.26 7.2 5.22 Z - - 3.1 1.0 N/A N/A P 3 - 3.97 0.67 2.93 1.90	-1.64	2.06
Z – – – 3.1 1.0 N/A N/A P 3 – 3.97 0.67 2.93 1.90		
P 3 – 3.97 0.67 2.93 1.90	-0.13	1.88
	-3.7	3.0
P 3 _ 3/1 125 368 / 07	-1.31	1.33
	-1.02	1.67
3.24 1.79 3.07 6.67	-1.41	2.07
P 2 NR 4.2 0.8 8.9 3.1	-0.6	1.0
P 3 – 1.65 3.74 0.93 8.26	-0.35	2.13
P 3 – 3.44 1.08 2.35 6.74	1.42	1.12
Z – – 3.80 1.16 7.41 1.5	-2.50	1.64
- 3.20 0.43 3.33 1.75	-0.93	0.16
P 2 R 5.3 2.1 0.1 12.4	-0.9	0.2
B – – 4.09 0.92 2.48 6.16	0.11	0.63
B – – <u>4.2</u> 2.0 0.6 3.8	-0.8	2.6
P 3 – 3.96 1.46 1.86 1.94	1.60	1.45
P 3 – 4.66 2.23 1.48 6.68	-0.25	3.48
P 3 – 2.69 1.76 0.28 3.24	-0.57	1.90
4.26 1.68 2.18 2.82	-0.15	1.76
P 3 – 3.35 0.42 N/A N/A	N/A	N/A
P 3 – 4.36 4.26 0.94 6.59	0.04	2.54
3.18 3.33 4.36 8.54	0.95	2.55
Z – – 4.0 4.5 N/A N/A	0.6	0.3
B – – 2.46 1.97 2.66 3.97	-0.92	1.16
P 3 – 5.4 1.1 3.3 1.4	-1.3	1.8
P 3 – 3.48 2.20 5.09 4.23	-2.53	2.39
P 3 – 4.4 2.6 0.8 1.0	-2.6	3.6
P 2 R 3.9 1.2 0.1 3.0	0.6	1.1
Z – – 4.0 1.04 11.3 5.31		

the 3-TAD-supported subgroup ranged from -2.6 mm^{46} (intrusion) to 1.6 mm³⁹ (extrusion).

Nonrigid devices had a slightly smaller distalization range (2.93 mm²¹ to 4.2 mm³⁵) than rigid devices (2.3 mm²⁶ to 5.3 mm³⁸). Distal tipping was greater in nonrigid devices ($8.9^{\circ 35}$ to $11.24^{\circ 30}$) than in rigid devices ($0.1^{\circ 38}$ to $11.02^{\circ 29}$). Vertical movement values were similar between nonrigid and rigid palatal devices, ranging

from -0.74 mm^{30} to -0.6 mm^{35} and from -1 mm^{22} to 0.7 mm²³, respectively.

Meta-analysis

Treatment comparison among buccal, palatal, and zygomatic TAD-supported appliances. Figure 2 compares devices with palatal, buccal, and zygomatic TADs in terms of distalization, tipping, and vertical

Table 3. ROB Table and Summary for the Nonrandomized Controlled Studies Included^a

Study	D1	D2	D3	D4	D5	D6	D7	D8	D9	D10	D11	Overall
Nur et al., ⁵³ 2012	+	+	+	+	+/-	+	+	+	+	+	+	+/-
Sar et al., ²¹ 2013	+	+	+	+	+	+	+	+	+	×	+	+
Suzuki and Suzuki, ²² 2013	+	+	+	+/-	+/-	+	+	+	+	×	+	+/-
Mariani et al., ¹⁰ 2014	+	+	+	+	+	+	+	+	+	×	+	+
Kook et al., ²⁴ 2014	+	+	+	+/-	+	+	+	+	+	×	×	+/-
Caprioglio et al., ²⁵ 2015	+	+	+	+	+	+	+	+	+	×	+	+
Miresmaeili et al., ²⁶ 2015	+	+	+	+/-	+/-	+	+	+	+	×	+	+/-
Sa'aed et al., ²⁷ 2015	+	+	+	+	+	+	+	+	+	×	+	+
Cozzani et al., ²⁸ 2016	+	+	+	+	+	+	+	+	+	×	+	+
Duran et al., ²⁹ 2016	+	+	+	+/-	+/-	+	+	+	+	×	+	+/-
Kilkis et al., ⁵⁵ 2016	+	+	+	+	+	+	+	+	+	+	+	+
Ali et al., ⁴⁹ 2016	+	+	+	+/-	+	+	+	+	+	×	×	+/-
Cambiano et al., ³⁰ 2017	+	+	+	+/-	+/-	+	+	+	+	+/-	+	_
Park et al., ³¹ 2017	+	+	+	+	+/-	+	+	+	+	×	×	+/-
Lee et al., ³² 2018	+	+	+	+	+/-	+	+	+	+	×	+	+/-
Wu et al., ⁵⁶ 2018	+	+	+	+/-	+	+	+	+	+	×	+	+/-
Jo et al., ³³ 2018	+	+	+	+	+	+	+	+	+	×	+	+
Park et al., ³⁴ 2018	+	+	+	+/-	+	+	+	+	+	×	+	+/-
Kırcalı and Yüksel, ³⁵ 2018	+	+	+	+/-	+/-	+	+	+	+	×	+	+/-
Lee et al., ³⁶ 2019	+	+	+	+	+	+	+	+	+	+	+	+
Shoaib et al., ³⁷ 2019	+/-	+/-	+	+/-	+	+	+	+	+	×	+	-
Shahani et al., ⁵⁷ 2019	+/-	+/-	+	?	+/-	+	+	+	+	×	×	?
Abdelhady et al., ⁵⁰ 2020	+	+	+	+/-	+/-	+	+	+	+	+/-	+	-
Bechtold et al., ⁵¹ 2020	+	+	+	+/-	+	+	+	+	+	×	+	+/-
Alfaifi et al., ³⁹ 2020	+	+	+	+	+/-	+	+	+	+	×	+	+/-
Chou et al.,40 2021	+/-	+/-	+	+/-	+	+	+	+	+	\times	+	-
Jung et al.,41 2021	+	+	+	+/-	+	+	+	+	+	×	×	+/-
Park et al., ⁴² 2021	+/-	+/-	+	+/-	+	+	+	+	+	×	+	-
Park et al.,43 2021	+	+	+	?	+	+	+	+	+	+	+/-	?
Shaikh et al., ⁵⁸ 2021	+/-	+/-	+	+/-	+	+	+	+	+	\times	×	-
Song et al., ⁵² 2022	+/-	+/-	+	+/-	+/-	+	+	+	+	×	+	-
Alfawaz et al.,44 2022	+	+	+	+	+/-	+	+	+	+	\times	+	+/-
Kim et al., ⁴⁵ 2022	+/-	+	+	+/-	+	+	+	+	+	×	+	+/-
Lim et al., ⁴⁶ 2022	+	+	+	+	+	+	+	+	+	×	+	+
Altieri et al., ⁴⁷ 2022	+	+	+	+/-	+/-	+	+	+	+	×	+	+/-
Rosa et al., ⁵⁹ 2023	+	+	+	+	+	+	+	+	+	\times	+	+

^a D1, were the two groups similar and recruited from the same population?; D2, were the exposures measured similarly to assign people to both exposed and unexposed groups?; D3, was the exposure measured in a valid and reliable way?; D4, were cofounding factors identified?; D5, were strategies to deal with confounding factors started?; D6, were the groups/participants free of the outcome at the start of the study?; D7, were the outcomes measured in a valid and reliable way?; D8, was the follow-up time reported and sufficient to be long enough for outcomes to occur?; D9, was the follow-up complete, and if not, were the reasons for loss to follow-up described and explored?; D10, were the strategies to address incomplete follow-up utilized?; D11, was the appropriate statistical analysis used?. ROB indicates risk of bias; +, low ROB; +/-, moderate ROB; -, serious ROB;?, critical ROB; and ×, no information.

movements. High heterogeneity ($I^2 = 95\%$) and no significant differences in the amount of distalization (P = .64) were found among palatal (3.74 mm; 95% confidence interval [CI], [3.51, 3.98]; P < .0001;

 $I^2 = 87\%$), zygomatic (3.68 mm; 95% CI, [3.21, 4.14]; P < .0001; $I^2 = 95\%$), and buccal (3.23 mm; 95% CI, [2.16, 4.30]; P < .0001; $I^2 = 98\%$) anchorage locations.

Study	D1	D2	D3	D4	D5	D6	D7	Overall
Bechtold et al.,48 2013	+	+	+/-	+/-	+	+/-	+/-	+/-
Cozzani et al., ²³ 2014	+	_	+/-	+/-	+	+	+/-	_
El-Dawlatly et al., ⁵⁴ 2014	+	+	+/-	+/-	+	+	+/-	+/-
Cassetta et al., ³⁸ 2019	+	+	+/-	_	+	+	+/-	_

^a D1, was true randomization used for assignment of participants to a treatment group? (selection bias); D2, was allocation to treatment groups concealed? (selection bias); D3, were participants blind to treatment assignment? (performance bias); D4, were outcomes measured in a reliable way? (detection bias); D5, was the follow-up complete, and if not, were differences between groups in terms of their follow-up adequately described and analyzed? (attrition bias); D6, was appropriate statistical analysis used? (reporting bias); D7, was the trial design appropriate, and were any deviations from the standard RCT design accounted for in the conduct and analysis of the trial? (statistical conclusion validity). ROB indicates risk of bias; –, low ROB; +/–, moderate ROB; and –, serious ROB.

			т0	T1		Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI Y	ear IV, Random, 95% Cl
Palatal							
Sar et al. 2013b		0.47	14	14	1.9%	2.93 [2.01, 3.85] 2	
Sar et al. 2013a	2.81	0.7	14	14	1.5%	2.81 [1.44, 4.18] 2	
Suzuki et al. 2013	4.5	0.33	20	20	2.2%	4.50 [3.85, 5.15] 2	
Cozzani et al. 2014	4.7	0.38	18	18	2.1%	4.70 [3.96, 5.44] 2	014
Kook et al 2014	3.3	0.4	20	20	2.1%	3.30 [2.52, 4.08] 2	014
Caprioglio et al. 2015	4.2	0.32	19	19	2.2%	4.20 [3.57, 4.83] 2	015
Miresmaelli et al. 2015	2.3	0.22	26	26	2.4%	2.30 [1.87, 2.73] 2	015 -
Sa'aed et al 2015	3.06	0.11	24	24	2.6%	3.06 [2.84, 3.28] 2	015 -
Cozzani et al. 2016b	3.2	0.14	24	24	2.5%	3.20 [2.93, 3.47] 2	016 -
Duran et al. 2016	4.1	0.34	21	21	2.2%	4.10 [3.43, 4.77] 2	016
Cambiano et al. 2017	3.45	0.36	18	18	2.2%	3.45 [2.74, 4.16] 2	017
Park et al 2017	4.22	0.43	22	22	2.0%	4.22 [3.38, 5.06] 2	017
Park et al 2018a	3.41	0.3	17	17	2.3%	3.41 [2.82, 4.00] 2	018
Park et al 2018b	3.24	0.45	16	16	2.0%	3.24 [2.36, 4.12] 2	018
Kircali et al. 2018	4.2	0.18	20	20	2.5%	4.20 [3.85, 4.55] 2	018 -
Jo et al 2018	3.97	0.15	20	20	2.5%	3.97 [3.68, 4.26] 2	
Lee et al 2018a	4.2	0.27	22	22	2.3%	4.20 [3.67, 4.73] 2	and a second s
Shoaib et al 2019		0.22	23	23	2.4%	3.44 [3.01, 3.87] 2	
Cassetta et al. 2019		0.66	10	10	1.5%	5.30 [4.01, 6.59] 2	
Lee et al 2019		0.84	20	20	1.2%	1.65 [0.00, 3.30] 2	
Alfaifi et al 2020		0.32	21	21	2.2%	3.96 [3.33, 4.59] 2	
Jung et al 2021a		0.39	20	20	2.1%	2.69 [1.93, 3.45] 2	
Jung et al 2021b		0.37	20	20	2.1%	4.26 [3.53, 4.99] 2	
Park et al 2021a		0.03	284	284	2.6%	3.35 [3.29, 3.41] 2	
Park et al 2021b	4.36	1.1	15	15	0.9%	4.36 [2.20, 6.52] 2	
Park et al 2021c		0.96	12	12	1.1%	3.18 [1.30, 5.06] 2	
Chou et al 2021	4.66	0.5	20	20	1.9%	4.66 [3.68, 5.64] 2	
Alfawaz et al 2022		0.22	25	25	2.4%		
Altieri et al. 2022		0.22	23	23	2.4%	5.40 [4.97, 5.83] 2	
Kim et al. 2022	3.48	0.20	30	30	2.3%	3.90 [3.39, 4.41] 2 3.48 [2.70, 4.26] 2	
			24	24	1.2%		
Lim et al. 2022 Subtotal (95% CI)	4.4	0.89	881	881	63.5%	4.40 [2.66, 6.14] 2 3.74 [3.51, 3.98]	J22
Test for overall effect: Z Buccal	= 31.40 (P < 0.0000	1)					
Bechtold et al 2013a	1 29	0.19	12	12	2.5%	1.29 [0.92, 1.66] 2	n13 -
Bechtold et al 2013b		0.26	13	13	2.3%	2.91 [2.40, 3.42] 2	
Mariani et al. 2014		0.05	30	30	2.6%	4.60 [4.50, 4.70] 2	
Ali et al 2016		0.34	17	17	2.2%	2.04 [1.37, 2.71] 2	
Cozzani et al 2016a		0.34	29	29	2.2%	5.50 [4.85, 6.15] 2	
Lee et al 2018b		0.29	18	18	2.3%	the second second second second second	
Abdelhady et al 2020		0.29	10	10	2.3%	2.00 [1.43, 2.57] 2 4.09 [3.54, 4.64] 2	
Bechtold et al 2020		0.20	19	19	1.9%	 Total Barrara Mannard Billion 	
Song et al 2020		0.46	39	39	2.3%	4.20 [3.30, 5.10] 2 2.46 [1.85, 3.07] 2	
Song et al 2022 Subtotal (95% CI)	2.40	0.31	188	188	2.3%	3.23 [2.16, 4.30]	
oubtotul (bo / ol)		f = 8 (I				0.20 [2.10, 4.00]	•
Heterogeneity: Tau ² = 2 Test for overall effect: Z							
Test for overall effect: Z							
Test for overall effect: Z Zygomatic	= 5.91 (P < 0.00001)	16	15	1 90/	A 36 [3 29 5 44] 2	n12
Test for overall effect: Z Zygomatic Nur et al 2012	= 5.91 (P < 0.00001 4.36) 0.55	15 10	15 10	1.8%	4.36 [3.28, 5.44] 2	
Test for overall effect: Z Zygomatic Nur et al 2012 El-Dawlaty et al 2014	= 5.91 (P < 0.00001 4.36 2.93) 0.55 0.22	10	10	2.4%	2.93 [2.50, 3.36] 2	014 -
Test for overall effect: Z Zygomatic Nur et al 2012 El-Dawlaty et al 2014 Kilkis et al 2016	= 5.91 (P < 0.00001 4.36 2.93 5.31) 0.55 0.22 0.53	10 21	10 21	2.4% 1.8%	2.93 [2.50, 3.36] 2 5.31 [4.27, 6.35] 2	014
Test for overall effect: Z Zygomatic Nur et al 2012 EI-Dawlaty et al 2014 Kilkis et al 2016 Wu et al 2018	= 5.91 (P < 0.00001 4.36 2.93 5.31 3.1) 0.55 0.22 0.53 0.22	10 21 20	10 21 20	2.4% 1.8% 2.4%	2.93 [2.50, 3.36] 2 5.31 [4.27, 6.35] 2 3.10 [2.67, 3.53] 2	014
Test for overall effect: Z Zygomatic Nur et al 2012 El-Dawlaty et al 2014 Kilkis et al 2016 Wu et al 2018 Shahani et al 2019a	= 5.91 (P < 0.00001 4.36 2.93 5.31 3.1 3.8) 0.55 0.22 0.53 0.22 0.47	10 21 20 6	10 21 20 6	2.4% 1.8% 2.4% 1.9%	2.93 [2.50, 3.36] 2 5.31 [4.27, 6.35] 2 3.10 [2.67, 3.53] 2 3.80 [2.88, 4.72] 2	014
Test for overall effect: Z Zygomatic Nur et al 2012 El-Dawlaty et al 2014 Kilkis et al 2016 Wu et al 2018 Shahani et al 2019a Shahani et al. 2019b	= 5.91 (P < 0.00001 4.36 2.93 5.31 3.1 3.8 3.2) 0.55 0.22 0.53 0.22 0.47 0.17	10 21 20 6 6	10 21 20 6 6	2.4% 1.8% 2.4% 1.9% 2.5%	2.93 [2.50, 3.36] 2 5.31 [4.27, 6.35] 2 3.10 [2.67, 3.53] 2 3.80 [2.88, 4.72] 2 3.20 [2.87, 3.53] 2	014
Test for overall effect: Z Zygomatic Nur et al 2012 El-Dawlaty et al 2014 Kilkis et al 2016 Wu et al 2018 Shahani et al 2019a Shahani et al. 2019b Shahikh et al 2021	= 5.91 (P < 0.00001 4.36 2.93 5.31 3.1 3.8 3.2 4) 0.55 0.22 0.53 0.22 0.47 0.17 1.42	10 21 20 6 6 10	10 21 20 6 6 10	2.4% 1.8% 2.4% 1.9% 2.5% 0.6%	2.93 [2.50, 3.36] 2 5.31 [4.27, 6.35] 2 3.10 [2.67, 3.53] 2 3.80 [2.88, 4.72] 2 3.20 [2.87, 3.53] 2 4.00 [1.22, 6.78] 2	014
Test for overall effect: Z Zygomatic Nur et al 2012 El-Dawlaty et al 2014 Kilkis et al 2016 Wu et al 2018 Shahani et al 2019a Shahani et al 2019b Shahikh et al 2021 Rosa et al. 2023	= 5.91 (P < 0.00001 4.36 2.93 5.31 3.1 3.8 3.2 4) 0.55 0.22 0.53 0.22 0.47 0.17	10 21 20 6 10 25	10 21 20 6 10 25	2.4% 1.8% 2.4% 1.9% 2.5% 0.6% 2.4%	2.93 [2.50, 3.36] 2 5.31 [4.27, 6.35] 2 3.10 [2.67, 3.53] 2 3.80 [2.88, 4.72] 2 3.20 [2.87, 3.53] 2 4.00 [1.22, 6.78] 2 4.00 [3.59, 4.41] 2	014
Test for overall effect: Z Zygomatic Nur et al 2012 El-Dawlaty et al 2014 Kilkis et al 2016 Wu et al 2018 Shahani et al 2019a Shahani et al. 2019b Shahikh et al 2021 Rosa et al. 2023 Subtotal (95% CI) Heterogeneity: Tau ² = 0	= 5.91 (P < 0.00001 4.36 2.93 5.31 3.1 3.8 3.2 4 4 30; Chi ² = 32.83, df) 0.55 0.22 0.53 0.22 0.47 0.17 1.42 0.21 = 7 (P	10 21 20 6 10 25 113	10 21 20 6 10 25 113	2.4% 1.8% 2.4% 1.9% 2.5% 0.6% 2.4% 15.9%	2.93 [2.50, 3.36] 2 5.31 [4.27, 6.35] 2 3.10 [2.67, 3.53] 2 3.80 [2.88, 4.72] 2 3.20 [2.87, 3.53] 2 4.00 [1.22, 6.78] 2	014
Test for overall effect: Z Zygomatic Nur et al 2012 El-Dawlaty et al 2014 Kilkis et al 2016 Wu et al 2018 Shahani et al 2019a Shahani et al 2019a Shahakh et al 2021 Rosa et al. 2023 Subtotal (95% CI) Heterogeneity: Tau ² = 0 Test for overall effect: Z	= 5.91 (P < 0.00001 4.36 2.93 5.31 3.1 3.8 3.2 4 4 30; Chi ² = 32.83, df) 0.55 0.22 0.53 0.22 0.47 0.17 1.42 0.21 = 7 (P	10 21 20 6 6 10 25 113 < 0.000	10 21 20 6 6 10 25 113 01); I ² =	2.4% 1.8% 2.4% 1.9% 2.5% 0.6% 2.4% 15.9% 79%	2.93 [2.50, 3.36] 2 5.31 [4.27, 6.35] 2 3.10 [2.67, 3.53] 2 3.80 [2.88, 4.72] 2 3.20 [2.87, 3.53] 2 4.00 [1.22, 6.78] 2 4.00 [3.59, 4.41] 2 3.68 [3.21, 4.14]	014
Test for overall effect: Z Zygomatic Nur et al 2012 El-Dawlaty et al 2014 Kilkis et al 2016 Wu et al 2018 Shahani et al 2019a Shahani et al 2019a Shahakh et al 2021 Rosa et al. 2023 Subtotal (95% CI) Heterogeneity: Tau ² = 0 Test for overall effect: Z Total (95% CI)	= 5.91 (P < 0.00001 4.36 2.93 5.31 3.1 3.8 3.2 4 30; Chi ² = 32.83, df = 15.40 (P < 0.0000) 0.55 0.22 0.53 0.22 0.47 0.17 1.42 0.21 = 7 (P 1)	10 21 20 6 10 25 113 < 0.000	10 21 20 6 10 25 113 01); l ² =	2.4% 1.8% 2.4% 1.9% 2.5% 0.6% 2.4% 15.9% 79%	2.93 [2.50, 3.36] 2 5.31 [4.27, 6.35] 2 3.10 [2.67, 3.53] 2 3.80 [2.88, 4.72] 2 3.20 [2.87, 3.53] 2 4.00 [1.22, 6.78] 2 4.00 [3.59, 4.41] 2	014
Test for overall effect: Z Zygomatic Nur et al 2012 El-Dawlaty et al 2014 Kilkis et al 2016 Wu et al 2018 Shahani et al 2019a Shahani et al 2019a Shahakh et al 2021 Rosa et al. 2023 Subtotal (95% CI) Heterogeneity: Tau ² = 0 Test for overall effect: Z	= 5.91 (P < 0.00001 4.36 2.93 5.31 3.1 3.8 3.2 4 30; Chi ² = 32.83, df = 15.40 (P < 0.0000) 0.55 0.22 0.53 0.22 0.47 0.17 1.42 0.21 = 7 (P 1)	10 21 20 6 10 25 113 < 0.000	10 21 20 6 10 25 113 01); l ² =	2.4% 1.8% 2.4% 1.9% 2.5% 0.6% 2.4% 15.9% 79%	2.93 [2.50, 3.36] 2 5.31 [4.27, 6.35] 2 3.10 [2.67, 3.53] 2 3.80 [2.88, 4.72] 2 3.20 [2.87, 3.53] 2 4.00 [1.22, 6.78] 2 4.00 [3.59, 4.41] 2 3.68 [3.21, 4.14]	014

Figure 2. Forest plot of U6 distalization (a), tipping (b), and vertical movement (c) of the palatal, buccal, and zygomatic subgroups.


b

Study or Subgroup			то	T1		Mean Difference	Mean Difference
	Mean Difference	SE			Weight	IV, Random, 95% CI Yea	
Palatal							
Sar et al. 2013a	1.65	1.94	14	14	1.3%	1.65 [-2.15, 5.45] 201	3
Suzuki et al. 2013		0.89	20	20	2.7%	1.80 [0.06, 3.54] 201	
Sar et al. 2013b	9	1.8	14	14	1.4%	9.00 [5.47, 12.53] 201	
Cozzani et al. 2014		0.52	18	18	3.4%	2.80 [1.78, 3.82] 201	
Kook et al 2014		1.29	20	20	2.0%	3.42 [0.89, 5.95] 201	
Caprioglio et al. 2015		0.69	19	19	3.1%	3.20 [1.85, 4.55] 201	
Miresmaelli et al. 2015		0.84	26	26	2.8%	0.60 [-1.05, 2.25] 201	
Sa'aed et al 2015	1.53	0.2	24	24	3.8%	1.53 [1.14, 1.92] 201	
Cozzani et al. 2016b	3	0.2	24	24	3.7%	3.00 [2.41, 3.59] 201	
Park et al 2017		0.66	22	24	3.1%	ne norto Des turos has tantes (C. sonore	
			20	20		3.85 [2.56, 5.14] 201	
Jo et al 2018		0.42			3.5%	2.93 [2.11, 3.75] 201	
Lee et al 2018a		0.89	22	22	2.7%	2.00 [0.26, 3.74] 201	
Park et al 2018a	3.68	1.2	17	17	2.2%	3.68 [1.33, 6.03] 201	
Park et al 2018b		1.69	16	16	1.5%	3.07 [-0.24, 6.38] 201	
Cassetta et al. 2019		3.92	10	10	0.4%	0.10 [-7.58, 7.78] 201	
Lee et al 2019		1.84	20	20	1.4%	0.93 [-2.68, 4.54] 201	
Shoaib et al 2019	2.35	1.4	23	23	1.9%	2.35 [-0.39, 5.09] 201	
Alfaifi et al 2020		0.42	21	21	3.5%	1.86 [1.04, 2.68] 202	
Chou et al 2021		1.49	20	20	1.8%	1.48 [-1.44, 4.40] 202	and the second sec
Jung et al 2021a		0.72	20	20	3.0%	0.28 [-1.13, 1.69] 202	
Jung et al 2021b		0.63	20	20	3.2%	2.18 [0.95, 3.41] 202	
Park et al 2021b	0.94	1.7	15	15	1.5%	0.94 [-2.39, 4.27] 202	
Park et al 2021c		2.46	12	12	0.9%	4.36 [-0.46, 9.18] 202	
Lim et al. 2022	0.8	0.2	24	24	3.8%	0.80 [0.41, 1.19] 202	
Alfawaz et al 2022		0.28	25	25	3.7%	3.30 [2.75, 3.85] 202	
Altieri et al. 2022	0.1	0.64	22	22	3.2%	0.10 [-1.15, 1.35] 202	
Kim et al. 2022	5.09	0.77	30	30	2.9%	5.09 [3.58, 6.60] 202	2
Subtotal (95% CI)			538	538	68.3%	2.37 [1.82, 2.92]	•
Heterogeneity: Tau ² = 1.2 Test for overall effect: Z =			(P < 0.0)0001);	12 = 82%		
Buccal							
Bechtold et al 2013a	2 10	1 22	12	12	2 0%	3 10 [0 59 5 90] 204	3
		1.33	12	12	2.0%	3.19 [0.58, 5.80] 201	and the second sec
Bechtold et al 2013b	1.55	0.36	13	13	3.6%	1.55 [0.84, 2.26] 201	3 -
Bechtold et al 2013b Ali et al 2016	1.55 4.59	0.36 1.93	13 17	13 17	3.6% 1.3%	1.55 [0.84, 2.26] 201 4.59 [0.81, 8.37] 201	3 -
Bechtold et al 2013b Ali et al 2016 Lee et al 2018b	1.55 4.59 7.2	0.36 1.93 1.23	13 17 18	13 17 18	3.6% 1.3% 2.1%	1.55[0.84, 2.26]2014.59[0.81, 8.37]2017.20[4.79, 9.61]201	3 - 6 <u>-</u>
Bechtold et al 2013b Ali et al 2016 Lee et al 2018b Abdelhady et al 2020	1.55 4.59 7.2 2.48	0.36 1.93 1.23 1.86	13 17 18 11	13 17 18 11	3.6% 1.3% 2.1% 1.3%	1.55 [0.84, 2.26] 201 4.59 [0.81, 8.37] 201 7.20 [4.79, 9.61] 201 2.48 [-1.17, 6.13] 202	
Bechtold et al 2013b Ali et al 2016 Lee et al 2018b Abdelhady et al 2020 Bechtold et al 2020	1.55 4.59 7.2 2.48 0.6	0.36 1.93 1.23 1.86 0.87	13 17 18 11 19	13 17 18 11 19	3.6% 1.3% 2.1% 1.3% 2.7%	1.55 [0.84, 2.26] 201 4.59 [0.81, 8.37] 201 7.20 [4.79, 9.61] 201 2.48 [-1.17, 6.13] 202 0.60 [-1.11, 2.31] 202	
Bechtold et al 2013b Ali et al 2016 Lee et al 2018b Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022	1.55 4.59 7.2 2.48 0.6	0.36 1.93 1.23 1.86	13 17 18 11 19 39	13 17 18 11 19 39	3.6% 1.3% 2.1% 1.3% 2.7% 3.2%	1.55 [0.84, 2.26] 201 4.59 [0.81, 8.37] 201 7.20 [4.79, 9.61] 201 2.48 [-1.17, 6.13] 202 0.60 [-1.11, 2.31] 202 2.66 [1.43, 3.89] 202	
Bechtold et al 2013b Ali et al 2016 Lee et al 2018b Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau ² = 2.4	1.55 4.59 7.2 2.48 0.6 2.66	0.36 1.93 1.23 1.86 0.87 0.63	13 17 18 11 19 39 129	13 17 18 11 19 39 129	3.6% 1.3% 2.1% 1.3% 2.7% 3.2% 16.3%	1.55 [0.84, 2.26] 201 4.59 [0.81, 8.37] 201 7.20 [4.79, 9.61] 201 2.48 [-1.17, 6.13] 202 0.60 [-1.11, 2.31] 202	
Bechtold et al 2013b Ali et al 2016 Lee et al 2018b Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau ² = 2.4	1.55 4.59 7.2 2.48 0.6 2.66	0.36 1.93 1.23 1.86 0.87 0.63	13 17 18 11 19 39 129	13 17 18 11 19 39 129	3.6% 1.3% 2.1% 1.3% 2.7% 3.2% 16.3%	1.55 [0.84, 2.26] 201 4.59 [0.81, 8.37] 201 7.20 [4.79, 9.61] 201 2.48 [-1.17, 6.13] 202 0.60 [-1.11, 2.31] 202 2.66 [1.43, 3.89] 202	
Bechtold et al 2013b Ali et al 2016 Lee et al 2018b Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau ² = 2.4	1.55 4.59 7.2 2.48 0.6 2.66	0.36 1.93 1.23 1.86 0.87 0.63	13 17 18 11 19 39 129	13 17 18 11 19 39 129	3.6% 1.3% 2.1% 1.3% 2.7% 3.2% 16.3%	1.55 [0.84, 2.26] 201 4.59 [0.81, 8.37] 201 7.20 [4.79, 9.61] 201 2.48 [-1.17, 6.13] 202 0.60 [-1.11, 2.31] 202 2.66 [1.43, 3.89] 202	
Bechtold et al 2013b Ali et al 2016 Lee et al 2018b Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau ² = 2.4 Test for overall effect: Z = Zygomatic	1.55 4.59 7.2 2.48 0.6 2.66 10; Chi ² = 25.67, df • 4.02 (P < 0.0001)	0.36 1.93 1.23 1.86 0.87 0.63	13 17 18 11 19 39 129	13 17 18 11 19 39 129	3.6% 1.3% 2.1% 1.3% 2.7% 3.2% 16.3%	1.55 [0.84, 2.26] 201 4.59 [0.81, 8.37] 201 7.20 [4.79, 9.61] 201 2.48 [-1.17, 6.13] 202 0.60 [-1.11, 2.31] 202 2.66 [1.43, 3.89] 202	
Bechtold et al 2013b Ali et al 2016 Lee et al 2018b Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau ² = 2.4 Test for overall effect: Z = Zygomatic Nur et al 2012	1.55 4.59 7.2 2.48 0.6 2.66 10; Chi ² = 25.67, df 4.02 (P < 0.0001) 3.3	0.36 1.93 1.23 1.86 0.87 0.63 = 6 (P	13 17 18 11 19 39 129 = 0.000	13 17 18 11 19 39 129 03); I ² =	3.6% 1.3% 2.1% 1.3% 2.7% 3.2% 16.3% 77%	1.55 [0.84, 2.26] 201 4.59 [0.81, 8.37] 201 7.20 [4.79, 9.61] 201 2.48 [-1.17, 6.13] 202 0.60 [-1.11, 2.31] 202 2.66 [1.43, 3.89] 202 2.91 [1.49, 4.33]	
Bechtold et al 2013b Ali et al 2016 Lee et al 2018b Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% Cl) Heterogeneity: Tau ² = 2.4 Test for overall effect: Z = Zygomatic Nur et al 2012 El-Dawlaty et al 2014	1.55 4.59 7.2 2.48 0.6 2.66 40; Chi ² = 25.67, df 4.02 (P < 0.0001) 3.3 1.21	0.36 1.93 1.23 1.86 0.87 0.63 = 6 (P	13 17 18 11 19 39 129 = 0.000	13 17 18 11 19 39 129)3); I ² =	3.6% 1.3% 2.1% 1.3% 2.7% 3.2% 16.3% 77%	1.55 [0.84, 2.26] 201 4.59 [0.81, 8.37] 201 7.20 [4.79, 9.61] 201 2.48 [-1.17, 6.13] 202 0.60 [-1.11, 2.31] 202 2.66 [1.43, 3.89] 202 2.91 [1.49, 4.33] 3.30 [2.14, 4.46] 201	$\begin{array}{c} 3 \\ 6 \\ 8 \\ 0 \\ 2 \\ 2 \\ 4 \end{array} \qquad \qquad$
Bechtold et al 2013b Ali et al 2016 Lee et al 2018b Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau ² = 2.4 Test for overall effect: Z = Zygomatic Nur et al 2012 El-Dawlaty et al 2014 Kilkis et al 2016	1.55 4.59 7.2 2.48 0.6 2.66 0; Chi ² = 25.67, df 4.02 (P < 0.0001) 3.3 1.21 6.39	0.36 1.93 1.23 1.86 0.87 0.63 = 6 (P 0.59 0.28	13 17 18 11 19 39 129 = 0.000	13 17 18 11 19 39 129 03); I ² = 15 10	3.6% 1.3% 2.1% 1.3% 2.7% 3.2% 16.3% 77% 3.3% 3.7%	1.55 [0.84, 2.26] 201 4.59 [0.81, 8.37] 201 7.20 [4.79, 9.61] 201 2.48 [-1.17, 6.13] 202 0.60 [-1.11, 2.31] 202 2.66 [1.43, 3.89] 202 2.91 [1.49, 4.33] 300 3.30 [2.14, 4.46] 201 1.21 [0.66, 1.76] 201	$\begin{array}{c} 3 \\ 6 \\ 8 \\ 0 \\ 0 \\ 2 \\ 2 \\ 4 \\ 6 \end{array} \qquad \begin{array}{c} - \\ - \\ - \\ - \\ - \\ - \\ - \\ - \\ - \\ - $
Bechtold et al 2013b Ali et al 2016 Lee et al 2018b Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau ² = 2.4 Test for overall effect: Z = Zygomatic Nur et al 2012 El-Dawlaty et al 2014 Kilkis et al 2016	1.55 4.59 7.2 2.48 0.6 2.66 40; Chi ² = 25.67, df 4.02 (P < 0.0001) 3.3 1.21 6.39 7.41	0.36 1.93 1.23 1.86 0.87 0.63 = 6 (P 0.59 0.28 1.17	13 17 18 11 19 39 129 = 0.000 15 10 21	13 17 18 11 19 39 129 03); l ² = 15 10 21	3.6% 1.3% 2.1% 1.3% 2.7% 3.2% 16.3% 77% 3.3% 3.7% 2.2%	1.55 [0.84, 2.26] 201 4.59 [0.81, 8.37] 201 7.20 [4.79, 9.61] 201 2.48 [-1.17, 6.13] 202 0.60 [-1.11, 2.31] 202 2.66 [1.43, 3.89] 202 2.91 [1.49, 4.33] 3.30 [2.14, 4.46] 201 1.21 [0.66, 1.76] 201 6.39 [4.10, 8.68] 201 7.41 [6.21, 8.61] 201	$\begin{array}{c} 3 \\ 6 \\ 8 \\ 0 \\ 0 \\ 2 \\ 2 \\ 4 \\ 6 \\ 9 \end{array}$
Bechtold et al 2013b Ali et al 2016 Lee et al 2018b Abdelhady et al 2020 Bechtold et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau ² = 2.4 Test for overall effect: Z = Zygomatic Nur et al 2012 El-Dawlaty et al 2014 Kilkis et al 2016 Shahani et al 2019a	1.55 4.59 7.2 2.48 0.6 2.66 40; Chi ² = 25.67, df 4.02 (P < 0.0001) 3.3 1.21 6.39 7.41	0.36 1.93 1.23 1.86 0.87 0.63 = 6 (P 0.59 0.28 1.17 0.61	13 17 18 11 19 39 129 = 0.000 15 10 21 6	13 17 18 11 19 39 129 03); l ² = 15 10 21 6	3.6% 1.3% 2.1% 1.3% 2.7% 3.2% 16.3% 77% 3.3% 3.7% 2.2% 3.2%	1.55 [0.84, 2.26] 201 4.59 [0.81, 8.37] 201 7.20 [4.79, 9.61] 201 2.48 [-1.17, 6.13] 202 0.60 [-1.11, 2.31] 202 2.66 [1.43, 3.89] 202 2.91 [1.49, 4.33] 3.30 [2.14, 4.46] 201 1.21 [0.66, 1.76] 201 6.39 [4.10, 8.68] 201	$\begin{array}{c} 3 \\ 6 \\ 8 \\ 0 \\ 0 \\ 2 \\ 2 \\ 4 \\ 6 \\ 9 \end{array}$
Bechtold et al 2013b Ali et al 2016 Lee et al 2018b Abdelhady et al 2020 Song et al 2022 Subtotal (95% CI) Heterogeneity: Tau ² = 2.4 Test for overall effect: Z = Zygomatic Nur et al 2012 El-Dawlaty et al 2014 Kilkis et al 2016 Shahani et al 2019b Subtotal (95% CI) Heterogeneity: Tau ² = 7.7	1.55 4.59 7.2 2.48 0.6 2.66 0; Chi ² = 25.67, df 4.02 (P < 0.0001) 3.3 1.21 6.39 7.41 3.33 75; Chi ² = 99.68, df	0.36 1.93 1.23 1.86 0.87 0.63 = 6 (P 0.59 0.28 1.17 0.61 0.71 = 4 (P	13 17 18 11 19 39 129 = 0.000 15 10 21 6 6 58	13 17 18 11 19 39 129 03); I ² = 15 10 21 6 58	3.6% 1.3% 2.1% 1.3% 2.7% 3.7% 77% 3.3% 3.3% 3.7% 2.2% 3.2% 3.0% 15.4%	1.55 [0.84, 2.26] 201 4.59 [0.81, 8.37] 201 7.20 [4.79, 9.61] 201 2.48 [-1.17, 6.13] 202 2.66 [1.43, 3.89] 202 2.91 [1.49, 4.33] 3.30 [2.14, 4.46] 201 1.21 [0.66, 1.76] 201 6.39 [4.10, 8.68] 201 7.41 [6.21, 8.61] 201 3.33 [1.94, 4.72] 201	$\begin{array}{c} 3 \\ 6 \\ 8 \\ 0 \\ 0 \\ 2 \\ 2 \\ 4 \\ 6 \\ 9 \end{array}$
Bechtold et al 2013b Ali et al 2016 Lee et al 2018b Abdelhady et al 2020 Bechtold et al 2020 Subtotal (95% CI) Heterogeneity: Tau ² = 2.4 Test for overall effect: Z = Zygomatic Nur et al 2012 El-Dawlaty et al 2014 Kilkis et al 2016 Shahani et al 2019a Shahani et al. 2019b Subtotal (95% CI) Heterogeneity: Tau ² = 7.7 Test for overall effect: Z =	1.55 4.59 7.2 2.48 0.6 2.66 0; Chi ² = 25.67, df 4.02 (P < 0.0001) 3.3 1.21 6.39 7.41 3.33 75; Chi ² = 99.68, df	0.36 1.93 1.23 1.86 0.87 0.63 = 6 (P 0.59 0.28 1.17 0.61 0.71 = 4 (P	13 17 18 11 19 39 129 = 0.000 15 10 21 6 58 < 0.000	13 17 18 11 19 39 129 03); I ² = 15 10 21 6 58 001); I ²	3.6% 1.3% 2.1% 1.3% 2.7% 16.3% 77% 3.3% 3.7% 2.2% 3.0% 15.4% = 96%	1.55 [0.84, 2.26] 201 4.59 [0.81, 8.37] 201 7.20 [4.79, 9.61] 201 2.48 [-1.17, 6.13] 202 0.60 [-1.11, 2.31] 202 2.66 [1.43, 3.89] 202 2.91 [1.49, 4.33] 201 3.30 [2.14, 4.46] 201 1.21 [0.66, 1.76] 201 6.39 [4.10, 8.68] 201 7.41 [6.21, 8.61] 201 3.33 [1.94, 4.72] 201 4.26 [1.74, 6.78] 201	$\begin{array}{c} 3 \\ 6 \\ 8 \\ 0 \\ 0 \\ 2 \\ 2 \\ 4 \\ 6 \\ 9 \end{array}$
Nur et al 2012 El-Dawlaty et al 2014 Kilkis et al 2016 Shahani et al 2019a Shahani et al. 2019b Subtotal (95% Cl) Heterogeneity: Tau ² = 7.7 Test for overall effect: Z = Total (95% Cl)	1.55 4.59 7.2 2.48 0.6 2.66 40; Chi ² = 25.67, df 4.02 (P < 0.0001) 3.3 1.21 6.39 7.41 3.33 75; Chi ² = 99.68, df 3.31 (P = 0.0009)	0.36 1.93 1.23 1.86 0.87 0.63 = 6 (P 0.59 0.28 1.17 0.61 0.71 = 4 (P	13 17 18 11 19 399 129 = 0.000 21 6 58 < 0.000 725	13 17 18 11 19 39 129 03); I ² = 15 10 21 6 6 58 001); I ²	3.6% 1.3% 2.1% 1.3% 2.7% 16.3% 77% 3.3% 3.7% 2.2% 3.0% 15.4% = 96%	1.55 [0.84, 2.26] 201 4.59 [0.81, 8.37] 201 7.20 [4.79, 9.61] 201 2.48 [-1.17, 6.13] 202 2.66 [1.43, 3.89] 202 2.91 [1.49, 4.33] 3.30 [2.14, 4.46] 201 1.21 [0.66, 1.76] 201 6.39 [4.10, 8.68] 201 7.41 [6.21, 8.61] 201 3.33 [1.94, 4.72] 201	$\begin{array}{c} 3 \\ 6 \\ 8 \\ 0 \\ 0 \\ 2 \\ 2 \\ 4 \\ 6 \\ 9 \end{array}$
Bechtold et al 2013b Ali et al 2016 Lee et al 2018b Abdelhady et al 2020 Bechtold et al 2020 Subtotal (95% CI) Heterogeneity: Tau ² = 2.4 Test for overall effect: Z = Zygomatic Nur et al 2012 El-Dawlaty et al 2014 Kilkis et al 2016 Shahani et al 2019a Shahani et al. 2019b Subtotal (95% CI) Heterogeneity: Tau ² = 7.7 Test for overall effect: Z =	1.55 4.59 7.2 2.48 0.6 2.66 40; Chi ² = 25.67, df 4.02 (P < 0.0001) 3.3 1.21 6.39 7.41 3.33 '5; Chi ² = 99.68, df : 3.31 (P = 0.0009) 35; Chi ² = 280.08, d	0.36 1.93 1.23 1.86 0.87 0.63 = 6 (P 0.59 0.28 1.17 0.61 0.71 = 4 (P	13 17 18 11 19 399 129 = 0.000 21 6 58 < 0.000 725	13 17 18 11 19 39 129 03); I ² = 15 10 21 6 6 58 001); I ²	3.6% 1.3% 2.1% 1.3% 2.7% 16.3% 77% 3.3% 3.7% 2.2% 3.0% 15.4% = 96%	1.55 [0.84, 2.26] 201 4.59 [0.81, 8.37] 201 7.20 [4.79, 9.61] 201 2.48 [-1.17, 6.13] 202 0.60 [-1.11, 2.31] 202 2.66 [1.43, 3.89] 202 2.91 [1.49, 4.33] 201 3.30 [2.14, 4.46] 201 1.21 [0.66, 1.76] 201 6.39 [4.10, 8.68] 201 7.41 [6.21, 8.61] 201 3.33 [1.94, 4.72] 201 4.26 [1.74, 6.78] 201	$\begin{array}{c} 3 \\ 6 \\ 8 \\ 0 \\ 0 \\ 2 \\ 2 \\ 4 \\ 6 \\ 9 \end{array}$

Figure 2. (Continued)

Distal tipping was higher, although not significantly (P = .30), in the zygomatic group than in the others (4.26 mm; 95% CI, [1.74, 6.78]; P < .0001; $I^2 = 96\%$) despite four studies being excluded because they had mean values strikingly outside the mean of the single subgroup.^{10,28,29,59} Intrusion was also higher (-1.16 mm; 95% CI, [-1.84, -0.48]; P < .0001; $I^2 = 97\%$) but not significantly (P = .28) different for zygomatic TADs than the other two groups. Treatment comparison between 2-TAD-supported and 3-TAD-supported appliances. Figure 3 shows the comparison between 2-TAD-supported and 3-TAD-supported appliances in terms of distalization, tipping, and vertical movement. The comparison showed high heterogeneity between subgroups ($I^2 = 87\%$) and no significant differences (P = .86) between the 2-TAD (3.78 mm; 95% Cl, [3.31, 4.24]; P < .0001; $I^2 = 87\%$) and 3-TAD (3.73 mm; 95% Cl, [3.43, 4.03]; P < .0001; $I^2 = 88\%$) subgroups.

С



There was heterogeneity ($I^2 = 82\%$) but no significant differences (P = .99) between the 2-TAD (2.37°; 95%) Cl, [1.26, 3.49]; P < .0001; $I^2 = 88\%$) and 3-TAD $(2.38^{\circ}; 95\% \text{ Cl}, [1.72, 3.04]; P < .0001; l^2 = 83\%)$ subgroups in terms of distal tipping, even though one study was dropped from the analysis due to a value outside the mean of the subgroup.³⁵ There was also heterogeneity within subgroups for vertical movement Downloaded from https://prime-pdf-watermark.prime-prod.pubfactory.com/ at 2025-05-14 via free access

а			TO	74		Maan Difference	Maan Difference
Study or Subgroup 2 TADs	Mean Difference	SE	T0 Total	T1 Total	Weight	Mean Difference IV, Random, 95% CI Year	Mean Difference IV, Random, 95% Cl
Sar et al. 2013b	2.93	0.47	14	14	2.8%	2.93 [2.01, 3.85] 2013	
Sar et al. 2013a	2.93	0.47	14	14	1.8%	2.81 [1.44, 4.18] 2013	
Suzuki et al. 2013		0.33	20	20	3.5%	4.50 [3.85, 5.15] 2013	-
Cozzani et al. 2014	4.7	0.38	18	18	3.2%	4.70 [3.96, 5.44] 2014	
Caprioglio et al. 2015		0.32	19	19	3.6%	4.20 [3.57, 4.83] 2015	-
Miresmaelli et al. 2015		0.22	26	26	4.1%	2.30 [1.87, 2.73] 2015	- - - -
Cozzani et al. 2016b		0.14	24	24	4.5%	3.20 [2.93, 3.47] 2016	-
Duran et al. 2016		0.34	21	21	3.5%	4.10 [3.43, 4.77] 2016	-
Cambiano et al. 2017	3.45		18	18	3.4%	3.45 [2.74, 4.16] 2017	
Kircali et al. 2018	4.2	0.18	20	20	4.3%	4.20 [3.85, 4.55] 2018	-
Cassetta et al. 2019	5.3	0.66	10	10	1.9%	5.30 [4.01, 6.59] 2019	
Altieri et al. 2022	3.9	0.26	22	22	3.9%	3.90 [3.39, 4.41] 2022	
Subtotal (95% CI)			226	226	40.6%	3.78 [3.31, 4.24]	•
Heterogeneity: Tau ² = 0. Test for overall effect: Z			P < 0.00	0001); I	² = 87%		
3 TADs							
Kook et al 2014	3.3	0.4	20	20	3.1%	3.30 [2.52, 4.08] 2014	
Sa'aed et al 2015	3.06	0.11	24	24	4.6%	3.06 [2.84, 3.28] 2015	-
Park et al 2017	4.22	0.43	22	22	3.0%	4.22 [3.38, 5.06] 2017	
Park et al 2018a	3.41	0.3	17	17	3.7%	3.41 [2.82, 4.00] 2018	
Park et al 2018b	3.24	0.45	16	16	2.9%	3.24 [2.36, 4.12] 2018	
Jo et al 2018	3.97	0.15	20	20	4.5%	3.97 [3.68, 4.26] 2018	-
Lee et al 2018a		0.27	22	22	3.9%	4.20 [3.67, 4.73] 2018	-
Lee et al 2019	1.65		20	20	1.4%	1.65 [0.00, 3.30] 2019	
Shoaib et al 2019	3.44		23	23	4.1%	3.44 [3.01, 3.87] 2019	
Alfaifi et al 2020	3.96		21	21	3.6%	3.96 [3.33, 4.59] 2020	
Jung et al 2021a		0.39	20	20	3.2%	2.69 [1.93, 3.45] 2021	
Jung et al 2021b	4.26	0.37	20	20	3.3%	4.26 [3.53, 4.99] 2021	
Park et al 2021a Park et al 2021b	3.35	0.03	284	284	4.8%	3.35 [3.29, 3.41] 2021	· · · · · · · · · · · · · · · · · · ·
	4.36	1.1	15 12	15	0.9%	4.36 [2.20, 6.52] 2021	
Park et al 2021c	3.18			12	1.2%	3.18 [1.30, 5.06] 2021	
Chou et al 2021	4.66 3.48	0.5 0.4	20 30	20 30	2.6%	4.66 [3.68, 5.64] 2021	
Kim et al. 2022 Lim et al. 2022		0.89	24	24	3.1% 1.3%	3.48 [2.70, 4.26] 2022	
Alfawaz et al 2022		0.89	24	24	4.1%	4.40 [2.66, 6.14] 2022 5.40 [4.97, 5.83] 2022	-
Subtotal (95% CI)	5.4	0.22	655	655	4.1%	5.40 [4.97, 5.83] 2022 3.73 [3.43, 4.03]	•
Heterogeneity: Tau ² = 0.	20: Chi2 = 146 57 d	f - 19				0.10 [0.40, 4.00]	
Test for overall effect: Z			(F = 0.0	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	1 - 00 %		
Total (95% CI)			881		100.0%	3.74 [3.51, 3.98]	•
Heterogeneity: Tau ² = 0.	29; Chi ² = 239.22, d	f = 30	(P < 0.0	00001);	l ² = 87%		-4 -2 0 2 4
Test for overall effect: Z	= 31.40 (P < 0.0000	1)					
		.,					mesialization distalization
Test for subgroup differe			P = 0.86	5). I² = (0%		mesialization distalization
			P = 0.86	6), l² = (0%		mesialization distalization
Test for subaroup differe)%	Mean Difference	
		f = 1 (F	то	т1)% Weight	Mean Difference IV, Random, 95% Cl Year	mesialization distalization Mean Difference IV, Random, 95% Cl
b	nces: Chi ² = 0.03, d	f = 1 (F	то	т1			Mean Difference
b Study or Subgroup	nces: Chi ² = 0.03, d Mean Difference	f = 1 (F	то	т1			Mean Difference
D Study or Subgroup 2 TADs	nces: Chi ² = 0.03, d Mean Difference	f = 1 (F SE	T0 Total	T1 Total	Weight	IV, Random, 95% CI Year	Mean Difference
b <u>Study or Subgroup</u> <u>2 TADs</u> Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013b	nces: Chi ² = 0.03, d <u>Mean Difference</u> 1.65 1.8 9	f = 1 (F SE 1.94 0.89 1.8	T0 Total 14 20 14	T1 Total 14 20 14	Weight 1.6% 3.9% 1.8%	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.54] 2013 9.00 [5.47, 12.53] 2013	Mean Difference
b <u>Study or Subgroup</u> 2 TADs Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013b Cozzani et al. 2014	nces: Chi ² = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8	f = 1 (F SE 1.94 0.89 1.8 0.52	T0 Total 14 20 14 18	T1 Total 14 20 14 18	Weight 1.6% 3.9% 1.8% 5.2%	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.54] 2013 9.00 [5.47, 12.53] 2013 2.80 [1.78, 3.82] 2014	Mean Difference
b <u>Study or Subgroup</u> 2 TADs Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013b Cozzani et al. 2014 Caprioglio et al. 2015	nces: Chi ² = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2	f = 1 (F SE 1.94 0.89 1.8 0.52 0.69	T0 Total 14 20 14 18 19	T1 Total 14 20 14 18 19	Weight 1.6% 3.9% 1.8% 5.2% 4.6%	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.54] 2013 9.00 [5.47, 12.53] 2013 2.80 [1.78, 3.82] 2014 3.20 [1.85, 4.55] 2015	Mean Difference
b <u>Study or Subgroup</u> 2 TADs Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013 Cozzani et al. 2014 Caprioglio et al. 2015	nces: Chi ² = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6	f = 1 (F SE 1.94 0.89 1.8 0.52 0.69 0.84	T0 Total 14 20 14 18 19 26	T1 Total 14 20 14 18 19 26	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.0%	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.54] 2013 9.00 [5.47, 12.53] 2013 2.80 [1.78, 3.82] 2014 3.20 [1.85, 4.55] 2015 0.60 [-1.05, 2.25] 2015	Mean Difference
b <u>Study or Subgroup</u> <u>2 TADs</u> Sar et al. 2013a Suzuki et al. 2013 Cozzani et al. 2014 Caprioglio et al. 2015 Miresmaelli et al. 2015	nces: Chi ² = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3	f = 1 (F SE 1.94 0.89 1.8 0.52 0.69 0.84 0.3	T0 Total 14 20 14 18 19 26 24	T1 Total 14 20 14 18 19 26 24	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.6% 4.0% 5.8%	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.64] 2013 9.00 [5.47, 12.53] 2013 2.80 [1.78, 3.82] 2014 3.20 [1.85, 4.55] 2015 0.60 [-1.05, 2.25] 2015 3.00 [2.41, 3.59] 2016	Mean Difference
b <u>Study or Subgroup</u> <u>2 TADs</u> Sar et al. 2013 Sar et al. 2013 Sar et al. 2013 Cozzani et al. 2014 Capriogilo et al. 2015 Miresmaelli et al. 2015 Cozzani et al. 2016 Cozsenti et al. 2016	nces: Chi² = 0.03. d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1	f = 1 (F SE 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92	T0 Total 14 20 14 18 19 26 24 10	T1 Total 14 20 14 18 19 26 24 10	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.0% 5.8% 0.5%	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.54] 2013 9.00 [5.47, 12.53] 2013 2.80 [1.76, 3.82] 2014 3.20 [1.85, 4.55] 2015 0.60 [-1.05, 2.25] 2015 3.00 [2.41, 3.59] 2016 0.10 [-7.58, 7.78] 2019	Mean Difference
b <u>Study or Subgroup</u> <u>2 TADs</u> Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013b Cozzani et al. 2014 Caprioglio et al. 2015 Miresmealli et al. 2015 Cozzani et al. 2016 Casseita et al. 2019 Atlieri et al. 2022	nces: Chi² = 0.03. d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1	f = 1 (F SE 1.94 0.89 1.8 0.52 0.69 0.84 0.3	T0 Total 14 20 14 18 19 26 24 10 22	T1 Total 14 20 14 18 19 26 24 10 22	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.6% 5.8% 0.5% 4.7%	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.54] 2013 9.00 [5.47, 12.53] 2013 2.80 [1.78, 3.82] 2014 3.20 [1.85, 4.55] 2015 0.60 [-1.05, 2.25] 2015 3.00 [2.41, 3.59] 2016 0.10 [-7.58, 7.78] 2019 0.10 [-1.15, 1.35] 2022	Mean Difference
b <u>Study or Subgroup</u> <u>2 TADs</u> Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2014 Cozzani et al. 2014 Caprioglio et al. 2015 Miresmaelli et al. 2015 Cozzani et al. 2016 Cozsetta et al. 2019 Altieri et al. 2022 Subtotal (95% CI)	nces: Chi ² = 0.03. d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1	SE 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92 0.64	T0 Total 14 20 14 18 19 26 24 10 22 167	T1 Total 14 20 14 18 19 26 24 10 22 167	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.6% 5.8% 0.5% 4.7% 32.0%	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.54] 2013 9.00 [5.47, 12.53] 2013 2.80 [1.76, 3.82] 2014 3.20 [1.85, 4.55] 2015 0.60 [-1.05, 2.25] 2015 3.00 [2.41, 3.59] 2016 0.10 [-7.58, 7.78] 2019	Mean Difference
b <u>Study or Subgroup</u> 2 TADs Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013 Cozzani et al. 2014 Capriogilo et al. 2015 Miresmaelli et al. 2015 Cozzani et al. 2016 Cassette et al. 2019 Altieri et al. 2022 Subtotal (95% Cl) Heterogeneity: Tau ² = 1.	nces: Chi ² = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi ² = 37.54, df	SE 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92 0.64	T0 Total 14 20 14 18 19 26 24 10 22 167	T1 Total 14 20 14 18 19 26 24 10 22 167	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.6% 5.8% 0.5% 4.7% 32.0%	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.54] 2013 9.00 [5.47, 12.53] 2013 2.80 [1.78, 3.82] 2014 3.20 [1.85, 4.55] 2015 0.60 [-1.05, 2.25] 2015 3.00 [2.41, 3.59] 2016 0.10 [-7.58, 7.78] 2019 0.10 [-1.15, 1.35] 2022	Mean Difference
b study or Subgroup 2 TADs Sar et al. 2013a Sar et al. 2013a Sar et al. 2013b Cozzani et al. 2014 Caprioglio et al. 2015 Miresmaelli et al. 2015 Cozzani et al. 2016 Cozsani et al. 2019 Attieri et al. 2020 Subtotal (55% Cl) Heterogeneity: Tau ² = 1. Test for overall effect: Z	nces: Chi ² = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi ² = 37.54, df	SE 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92 0.64	T0 Total 14 20 14 18 19 26 24 10 22 167	T1 Total 14 20 14 18 19 26 24 10 22 167	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.6% 5.8% 0.5% 4.7% 32.0%	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.54] 2013 9.00 [5.47, 12.53] 2013 2.80 [1.78, 3.82] 2014 3.20 [1.85, 4.55] 2015 0.60 [-1.05, 2.25] 2015 3.00 [2.41, 3.59] 2016 0.10 [-7.58, 7.78] 2019 0.10 [-1.15, 1.35] 2022	Mean Difference
b <u>Study or Subgroup</u> <u>2 TAD8</u> Sar et al. 2013a Suzuki et al. 2013b Cozzani et al. 2014b Cozzani et al. 2014b Cassetta et al. 2019b Cassetta et al. 2019 Altieri et al. 2022 Subtotal (95% Cl) Heterogenetiy: Tau" = 1. Test for overall effect: Zl	Mean Difference 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi ² = 37.54, df = 4.16 (P < 0.0001)	se 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92 0.64 = 8 (P	T0 Total 14 20 14 18 19 26 24 10 22 167	T1 Total 14 20 14 18 19 26 24 10 22 167	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.6% 5.8% 0.5% 4.7% 32.0%	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.54] 2013 9.00 [5.47, 12.53] 2013 2.80 [1.78, 3.82] 2014 3.20 [1.85, 4.55] 2015 0.60 [-1.05, 2.25] 2015 3.00 [2.41, 3.59] 2016 0.10 [-7.58, 7.78] 2019 0.10 [-1.51, 1.35] 2022 2.37 [1.26, 3.49]	Mean Difference
b 2TADs 2TADs Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013b Cozzani et al. 2014 Caprioglio et al. 2015 Miresmaelli et al. 2016 Cozzani et al. 2014 Caprioglio et al. 2015 Attieri et al. 2022 Subtotal (95% CI) Heterogeneity: Tau² = 1. Test for oreall effect: Z 3TADs Kook et al 2014	nces: Chi ² = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1 85; Chi ² = 37.54, df = 4.16 (P < 0.0001) 3.42	se 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92 0.64 = 8 (P	T0 Total 14 20 14 18 19 26 24 10 22 167	T1 Total 14 20 14 18 19 26 24 10 22 167 001); I ² 20	Weight 1.6% 3.9% 1.8% 5.2% 4.0% 5.8% 0.5% 4.7% 32.0% = 79%	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.64] 2013 9.00 [5.47, 12.53] 2013 3.20 [1.78, 3.82] 2014 3.20 [1.85, 4.55] 2015 0.60 [-1.05, 2.25] 2015 0.10 [-7.58, 7.78] 2019 0.10 [-1.15, 1.35] 2022 2.37 [1.26, 3.49] 3.42 [0.89, 5.95] 2014	Mean Difference
b <u>Study or Subgroup</u> <u>2 TAD8</u> Sar et al. 2013a Suzuki et al. 2013b Cozzani et al. 2014b Cozzani et al. 2014b Cassetta et al. 2019b Cassetta et al. 2019 Altieri et al. 2022 Subtotal (95% Cl) Heterogenetiy: Tau" = 1. Test for overall effect: Zl	Mean Difference 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi ² = 37.54, df = 4.16 (P < 0.0001)	se 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92 0.64 = 8 (P	T0 Total 14 20 14 18 19 26 24 10 22 167 < 0.000	T1 Total 14 20 14 18 19 26 24 10 22 167 001); I ²	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.0% 5.8% 0.5% 4.7% 32.0% = 79%	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.54] 2013 9.00 [5.47, 12.53] 2013 2.80 [1.78, 3.82] 2014 3.20 [1.85, 4.55] 2015 0.60 [-1.05, 2.25] 2015 3.00 [2.41, 3.59] 2016 0.10 [-7.58, 7.78] 2019 0.10 [-1.51, 1.35] 2022 2.37 [1.26, 3.49]	Mean Difference
b study of Subgroup 2 TAD8 Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013b Cozzani et al. 2014 Caprioglio et al. 2015 Miresmeelli et al. 2015 Cozzani et al. 2019 Altieri et al. 2029 Subtotal (95% CI) Heterogeneity: Tau ² el. 2019 Heterogeneity: Tau ² el. 2019 Moke et al 2014 Sa'aed et al 2015 Park et al 2017	nces: Chi² = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85	f = 1 (f SE 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92 0.64 = 8 (P 1.29 0.2 0.66	T0 Total 14 200 14 18 19 26 24 107 22 167 < 0.000 24 20 24 22	T1 Total 14 200 14 18 19 26 24 167 001); I ² 20 20 24 22	Weight 1.6% 3.9% 5.2% 4.6% 4.0% 5.8% 0.5% 4.7% 32.0% = 79%	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.54] 2013 9.00 [5.47, 12.53] 2013 9.00 [5.47, 12.53] 2014 3.20 [1.78, 3.82] 2014 3.20 [1.78, 3.82] 2014 3.00 [2.41, 3.59] 2016 0.10 [-7.58, 7.78] 2019 0.10 [-1.15, 1.35] 2022 2.37 [1.26, 3.49] 3.42 [0.89, 5.95] 2014 1.53 [1.14, 1.92] 2015 3.85 [2.56, 5.14] 2017	Mean Difference
b 2 TADs 2 TADs Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013b Cozzani et al. 2014 Caprioglio et al. 2015 Miresmaelli et al. 2016 Cassetta et al. 2019 Attieri et al. 2022 Subtotal (95% Cl) Heterogeneity: Tau ² = 1. Test for overal effect. 2 3 TADs Kook et al 2014 Sa'aed et al 2015 Park et al 2017 Jo et al 2018	nces: Chi² = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93	se 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92 0.64 = 8 (P 1.29 0.2 0.66 0.42	T0 Total 14 20 14 18 19 26 24 10 22 167 < 0.000 20 20 20 22 20	T1 Total 14 20 14 18 19 22 20 20 24 10 22 20 20 20	Weight 1.6% 3.9% 5.2% 4.6% 4.6% 0.5% 4.7% 32.0% 5.8% 2.7% 6.1% 4.7% 5.5%	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.54] 2013 9.00 [5.47, 12.53] 2013 3.20 [1.78, 3.82] 2014 3.20 [1.85, 4.55] 2015 0.60 [-1.05, 2.25] 2015 0.10 [-7.58, 7.78] 2019 0.10 [-1.15, 1.35] 2022 2.37 [1.26, 3.49] 3.42 [0.89, 5.95] 2014 1.53 [1.14, 1.92] 2015 3.85 [2.56, 5.14] 2017 2.93 [2.11, 3.75] 2018	Mean Difference
b <u>Study or Subgroup</u> <u>2 TAD8</u> Sar et al. 2013a Suzuki et al. 2013 Cozzani et al. 2014 Cozzani et al. 2014 Cozzani et al. 2015 Miresmeelli et al. 2015 Altieri et al. 2019 Altieri et al. 2019 Altieri et al. 2022 Subtotal (95% CI) Heterogeneity: Tau ² = 1. Test for overall effect: Z <u>3 TAD8</u> Kook et al 2014 Sa ² aed et al 2015 Park et al 2018 Lee et al 2018a	nces: Chi² = 0.03, d Mean Difference 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 2	f = 1 (f SE 1.94 0.89 1.8 0.52 0.69 0.84 0.84 0.3 3.92 0.64 = 8 (P 1.29 0.2 0.66 0.42 0.68	T0 Total 14 20 14 18 19 26 24 10 22 167 < 0.000 20 24 22 20 22	T1 Total 14 20 14 18 19 26 24 10 22 167 001); ² 20 20 24 22 20 22	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 5.8% 0.5% 4.7% 32.0% = 79% 2.7% 6.1% 4.7% 5.5% 3.9%	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.54] 2013 9.00 [5.47, 12.53] 2013 2.80 [1.76, 3.82] 2014 3.20 [1.85, 4.55] 2015 0.60 [-1.05, 2.25] 2015 0.10 [-7.58, 7.78] 2019 0.10 [-1.15, 1.35] 2022 2.37 [1.26, 3.49] 3.42 [0.89, 5.95] 2014 1.53 [1.14, 1.92] 2015 3.85 [2.56, 5.14] 2017 2.93 [2.11, 3.75] 2018 2.00 [0.26, 3.74] 2018	Mean Difference
b <u>Study or Subgroup</u> <u>2 TADs</u> Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013b Cozzani et al. 2014 Caprioglio et al. 2015 Miresmeelli et al. 2015 Cozzani et al. 2016 Cassetta et al. 2019 Atlieri et al. 2022 Subtotal (95% CI) Heterogeneity: Tau² = 1. Test for overall effect: Z <u>3 TADs</u> Kook et al 2014 Sa'aed et al 2015 Park et al 2017 Jo et al 2018 Lee et al 2018a Park et al 2018a	nces: Chi² = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 2.8 3.85 2.93 2.83 3.68	F = 1 (F SE 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92 0.64 = 8 (P 1.29 0.2 0.64 1.29 0.2 0.64 1.29 0.2 0.64 1.29 0.2 0.64 1.20 0.64 1.29 0.2 0.64 1.20 0.64 1.20 0.65 1.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20	T0 Total 14 20 14 18 19 26 24 10 22 167 < 0.000 24 22 20 24 22 20 22 217	T1 Total 14 20 14 18 20 22 24 107 20 22 20 24 22 20 22 20 22 217	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.0% 5.8% 0.5% 4.7% 32.0% 2.7% 6.1% 4.7% 5.5% 3.9%	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.54] 2013 9.00 [5.47, 12.53] 2013 3.280 [1.78, 3.82] 2014 3.20 [1.85, 4.55] 2015 3.00 [2.41, 3.59] 2016 0.10 [-7.58, 7.78] 2019 0.10 [-1.15, 1.35] 2022 2.37 [1.26, 3.49] 3.42 [0.89, 5.95] 2014 1.53 [1.14, 1.92] 2015 3.85 [2.56, 5.14] 2017 2.93 [2.11, 3.75] 2018 2.00 [0.26, 3.74] 2018 2.00 [0.26, 3.74] 2018 3.68 [1.33, 6.03] 2018	Mean Difference
b 2 TADs 2 TADs Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013b Cozzani et al. 2014 Caprioglio et al. 2015 Miresmaelli et al. 2016 Cozsani et al. 2019 Attieri et al. 2022 Subtotal (95% Cl) Heterogeneity: Tau ² = 1. Test for overall effect: Z 3 TADs Kook et al 2014 Sa'aed et al 2015 Park et al 2018 Lee et al 2018a Park et al 2018a Park et al 2018a Park et al 2018a	nces: Chi² = 0.03. d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 2.93 2.93 3.07	F = 1 (f SE 1.94 0.89 1.8 0.69 0.69 0.69 0.69 0.64 0.3 3.92 0.64 = 8 (P 1.29 0.2 0.66 0.42 0.84 0.42 0.84 0.42 0.42 0.84 0.129 0.120	T0 Total 14 20 14 18 19 9 9 26 24 10 22 167 < 0.000 24 22 20 0 24 22 20 0 22 17 16	T1 Total 14 20 14 18 19 9 26 24 10 22 167 7001); I ² 20 24 22 20 0 24 22 20 0 22 17 16	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 0.5% 32.0% = 79% 2.7% 6.1% 4.7% 3.9% 2.9%	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.54] 2013 9.00 [5.47, 12.53] 2013 3.20 [1.76, 3.82] 2014 3.20 [1.85, 4.55] 2015 0.60 [-1.05, 2.25] 2015 0.10 [-7.58, 7.78] 2019 0.10 [-1.15, 1.35] 2022 2.37 [1.26, 3.49] 3.42 [0.89, 5.95] 2014 1.53 [1.14, 1.92] 2015 3.85 [2.56, 5.14] 2017 3.85 [2.56, 5.14] 2017 3.93 [2.11, 3.75] 2018 3.00 [0.24, 3.36] 2018 3.07 [-0.24, 6.38] 2018	Mean Difference
b <u>study or Subgroup</u> <u>2 TADa</u> Sar et al. 2013a Suzuki et al. 2013 Cozzani et al. 2014 Caprioglio et al. 2015 Miresmeelli et al. 2015 Miresmeelli et al. 2015 Cazzani et al. 2019 Altieri et al. 2022 Subtotal (95% CI) Heterogeneity: Tau² et al. Test for overall effect: ZI <u>3 TADs</u> Kook et al 2014 Sa'aed et al 2015 Park et al 2018 Dark et al 2018a Park et al 2018a	nces: Chi² = 0.03, d Mean Difference 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 2.68 3.07 2.35	SE 1.94 0.89 0.52 0.69 0.84 0.33 3.92 0.64 1.29 0.20 0.66 0.42 0.89 1.22 1.69 1.4	T0 Total 14 20 14 18 19 26 24 10 22 167 < 0.000 24 20 22 20 22 20 22 21 7 16 23	T1 Total 14 20 14 18 19 26 24 10 22 167 7001); ² 20 24 22 20 22 20 22 21 7 16 23	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.0% 5.8% 0.5% 4.7% 32.0% 6.1% 4.7% 5.5% 2.9% 1.9%	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.54] 2013 9.00 [5.47, 12.53] 2013 9.20 [1.78, 3.82] 2014 3.20 [1.78, 3.82] 2014 3.20 [1.85, 4.55] 2015 3.00 [2.41, 3.89] 2016 0.10 [-7.58, 7.78] 2019 0.10 [-1.15, 1.35] 2022 2.37 [1.26, 3.49] 3.42 [0.89, 5.95] 2014 1.53 [1.14, 1.92] 2015 3.85 [2.56, 5.14] 2017 2.93 [2.11, 3.75] 2018 3.68 [1.33, 6.03] 2018 3.07 [-0.24, 6.38] 2018 3.07 [-0.24, 6.38] 2018 3.07 [-0.24, 6.38] 2018 3.07 [-0.39, 5.09] 2019	Mean Difference
b 2 TADs 2 TADs Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013b Cozzani et al. 2014 Caprioglio et al. 2014 Caprioglio et al. 2015 Miresmaelli et al. 2016 Cassetta et al. 2019 Attieri et al. 2022 Subtotal (95% CI) Heterogeneity: Tau² = 1. Test for overall effect: Z 3 TADs Kook et al 2014 Sa'aed et al 2015 Park et al 2017 Jo et al 2018 Park et al 2018a Park et al 2019 Lee et al 2019	nces: Chi² = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 2 3.68 3.07 2.35 0.93	SE 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92 0.64 1.29 0.64 1.29 0.64 1.29 0.26 0.64 1.29 0.26 0.64 1.29 0.26 1.69 0.44 0.84 0.52 0.64 0.44 0.42 0.64 0.42 0.44 0.42 0.44 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.44 0.42 0.42 0.44 0.42 0.44	T0 Total 14 20 14 18 19 26 24 10 22 167 20 24 22 20 24 22 20 22 217 7 16 23 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 20	T1 Total 14 200 14 18 19 26 20 22 167 2001); I ² 200 24 22 20 20 24 22 20 20 22 177 16 22 20 20 22 21 77 16 22 20 20 22 22 20 20 22 22 20 20 22 22	Weight 1.6% 3.9% 1.8% 4.6% 4.0% 5.2% 4.6% 32.0% = 79% 2.7% 6.1% 4.7% 2.5% 3.9% 2.9% 1.9% 2.9% 1.9% 2.9%	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.64] 2013 9.00 [5.47, 12.53] 2013 3.20 [1.78, 3.82] 2014 3.20 [1.78, 3.82] 2014 3.20 [1.85, 4.55] 2015 0.60 [-1.05, 2.25] 2015 0.10 [-7.58, 7.78] 2019 0.10 [-1.15, 1.35] 2022 2.37 [1.26, 3.49] 3.42 [0.89, 5.95] 2014 1.53 [1.14, 1.92] 2015 3.85 [2.56, 5.14] 2018 2.00 [0.26, 3.74] 2018 2.00 [0.26, 3.74] 2018 3.07 [-0.24, 6.38] 2018 2.35 [-0.39, 5.09] 2019 0.33 [2.268, 4.54] 2019	Mean Difference
b study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013a Sar et al. 2014 Caprioglio et al. 2014 Caprioglio et al. 2015 Miresmaelli et al. 2015 Cozzani et al. 2014 Capset al. 2014 Cassetta et al. 2019 Altieri et al. 2022 Subtotal (95% Cl) Heterogeneity: Tau ² = 1. Test for overall effect: Z 3 TADs Kook et al 2014 Sa'aed et al 2015 Park et al 2017 Jo et al 2018 Lee et al 2018a Park et al 2018a Park et al 2018b Shoaib et al 2019 Lee et al 2019	nces: Chi² = 0.03. d Mean Difference 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 2.368 3.07 2.35 0.93 1.86	SE 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92 0.64 1.29 0.2 0.66 0.42 0.89 1.2 1.69 1.4 0.42 0.89 1.8 0.52 0.64 0.3 0.52 0.64 0.3 0.52 0.64 0.3 0.52 0.64 0.3 0.52 0.64 0.42 0.69 0.89 1.29 1.69 1.84 0.89 1.64 0.89 1.64 0.89 1.64 0.89 1.64 0.89 1.64 0.89 1.64 0.89 1.64 0.84 0	T0 Total 14 20 14 18 19 26 24 10 22 167 < 0.000 24 22 20 22 20 22 21 7 16 23 20 22 21 7	T1 Total 14 20 14 18 19 26 24 10 22 167 0001); l ² 20 24 22 00 24 22 20 02 24 22 20 02 24 22 20 02 24 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 24 22 20 24 24 20 26 24 24 20 26 24 24 20 26 26 24 24 26 26 24 26 26 24 26 26 26 26 26 26 26 26 26 26 26 26 26	Weight 1.6% 3.9% 1.8% 4.6% 4.6% 4.6% 4.7% 32.0% 6.1% 4.7% 3.2% 6.1% 1.7% 5.5%	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.54] 2013 9.00 [5.47, 12.53] 2013 3.20 [1.76, 3.82] 2014 3.20 [1.85, 4.55] 2015 0.60 [-1.05, 2.25] 2015 0.10 [-7.58, 7.78] 2019 0.10 [-1.15, 1.35] 2022 2.37 [1.26, 3.49] 3.42 [0.89, 5.95] 2014 1.53 [1.14, 1.92] 2015 3.85 [2.56, 5.14] 2017 3.85 [2.56, 5.14] 2017 3.85 [2.56, 5.14] 2017 3.85 [2.56, 5.14] 2017 3.86 [1.33, 6.03] 2018 3.07 [-0.24, 6.38] 2018 3.07 [-0.24, 6.38] 2018 2.35 [-0.39, 5.09] 2019 0.33 [-2.68, 4.54] 2019 0.33 [-2.68, 4.54] 2019 0.39 [-2.68] 4.501	Mean Difference
b study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013b Cozzani et al. 2014 Caprioglio et al. 2014 Caprioglio et al. 2015 Miresmeelli et al. 2015 Altieri et al. 2019 Alteri et al. 2019 Alter et al. 2019 Heterogeneity: Tau ² = 1. Test for overall effect: Z 3 TADS Kook et al 2014 Sa'aed et al 2015 Park et al 2017 Jo et al 2018 Lee et al 2018a Park et al 2018a P	nces: Chi² = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 2.35 0.93 1.86 3.07 2.35 0.93 1.86 1.48	SE 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92 0.64 1.29 0.2 0.66 0.42 0.89 1.2 1.69 1.2 1.69 1.4 1.49	T0 Total 14 200 266 24 167 < 0.000 24 22 200 222 200 222 200 222 217 166 23 200 222 217 20 222 200 220 200 220 200	T1 Total 14 20 26 24 167 20 22 167 20 22 20 22 20 22 20 22 20 22 21 77 16 23 20 22 21 21 20 22 21 21 20 22 20 22 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 20	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 5.8% 0.5% 5.8% 0.5% 32.0% 2.7% 6.1% 4.7% 5.5% 3.9% 2.7% 1.9% 2.9% 1.9% 2.9% 1.9% 2.9% 1.9% 2.9% 1.9% 2.9% 1.9% 2.9% 1.9% 2.9% 1.9% 2.9% 1.9% 2.9% 1.9% 2.9% 1.9% 2.9% 1.9% 2.9% 1.9% 2.9% 1.9% 2.9% 1.9% 2.7% 2.9% 2.7% 2.9% 2.3% 2.9% 2.9% 2.3% 2.9% 2.3% 2.9% 2.3% 2.9% 2.3% 2.3% 2.9% 2.3% 2.3% 2.3% 2.9% 2.3% 2.3% 2.3% 2.9% 2.3% 2.3% 2.3% 2.9% 2.3% 2.3% 2.3% 2.3% 2.3% 2.9% 2.3% 2.3% 2.3% 2.3% 2.3% 2.9% 2.3	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.54] 2013 9.00 [5.47, 12.53] 2013 2.80 [1.78, 3.82] 2014 3.20 [1.85, 4.55] 2015 0.06 [-1.05, 2.25] 2015 3.00 [2.41, 3.59] 2016 0.10 [-7.58, 7.78] 2019 0.10 [-7.58, 7.78] 2022 2.37 [1.26, 3.49] 2022 3.42 [0.89, 5.95] 2014 1.53 [1.14, 1.92] 2015 3.85 [2.56, 5.14] 2017 2.93 [2.11, 3.75] 2018 2.00 [0.26, 3.74] 2018 3.07 [-0.24, 6.38] 2018 3.07 [-0.24, 6.38] 2018 3.07 [-0.24, 6.38] 2019 0.93 [-2.68, 4.54] 2019 0.93 [-2.68, 4.54] 2020 1.48 [1.44, 4.60] 2021	Mean Difference
b study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013b Cozzani et al. 2014 Caprioglio et al. 2014 Caprioglio et al. 2015 Miresmaelli et al. 2016 Cassetta et al. 2019 Attieri et al. 2022 Subtotal (95% CI) Heterogeneilty: Tau ² = 1. Test foreall effect: Z 3 TADs Kook et al 2014 Sa'aed et al 2015 Park et al 2017 Jo et al 2018 Lee et al 2018 Park et al 2019 Lee et al 2019 Atfaifi et al 2020 Chou et al 2021 Aug et al 2021	nces: Chi² = 0.03. d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 2.93 2.93 3.68 3.07 2.35 0.93 1.86 1.48 0.42 0.93 0.28 0.93 0.28 0.93 0.28	SE 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92 0.64 1.29 0.2 0.66 1.29 0.2 0.69 1.2 1.69 1.2 1.49 0.42 0.42 0.42 0.42 0.49 1.2 0.49 0.4 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5	T0 Total 14 20 14 18 19 26 24 107 22 167 < 0.000 24 22 20 24 22 20 24 22 20 24 22 20 24 22 20 20	T1 Total 14 20 14 18 19 26 24 22 167 7001); ² 20 001); ² 20 24 22 20 00 24 22 20 00 24 22 20 00 22 17 7 16 3 20 20 22 20 20 22 20 20 20 20 20 20 20	Weight 1.6% 3.9% 1.8% 4.6% 4.6% 4.7% 32.0% 2.7% 6.1% 4.7% 5.5% 3.9% 2.5% 1.9% 5.5% 3.2%	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.64] 2013 9.00 [5.47, 12.53] 2013 3.20 [1.78, 3.82] 2014 3.20 [1.85, 4.55] 2015 0.60 [-1.05, 2.25] 2015 0.10 [-7.58, 7.78] 2019 0.10 [-1.15, 1.35] 2022 2.37 [1.26, 3.49] 3.42 [0.89, 5.95] 2014 1.53 [1.14, 1.92] 2015 3.85 [2.56, 5.14] 2017 2.93 [2.11, 3.75] 2018 2.00 [0.26, 3.74] 2018 3.07 [-0.24, 6.38] 2018 3.07 [-0.24, 6.38] 2018 3.07 [-0.24, 6.38] 2018 2.35 [-0.39, 5.09] 2019 1.86 [1.04, 2.68] 2020 1.48 [-1.44, 4.40] 2021 1.86 [-1.13, 1.69] 2021	Mean Difference
b <u>study or Subgroup</u> <u>2 TADa</u> Sar et al. 2013a Suzuki et al. 2013 Cozzani et al. 2013 Cozzani et al. 2014 Caprioglio et al. 2015 Miresmeelli et al. 2015 Altieri et al. 2019 Altieri et al. 2022 Subtotal (95% CI) Heterogeneity: Tau ² e1 Heterogeneity: Tau ² e1 Heterogeneity: Tau ² e1 Heterogeneity: Tau ² e1 Subtotal (95% CI) Heterogeneity: Tau ² e1 Betrogeneity: Tau ² e1 Subtotal (95% CI) Heterogeneity: Tau ² e1 Betrogeneity: Tau ² e1 Subtotal (95% CI) Heterogeneity: Tau ² e1 Heterogeneity: Tau ²	nces: Chi² = 0.03, d Mean Difference 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 2 3.68 3.07 2.35 0.93 1.86 1.48 0.28 2.48	SE 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92 0.64 0.42 1.29 0.2 0.66 0.42 0.89 1.2 1.69 1.2 0.69 0.4 0.52 0.64 0.42 1.84 0.42 0.42 0.72 0.63	T0 Total 14 200 22 167 < 0.000 22 20 20	T1 Total 14 200 14 18 19 26 24 107 22 20 20	Weight 1.6% 3.9% 1.8% 5.2% 5.5%	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.54] 2013 9.00 [5.47, 12.53] 2013 3.20 [1.78, 3.82] 2014 3.20 [1.85, 4.55] 2015 0.60 [-1.05, 2.25] 2015 0.10 [-7.58, 7.78] 2019 0.10 [-7.58, 7.78] 2019 0.10 [-1.15, 1.35] 2022 2.37 [1.26, 3.49] 3.42 [0.89, 5.95] 2014 1.53 [1.14, 1.92] 2015 3.85 [2.56, 5.14] 2017 2.93 [2.11, 3.75] 2018 2.00 [0.26, 3.74] 2018 3.68 [1.33, 6.03] 2018 3.67 [-0.24, 6.38] 2018 2.35 [-0.39, 5.09] 2019 1.86 [1.04, 2.68] 2020 1.48 [-1.44, 4.40] 2021 0.28 [-1.13, 169] 2021 0.28 [-1.13, 169] 2021 0.28 [-1.13, 169] 2021	Mean Difference
b <u>study or Subgroup</u> <u>2 TADs</u> Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013b Cozzani et al. 2014 Caprioglio et al. 2015 Miresmealli et al. 2015 Atlieri et al. 2012 Subtotal (95% CI) Heterogeneity: Tau² = 1. Test for overall effect: Z 3 TADs Kook et al 2014 Sa'aed et al 2015 Park et al 2018 Lee et al 2018a Park et al 2018b Consultati et al 2021 Lee et al 2019 Atliatifi et al 2020 Chou et al 2021 Jung et al 2021b Park et al 2021b	nces: Chi² = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 2.35 0.93 1.86 3.07 2.35 0.93 1.86 1.48 0.28 2.18 0.94	SE 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92 0.64 1.29 0.2 0.64 1.29 0.2 0.64 1.29 0.2 0.64 1.29 0.2 0.69 1.4 1.49 0.42 0.42 0.42 0.49 1.49 0.2 0.69 1.4 0.52 0.64 1.49 0.52 0.64 1.29 0.54	T0 Total 14 20 14 18 9 26 24 22 167 < 0.000 24 22 20 22 21 77 16 23 20 22 21 77 16 23 20 22 21 17 20 22 21 17 20 20 22 21 17 20 20 20 22 21 17 20 20 20 20 21 20 20 20 20 20 20 20 20 20 20 20 20 20	T1 Total 14 20 14 18 9 26 24 40 10 22 167 0001); ² 20 24 22 20 22 21 17 16 23 20 22 21 17 16 23 20 22 21 17 16 23 20 20 22 21 17 16 23 20 20 22 21 17 16 23 20 20 22 21 17 16 23 20 20 22 21 17 16 24 24 16 24 24 16 24 24 16 24 24 16 24 24 16 24 24 16 24 24 16 24 24 16 24 16 24 16 24 16 24 16 24 16 24 16 24 16 24 16 24 16 24 16 24 16 24 16 24 16 24 16 24 16 24 16 24 16 22 20 22 22 20 22 20 22 22 16 7 16 20 20 22 16 7 16 20 16 20 20 22 16 7 16 20 20 22 20 22 20 22 20 20 22 20 20 22 22	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.6% 5.8% 0.5% 32.0% 2.7% 6.1% 5.5% 3.9% 2.7% 6.1% 5.5% 3.9% 1.9% 2.9% 1.9% 2.9% 1.9% 1.7% 5.5% 1.9% 1.8% 1.7% 1.9	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.54] 2013 9.00 [5.47, 12.53] 2013 2.80 [1.78, 3.82] 2014 3.20 [1.85, 4.55] 2015 0.06 [-1.05, 2.25] 2013 3.00 [2.41, 3.59] 2016 0.10 [-7.58, 7.78] 2019 0.10 [-1.15, 1.35] 2022 2.37 [1.26, 3.49] 2022 3.42 [0.89, 5.95] 2014 1.53 [1.14, 1.92] 2015 3.85 [2.56, 5.14] 2017 2.93 [2.11, 3.76] 2018 3.68 [1.33, 6.03] 2018 3.68 [1.33, 6.03] 2018 3.69 [1.33, 6.03] 2018 3.69 [1.33, 6.03] 2018 3.69 [1.33, 6.03] 2018 3.69 [1.34, 6.03] 2018 3.69 [1.34, 6.03] 2018 3.61 [1.34, 4.40] 2019 1.86 [1.44, 4.40] 2021 2.85 [-4.44, 4.40] 2021 0.28 [-1.13, 1.69] 2021 0.28 [-1.14, 4.40] 2021	Mean Difference
b study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013a Sar et al. 2013a Cozzani et al. 2014 Caprioglio et al. 2015 Miresmaelli et al. 2016 Cassenta et al. 2019 Attieri et al. 2022 Subtotal (95% Cl) Heterogeneity: Tau ² = 1. Test for overal leffect: 2 3 TADs Kook et al 2014 Sa'aed et al 2015 Park et al 2018 Lee et al 2019 Atfaifi et al 2020 Chou et al 2021 Jung et al 2021b Park et al 2021b	nces: Chi² = 0.03. d Mean Difference 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.422 1.53 3.85 2.93 2.368 3.42 1.65 0.93 1.86 1.48 0.94 1.48	f = 1 (f SE 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92 0.64 = 8 (P 1.29 0.2 0.64 0.42 0.69 1.2 1.69 1.2 1.69 1.4 1.49 0.72 0.63 1.4 9 0.72 0.63 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4	T0 Total 14 20 14 19 26 24 10 22 20 24 20 24 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 21 14 20 20 20 22 20 20	T1 Total 14 20 14 19 26 24 10 22 26 20 24 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 20 22 21 7 16 6 32 32 17 20 20 20 20 20 20 20 20 20 20 20 20 20	Weight 1.6% 3.9% 1.8% 4.6% 4.6% 4.6% 4.7% 6.1% 4.7% 6.1% 4.7% 5.5% 3.2.0% 2.7% 6.1% 4.7% 5.5% 3.9% 2.5% 4.6% 4.7% 4.7% 5.5% 3.2% 4.7% 4.7% 5.5% 4.7% 4.7% 5.5% 4.7% 4.7% 5.5% 4.7% 5.5% 4.7% 5.5% 4.7% 5.5% 5.7% 6.1% 4.7% 5.5% 5.5% 6.1% 4.7% 5.5% 5.5% 6.1% 6.1% 6.1% 6.5% 5.5% 6.1% 6.1% 6.5% 6.2% 6.4% 6.4% 6.4% 6.4% 6.4% 6.4% 6.5% 6.5% 6.5% 6.2% 6.5% 6.2% 6.5% 6.2% 6.5% 6.2% 6.5% 6.2% 6.5% 6.2% 6.5% 6.2% 6.5% 6.2% 6.5% 6.2% 6.5% 6.2% 6.5% 6.2% 6.5% 6.2% 6.5% 6.2% 6.5% 6.2% 6.5% 6.2% 6.5% 6.2% 6.5% 6.5% 6.5% 6.5% 6.5% 6.5% 6.5% 6.4% 6.	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.54] 2013 9.00 [5.47, 12.53] 2013 3.20 [1.78, 3.82] 2014 3.20 [1.85, 4.55] 2015 0.60 [-1.05, 2.25] 2015 0.10 [-7.58, 7.78] 2019 0.10 [-1.15, 1.35] 2022 2.37 [1.26, 3.49] 3.42 [0.89, 5.95] 2014 1.53 [1.14, 1.92] 2015 3.85 [2.56, 5.14] 2017 2.93 [2.11] 3.75] 2018 2.00 [0.26, 3.74] 2018 3.68 [1.33, 6.03] 2018 3.68 [1.33, 6.03] 2018 3.68 [1.33, 6.03] 2018 3.68 [1.34, 6.38] 2018 3.65 [-0.46, 6.38] 2019 1.86 [1.04, 2.68] 2020 1.48 [-1.44, 4.40] 2021 0.28 [-1.13, 1.69] 2021 2.18 [0.95, 3.41] 2021 0.44 [-2.39, 4.27] 2021	Mean Difference
b <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>strate</u> <u>st</u>	nces: Chi² = 0.03, d Mean Difference 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 3.68 3.07 2.35 0.93 1.86 1.48 0.28 2.48 0.94 1.48 0.28 3.67 2.35 0.93 1.86 1.86 1.83 3.75 1.53 3.85 2.93 3.68 3.07 2.35 0.93 1.86 1.86 1.86 1.87 1.53 1.87 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.65 1.53 1.53 1.53 1.65 1.53 1.53 1.53 1.53 1.53 1.65 1.53 1.53 1.53 1.65 1.53 1.53 1.65 1.53 1.53 1.53 1.65 1.86 1.75 1.53 1.86 1.86 1.86 1.75 1.53 1.86 1.75 1.86 1.86 1.75 1.86 1.75 1.86	se 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92 0.64 1.29 0.2 0.66 0.42 0.69 0.2 1.69 1.4 0.42 1.69 1.49 1.49 0.42 1.69 1.44 0.42 1.69 1.44 0.42 1.69 1.44 0.42 0.62 0.62 0.62 0.62 0.62 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.66 0.52 0.64 0.52 0.66 0.42 0.62 0.62 0.62 0.62 0.62 0.62 0.62 0.62 0.64 0.52 0.62 0	T0 Total 14 20 14 18 19 26 24 10 22 167 < 0.000 20 24 22 20 20	T1 Total 14 20 14 18 19 26 24 10 22 167 7001); l ² 20 22 22	Weight 1.6% 3.9% 1.8% 5.2% 5.2% 5.2% 5.2% 5.2% 5.2% 5.2% 2.7% 6.1% 5.5% 2.9% 1.9% 2.3% 4.4% 4.4% 4.4% 4.4% 4.4% 5.5%	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.54] 2013 9.00 [5.47, 12.53] 2013 2.80 [1.78, 3.82] 2014 3.20 [1.85, 4.55] 2015 0.00 [-7.68, 7.78] 2019 0.10 [-7.58, 7.78] 2019 0.10 [-7.58, 7.78] 2019 0.10 [-7.58, 7.78] 2019 0.10 [-7.58, 7.78] 2019 0.10 [-7.58, 7.78] 2019 0.10 [-7.58, 7.78] 2019 0.10 [-7.58, 7.78] 2019 0.10 [-7.58, 7.78] 2019 0.10 [-7.58, 7.78] 2019 0.10 [-7.58, 7.78] 2019 0.10 [-7.58, 7.78] 2019 0.10 [-7.58, 7.78] 2019 0.36 [2.56, 5.14] 2017 2.93 [2.16, 3.59] 2014 1.53 [1.14, 1.92] 2015 3.68 [1.33, 6.03] 2018 3.07 [-2.4, 6.38] 2018 2.03 [0.26, 3.74] 2018 3.30 [2.46, 4.54] 2019 0.38 [2.66, 5.44] 2020	Mean Difference
b <u>Study or Subgroup</u> <u>2 TADs</u> Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013b Cozzani et al. 2014 Caprioglio et al. 2014 Caprioglio et al. 2016 Cassetta et al. 2019 Atlieri et al. 2022 Subtotal (95% CI) Heterogeneity: Tau ² = 1. Test for overall effect: Z <u>3 TADs</u> Kook et al 2014 Sa'aed et al 2015 Park et al 2017 Jo et al 2018 Lee et al 2018 Park et al 2018a Park et al 2018a Park et al 2018b Shoaib et al 2019 Lee et al 2019 Lee et al 2019 Lee et al 2019 Atlifi et al 2020 Chou et al 2021 Jung et al 2021b Park et al 2021b	nces: Chi ² = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi ² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 2.35 0.93 1.86 3.07 2.35 0.93 1.86 1.48 0.28 2.18 0.94 4.36 0.94 4.36 0.94	SE 1.94 0.89 1.8 0.52 0.69 0.84 0.33 3.92 0.64 1.29 0.26 0.62 0.69 0.84 0.33 3.92 0.64 1.29 0.26 0.69 0.42 0.69 1.29 1.29 0.26 0.69 0.42 0.69 1.29 0.26 0.69 0.42 0.69 1.29 0.26 0.69 0.42 0.69 0.20 0.69 0.42 0.69 0.20 0.69 0.84 0.52 0.69 0.84 0.52 0.69 0.84 0.52 0.69 0.84 0.52 0.69 0.84 0.52 0.69 0.84 0.52 0.69 0.84 0.52 0.69 0.84 0.52 0.69 0.89 0.42 0.69 0.26 0.69 0.26 0.69 0.69 0.69 0.69 0.69 0.69 0.69 0.69 0.69 0.69 0.62 0.69 0.72 1.69 1.72 1.69 0.72 0.4	T0 Total 14 20 14 18 19 26 20 2167 7 6 7 6 7 7 7 7 6 6 20 24 22 20 0 24 22 20 0 24 22 20 0 24 22 20 20 24 22 20 20 20 20 21 7 7 7 16 7 7 7 7 7 8 7 8 7 9 26 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	T1 Total 14 20 14 18 19 26 20 21 20 20 20 20 20 20 20 20 22 20 00 21 22 20 00 21 22 20 00 21 21 20 20 20 21 21 23 20 20 20 20 20 20 20 20 20 20 20 20 20	Weight 1.6% 3.9% 1.8% 4.6% 4.6% 4.6% 4.7% 32.0% 5.8% 5.8% 5.5% 3.9% 2.7% 6.1% 5.5% 3.9% 1.7% 5.5% 4.4% 1.7% 5.5% 4.4% 1.7% 5.5% 4.4% 1.7% 5.5% 4.6% 1.7% 5.8% 1.7% 5.5% 1.7% 5.5% 1.7% 5.5% 1.7% 5.5% 1.7% 5.5% 1.7% 5.5% 1.7% 5.5% 1.7% 5.5% 1.7% 5.5% 1.7% 5.5% 1.7% 5.5% 1.7% 5.5% 1.7% 5.5% 1.7% 5.5% 1.7% 1.7% 5.5% 1.7% 1.7% 1.7% 1.7% 5.5% 1.7% 1.4% 1.7	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.64] 2013 9.00 [5.47, 12.53] 2013 2.80 [1.78, 3.82] 2014 3.20 [1.85, 4.55] 2015 0.00 [5.47, 12.53] 2013 0.00 [1.76, 3.82] 2014 3.00 [2.41, 3.59] 2016 0.10 [-7.58, 7.78] 2019 0.10 [-1.15, 1.35] 2022 2.37 [1.26, 3.49] 2022 2.37 [1.26, 5.44] 2017 2.93 [2.11, 3.75] 2018 2.05 [-0.24, 6.38] 2018 2.05 [-0.39, 5.09] 2019 0.33 [-2.68, 4.54] 2019 0.33 [-2.68, 4.54] 2019 0.34 [-1.44, 4.40] 2021 2.18 [-0.44, 8.40] 2021 2.18 [-0.45, 3.41] 2021 0.28 [-1.13, 1.69] 2021 2.18 [-4.44, 4.01] 2021 0.36 [-2.39, 4.27] 2021 2.48 [-0.46, 9.18] 2021 2.48 [-0.46, 9.18] 2021 2.48 [-0.46, 9.18] 2021	Mean Difference
b <u>Study or Subgroup</u> <u>2 TADa</u> Sar et al. 2013a Suzuki et al. 2013 Cozzani et al. 2013 Cozzani et al. 2014 Caprioglio et al. 2015 Miresmeelli et al. 2015 Miresmeelli et al. 2015 Altieri et al. 2022 Subtotal (95% CI) Heterogeneity: Tau ² e1 Heterogeneity: Tau ² e1 Heterogeneity: Tau ² e1 Heterogeneity: Tau ² e1 Mok et al 2014 Sarade et al 2015 Park et al 2018 Dark et al 2019 Lee et al 2019 Lee et al 2019 Lee et al 2021 Jung et al 2021b Dark et al 2022b Dark et al 2021b Dark et al 2021b D	nces: Chi² = 0.03, d Mean Difference 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 3.68 3.07 2.35 0.93 1.86 1.48 0.28 2.48 0.94 1.48 0.28 3.67 2.35 0.93 1.86 1.86 1.83 3.75 1.53 3.85 2.93 3.68 3.07 2.35 0.93 1.86 1.86 1.86 1.87 1.53 1.87 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.65 1.53 1.53 1.53 1.65 1.53 1.53 1.53 1.53 1.53 1.65 1.53 1.53 1.53 1.65 1.53 1.53 1.65 1.53 1.53 1.53 1.65 1.86 1.75 1.53 1.86 1.86 1.86 1.75 1.53 1.86 1.75 1.86 1.86 1.75 1.86 1.75 1.86	se 1.94 0.89 1.8 0.52 0.69 0.84 0.3 3.92 0.64 1.29 0.2 0.66 0.42 0.69 0.2 1.69 1.4 0.42 1.69 1.49 1.49 0.42 1.69 1.44 0.42 1.69 1.44 0.42 1.69 1.44 0.42 0.62 0.62 0.62 0.62 0.62 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.66 0.52 0.64 0.52 0.66 0.42 0.62 0.62 0.62 0.62 0.62 0.62 0.62 0.62 0.64 0.52 0.62 0	T0 Total 14 20 14 18 19 26 22 167 < 0.000 24 22 20 24 22 20 22 21 77 16 23 20 22 21 71 6 23 20 22 21 20 22 21 12 20 22 21 14 20 22 21 14 20 22 20 22 21 14 20 22 20 20	T1 Total 14 20 14 18 19 26 22 167 1001); l ² 20 24 22 20 24 22 20 22 21 77 16 23 20 22 21 20 22 21 20 22 21 20 22 21 20 22 21 16 23 20 20 22 21 16 21 22 20 22 20 22 21 20 22 22 20 20	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 5.2% 4.7% 5.2% 4.7% 5.5% 2.7% 4.7% 2.7% 4.7% 2.7% 4.7% 2.7% 4.7% 2.5% 2.9% 1.9% 1.9% 2.5%	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.54] 2013 9.00 [5.47, 12.53] 2013 2.80 [1.78, 3.82] 2014 3.20 [1.85, 4.55] 2015 0.00 [-1.05, 2.25] 2015 3.00 [2.41, 3.89] 2016 0.10 [-7.58, 7.78] 2019 0.10 [-1.15, 1.35] 2022 2.37 [1.26, 3.49] 3.42 [0.89, 5.95] 2014 1.53 [1.14, 1.92] 2015 3.85 [2.56, 5.14] 2017 2.93 [2.11, 3.75] 2018 3.06 [1.33, 6.03] 2018 3.07 [-0.24, 6.38] 2018 3.07 [-0.24, 6.38] 2018 3.07 [-0.24, 6.38] 2019 0.33 [-2.68, 4.54] 2019 0.33 [-2.68, 4.54] 2019 0.39 [-2.68, 4.54] 2019 0.48 [-1.44, 4.40] 2021 0.28 [-1.13, 1.69] 2021 1.48 [-1.44, 4.40] 2021 0.29 [-2.39, 4.27] 2021 1.48 [-1.44, 4.40] 2021 0.59 [3.58, 6.60] 2022 0.80 [0.41, 1.19] 2022	Mean Difference
b study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013b Cozzani et al. 2014 Caprioglio et al. 2015 Miresmealli et al. 2015 Altieri et al. 2019 Altieri et al. 2022 Subtotal (95% CI) Heterogeneity: Tau ² = 1. Test for overall effect: Z 3 TADs Kook et al 2014 Sa'aed et al 2015 Park et al 2017 Jo et al 2018 Lee et al 2018a Park et al 2018b Shoaib et al 2019 Lee et al 2018a Park et al 2018b Park et al 2021b Park et al 2021c Jung et al 2021b Park et al 2022b Park e	nces: Chi ² = 0.03, d <u>Mean Difference</u> 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi ² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 1.86 3.07 2.35 0.93 1.86 3.07 2.35 0.93 1.86 3.07 2.35 0.93 1.86 3.07 2.35 0.93 1.86 3.07 2.35 0.93 1.86 3.07 2.35 0.93 1.86 3.07 2.35 0.93 1.86 3.07 2.35 0.93 1.86 3.07 2.35 0.93 1.86 3.07 2.35 0.93 1.86 3.07 2.35 0.93 1.86 3.07 0.93 1.86 3.35 0.93 1.86 3.35 0.93 1.86 3.35 0.93 1.86 0.94 4.36 0.94 4.36 0.94 4.36 0.94 4.36 0.94 0.95 0	f = 1 (f SE 1.94 0.89 0.62 0.69 0.84 0.3 3.92 0.64 1.29 0.2 0.66 0.42 0.89 1.2 1.69 1.4 1.84 0.42 1.69 1.4 1.84 0.42 0.63 0.42 0.63 0.42 0.62 0.64 0.89 1.4 0.89 0.4 0.89 0.4 0.89 0.64 0.89 0.64 0.89 0.64 0.89 0.64 0.89 0.64 0.89 0.64 0.89 0.64 0.89 0.64 0.65 0.65 0.64 0.65 0.64 0.65 0.64 0.65 0.64 0.65 0.65 0.64 0.65 0.64 0.65 0.65 0.65 0.65 0.65 0.65 0.65 0.65	T0 Total 14 20 14 18 19 26 24 20 20 24 22 20 0 24 22 20 0 24 22 20 0 22 20 20 22 20 20 22 20 0 22 17 7 167 32 20 20 20 20 20 20 20 20 20 20 20 20 20	T1 Total 14 20 14 18 19 26 24 20 20 20 22 20 00 1); l ² 20 20 22 20 20 22 20 20 22 20 20 22 20 20	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.6% 5.8% 0.5% 32.0% 2.7% 6.1% 5.5% 3.9% 2.7% 6.1% 5.5% 3.9% 1.9% 2.9% 1.9% 2.9% 1.9% 4.6% 4.6% 4.6% 4.6% 4.6% 6.1% 5.5% 6.1% 6.1% 5.5% 6.1	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.64] 2013 9.00 [5.47, 12.53] 2013 2.80 [1.78, 3.82] 2014 3.20 [1.85, 4.55] 2015 0.00 [5.47, 12.53] 2013 0.00 [1.76, 3.82] 2014 3.00 [2.41, 3.59] 2016 0.10 [-7.58, 7.78] 2019 0.10 [-1.15, 1.35] 2022 2.37 [1.26, 3.49] 2022 2.37 [1.26, 5.44] 2017 2.93 [2.11, 3.75] 2018 2.05 [-0.24, 6.38] 2018 2.05 [-0.39, 5.09] 2019 0.33 [-2.68, 4.54] 2019 0.33 [-2.68, 4.54] 2019 0.34 [-1.44, 4.40] 2021 2.18 [-0.44, 8.40] 2021 2.18 [-0.45, 3.41] 2021 0.28 [-1.13, 1.69] 2021 2.18 [-4.44, 4.01] 2021 0.36 [-2.39, 4.27] 2021 2.48 [-0.46, 9.18] 2021 2.48 [-0.46, 9.18] 2021 2.48 [-0.46, 9.18] 2021	Mean Difference
b study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013a Suzuki et al. 2013 Cozzani et al. 2014 Caprioglio et al. 2014 Caprioglio et al. 2015 Miresmaelli et al. 2016 Cassetta et al. 2019 Attieri et al. 2022 Subtotal (95% CI) Heterogeneity: Tau ² = 1. Test for overall effect: 2 State al 2014 Sa'aed et al 2015 Park et al 2017 Jo et al 2018 Lee et al 2018 Lee et al 2018 Park et al 2018 Park et al 2018 Lee et al 2018 Lee et al 2018 Lee et al 2019 Atfaifi et al 2020 Chou et al 2021 Jung et al 2021b Park et al 2021b Lee et al 2021b Lea et al 2021b Lea et al 2021b Park et al 2021b Lea et al 2021b Park et al 2021b Park et al 2021b Park et al 2021b Lea et al 2021b Park et al 2021b Lea et al 2021b Park et al 2021b Par	nces: Chi² = 0.03. d Mean Difference 1.65 1.8 9 2.8 3.2 0.6 3.3 0.1 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 2.93 2.93 3.68 1.48 0.93 1.86 1.48 0.94 1.53 1.86 1.48 0.93 1.86 1.48 0.94 1.53 1.86 1.48 0.93 1.86 1.48 0.94 1.53 1.86 1.48 0.94 1.53 1.86 1.48 0.93 1.86 1.48 0.94 1.53 1.86 1.48 0.94 1.53 1.86 1.48 0.94 1.53 1.86 1.48 1.86 1.48 0.94 1.86 1.93 1.86	SE 1.94 0.89 0.82 0.69 0.84 0.33 0.64 0.33 0.64 0.8 0.8 0.64 1.29 0.66 0.42 0.64 0.44 0.84 0.42 0.66 0.49 1.2 1.69 1.4 1.84 0.42 0.63 1.7 2.466 0.77 0.7 0.2 f = 17	T0 Total 14 20 14 18 19 26 24 20 20 24 22 20 0 24 22 20 0 24 22 20 0 22 20 20 22 20 20 22 20 0 22 17 7 167 32 20 20 20 20 20 20 20 20 20 20 20 20 20	T1 Total 14 20 14 18 19 26 24 20 20 20 22 20 00 1); l ² 20 20 22 20 20 22 20 20 22 20 20 22 20 20	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.6% 5.8% 0.5% 32.0% 2.7% 6.1% 5.5% 3.9% 2.7% 6.1% 5.5% 3.9% 1.9% 2.9% 1.9% 2.9% 1.9% 4.6% 4.6% 4.6% 4.6% 4.6% 6.1% 5.5% 6.1% 6.1% 5.5% 6.1	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.54] 2013 9.00 [5.47, 12.53] 2013 2.80 [1.78, 3.82] 2014 3.20 [1.85, 4.55] 2015 0.00 [-1.05, 2.25] 2015 3.00 [2.41, 3.89] 2016 0.10 [-7.58, 7.78] 2019 0.10 [-1.15, 1.35] 2022 2.37 [1.26, 3.49] 3.42 [0.89, 5.95] 2014 1.53 [1.14, 1.92] 2015 3.85 [2.56, 5.14] 2017 2.93 [2.11, 3.75] 2018 3.06 [1.33, 6.03] 2018 3.07 [-0.24, 6.38] 2018 3.07 [-0.24, 6.38] 2018 3.07 [-0.24, 6.38] 2019 0.33 [-2.68, 4.54] 2019 0.33 [-2.68, 4.54] 2019 0.39 [-2.68, 4.54] 2019 0.48 [-1.44, 4.40] 2021 0.28 [-1.13, 1.69] 2021 1.48 [-1.44, 4.40] 2021 0.29 [-2.39, 4.27] 2021 1.48 [-1.44, 4.40] 2021 0.59 [3.58, 6.60] 2022 0.80 [0.41, 1.19] 2022	Mean Difference
b study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013b Cozzani et al. 2014 Caprioglio et al. 2015 Miresmealli et al. 2015 Altieri et al. 2019 Altieri et al. 2022 Subtotal (95% CI) Heterogeneity: Tau ² = 1. Test for overall effect: Z 3 TADs Kook et al 2014 Sa'aed et al 2015 Park et al 2017 Jo et al 2018 Lee et al 2018a Park et al 2018b Shoaib et al 2019 Lee et al 2018a Park et al 2018b Park et al 2021b Park et al 2021c Jung et al 2021b Park et al 2022b Park e	nces: Chi² = 0.03. d Mean Difference 1.65 1.8 9 2.8 3.2 0.6 3.3 0.1 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 2.93 2.93 3.68 1.48 0.93 1.86 1.48 0.94 1.53 1.86 1.48 0.93 1.86 1.48 0.94 1.53 1.86 1.48 0.93 1.86 1.48 0.94 1.53 1.86 1.48 0.94 1.53 1.86 1.48 0.93 1.86 1.48 0.94 1.53 1.86 1.48 0.94 1.53 1.86 1.48 0.94 1.53 1.86 1.48 1.86 1.48 0.94 1.86 1.93 1.86	SE 1.94 0.89 0.82 0.69 0.84 0.33 0.64 0.33 0.64 0.8 0.8 0.64 1.29 0.66 0.42 0.64 0.44 0.84 0.42 0.66 0.49 1.2 1.69 1.4 1.84 0.42 0.63 1.7 2.466 0.77 0.7 0.2 f = 17	T0 Total 14 20 14 18 19 26 24 20 20 24 22 20 0 24 22 20 0 24 22 20 0 22 20 20 22 20 20 22 20 0 22 17 7 167 32 20 20 20 20 20 20 20 20 20 20 20 20 20	T1 Total 14 20 14 18 19 26 24 20 20 20 22 20 00 1); l ² 20 20 22 20 20 22 20 20 22 20 20 22 20 20	Weight 1.6% 3.9% 1.8% 5.2% 4.6% 4.6% 5.8% 0.5% 32.0% 2.7% 6.1% 5.5% 3.9% 2.7% 6.1% 5.5% 3.9% 1.9% 2.9% 1.9% 2.9% 1.9% 4.6% 4.6% 4.6% 4.6% 4.6% 6.1% 5.5% 6.1% 6.1% 5.5% 6.1	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.54] 2013 9.00 [5.47, 12.53] 2013 2.80 [1.78, 3.82] 2014 3.20 [1.85, 4.55] 2015 0.00 [-1.05, 2.25] 2015 3.00 [2.41, 3.89] 2016 0.10 [-7.58, 7.78] 2019 0.10 [-1.15, 1.35] 2022 2.37 [1.26, 3.49] 3.42 [0.89, 5.95] 2014 1.53 [1.14, 1.92] 2015 3.85 [2.56, 5.14] 2017 2.93 [2.11, 3.75] 2018 3.06 [1.33, 6.03] 2018 3.07 [-0.24, 6.38] 2018 3.07 [-0.24, 6.38] 2018 3.07 [-0.24, 6.38] 2019 0.33 [-2.68, 4.54] 2019 0.33 [-2.68, 4.54] 2019 0.39 [-2.68, 4.54] 2019 0.48 [-1.44, 4.40] 2021 0.28 [-1.13, 1.69] 2021 1.48 [-1.44, 4.40] 2021 0.29 [-2.39, 4.27] 2021 1.48 [-1.44, 4.40] 2021 0.59 [3.58, 6.60] 2022 0.80 [0.41, 1.19] 2022	Mean Difference
b study or Subgroup 2 TADs Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013b Cozzani et al. 2014 Caprioglio et al. 2014 Caprioglio et al. 2015 Miresmealli et al. 2015 Atlieri et al. 2022 Subtotal (95% CI) Heterogeneity: Tau ² = 1. Test for overall effect: 2 State al. 2018 Park et al 2018 De et al 2018 Park et al 2018 Park et al 2018 De et al 2019 Atliafi et al 2020 Chou et al 2021 Jung et al 2021b Park et al 2022b Park et al 2022b Park et al 2022b Park et al 2022b Park	nces: Chi² = 0.03. d Mean Difference 1.65 1.8 9 2.8 3.2 0.6 3.3 0.1 0.1 85; Chi² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 2.93 2.93 3.68 1.48 0.93 1.86 1.48 0.94 1.53 1.86 1.48 0.93 1.86 1.48 0.94 1.53 1.86 1.48 0.93 1.86 1.48 0.94 1.53 1.86 1.48 0.94 1.53 1.86 1.48 0.93 1.86 1.48 0.94 1.53 1.86 1.48 0.94 1.53 1.86 1.48 0.94 1.53 1.86 1.48 1.86 1.48 0.94 1.86 1.93 1.86	SE 1.94 0.89 0.82 0.69 0.84 0.33 0.64 0.33 0.64 0.8 0.8 0.64 1.29 0.66 0.42 0.64 0.44 0.84 0.42 0.66 0.49 1.2 1.69 1.4 1.84 0.42 0.63 1.7 2.466 0.77 0.7 0.2 f = 17	T0 Total 14 20 14 18 19 22 24 167 22 20 24 22 20 22 20 22 20 22 17 16 23 20 22 17 16 23 20 20 22 17 16 23 20 20 22 20 20 20 22 17 14 18 19 20 20 24 20 20 22 20 20 20 20 20 20 20 20 20 20	T1 Total 14 20 14 18 19 22 24 107 20 24 22 20 02 22 00 22 107 16 23 20 22 20 02 22 17 16 23 20 20 22 17 16 23 20 20 20 20 20 20 20 20 20 20 20 20 20	Weight 1.6% 3.9% 1.8% 4.6% 4.6% 4.7% 5.2% 32.0% 2.7% 6.1% 4.7% 5.5% 3.9% 2.7% 6.1% 4.7% 5.5% 3.9% 1.9% 2.7% 6.1% 4.7% 5.2% 4.7% 5.2% 6.1% 4.7% 5.2% 6.1% 4.7% 5.2% 6.1% 4.7% 5.2% 6.1% 5.2% 6.1% 6.1% 6.1% 5.2% 6.1% 6.2% 6.1	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.54] 2013 9.00 [5.47, 12.53] 2013 2.80 [1.78, 3.82] 2014 3.20 [1.85, 4.55] 2015 0.00 [5.47, 12.53] 2013 3.00 [2.41, 3.59] 2016 0.10 [-7.58, 7.78] 2019 0.10 [-1.15, 1.35] 2022 2.37 [1.26, 3.49] 2014 1.53 [1.14, 1.92] 2015 3.85 [2.56, 5.14] 2017 2.93 [2.11, 3.76] 2018 3.68 [1.33, 6.03] 2018 3.68 [1.33, 6.03] 2018 3.68 [1.33, 6.03] 2018 3.69 [.03, 5.96] 2014 1.53 [1.44, 4.40] 2021 2.36 [-0.46, 9.18] 2021 2.48 [-1.44, 4.40] 2021 0.28 [-1.13, 1.69] 2021 1.86 [1.44, 4.40] 2021 0.28 [-1.13, 1.69] 2021 2.48 [-0.46, 9.18] 2021 3.00 [2.75, 3.85] 2022 3.00 [2.75, 3.85] 2022 <td>Mean Difference</td>	Mean Difference
b Study or Subgroup 2 TAD2 Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013a Suzuki et al. 2014 Caprioglio et al. 2015 Miresmaelli et al. 2016 Cozzani et al. 2016 Cozzani et al. 2017 Miresmaelli et al. 2017 Subtotal (95% CI) Heterogeneily: Tau² = 1. Test for overall effect: Z D'ADD Altieri et al. 2017 Sade et al 2018 Lee et al 2018 Dark et al 2019 Alfaifi et al 2020 Chou et al 2021 Jung et al 2021b Park et al 2021b Park et al 2021b Park et al 2021b Dark	nces: Chi ² = 0.03, d Mean Difference 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi ² = 37.54, df = 4.16 (P < 0.0001) 3.422 1.53 3.85 2.93 2.368 1.48 0.93 1.86 1.48 0.93 0.93 1.86 1.48 0.93 0.93 1.86 1.93 0.93 1.86 1.94 1.95 1	f = 1 (f SE 1.94 0.89 1.8 0.69 0.84 0.3 0.69 0.84 0.3 0.64 = 8 (P 1.29 0.2 0.66 0.42 0.89 1.2 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.45 0.42 0.45 0.42 0.45 0.42 0.45 0.42 0.45 0.42 0.45 0.42 0.45 0.42 0.42 0.45 0.42 0.45 0.42 0.45 0.42 0.45 0.42 0.45 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.	T0 Total 14 20 14 18 19 26 24 22 167 <0.000 24 22 20 22 20 22 20 22 20 22 20 22 21 20 20 22 21 167 16 23 30 20 20 20 21 18 (20) 20 20 21 20 20 21 20 20 20 21 20 20 20 21 20 20 20 20 20 20 20 20 20 20 20 20 20	T1 Total 14 20 14 18 19 26 24 22 167 7001); ² 20 24 22 20 22 20 22 20 22 20 22 20 22 21 16 23 30 20 20 20 21 20 20 21 12 20 20 20 21 21 20 20 21 21 20 20 21 21 20 20 21 21 20 20 21 21 20 20 21 21 20 20 21 21 20 20 21 21 20 20 21 21 20 20 21 20 20 21 20 20 20 20 21 20 20 20 20 20 20 20 20 20 20 20 20 20	Weight 1.6% 3.9% 1.8% 4.6% 4.6% 4.7% 5.2% 4.7% 32.0% 2.7% 6.1% 4.7% 5.5% 3.9% 2.5% 5.5% 3.9% 2.5% 1.9% 5.5% 5.5% 4.4% 4.7% 5.5% 6.1% 4.7% 6.1% 6.1% 6.1% 6.2% 6.1% 6.1% 6.2% 6.1% 6.1% 6.2% 6.1% 6.1% 6.1% 6.1% 6.2% 6.2	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.54] 2013 9.00 [5.47, 12.53] 2013 2.80 [1.78, 3.82] 2014 3.20 [1.85, 4.55] 2015 0.00 [-1.05, 2.25] 2015 3.00 [2.41, 3.89] 2016 0.10 [-7.58, 7.78] 2019 0.10 [-1.15, 1.35] 2022 2.37 [1.26, 3.49] 3.42 [0.89, 5.95] 2014 1.53 [1.14, 1.92] 2015 3.85 [2.56, 5.14] 2017 2.93 [2.11, 3.75] 2018 3.06 [1.33, 6.03] 2018 3.07 [-0.24, 6.38] 2018 3.07 [-0.24, 6.38] 2018 3.07 [-0.24, 6.38] 2018 3.07 [-0.24, 6.38] 2019 0.33 [-2.68, 4.54] 2019 0.39 [-2.68, 4.54] 2019 0.48 [-1.44, 4.40] 2021 0.28 [-1.13, 1.69] 2021 1.48 [-1.44, 4.40] 2021 0.29 [-2.39, 4.27] 2021 1.48 [-1.44, 4.40] 2021 0.59 [3.58, 6.60] 2022 0.80 [0.41, 1.19] 2022	Mean Difference IV, Random, 95% CI
b straight for subgroup 2 TADa Sar et al. 2013a Suzuki et al. 2013a Suzuki et al. 2013 Sar et al. 2013b Cozzani et al. 2014 Caprioglio et al. 2015 Miresmeelli et al. 2015 Miresmeelli et al. 2015 Altieri et al. 2022 Subtotal (95% CI) Heterogeneity: Tau ² = 1. Tats for overall effect: Z 3 TADs Kook et al 2014 Sa'aed et al 2015 Park et al 2017 Jo et al 2018 Lee et al 2018 Park et al 2018 Park et al 2018 Park et al 2018 Park et al 2019 Lee et al 2021b Park et al 2021c Alfawaz et al 2022 Lim et al. 2022 Subtotal (95% CI) Heterogeneity: Tau ² = 1.	nces: Chi ² = 0.03, d Mean Difference 1.65 1.8 9 2.8 3.2 0.6 3 0.1 0.1 85; Chi ² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 3.68 3.07 2.35 0.93 1.86 1.48 0.28 2.18 0.94 4.36 1.86 1.48 0.28 2.18 0.94 4.36 1.86 1.86 1.85 1.53 3.85 2.93 3.68 3.07 2.35 0.93 1.86 1.86 1.86 1.86 1.85 3.97 2.35 0.93 1.86 1.86 1.86 1.86 1.85 3.97 2.35 0.93 1.86 1.86 1.86 1.86 1.86 1.87 1.86 1.85 1.85 1.86 1.87 1.86 1.86 1.86 1.86 1.86 1.86 1.86 1.86 1.86 1.86 1.86 1.86 1.86 1.86 1.86 1.87 1.86 1.86 1.87 1.86 1.86 1.86 1.86 1.86 1.87 1.86 1.86 1.87 1.86 1.86 1.87 1.87 1.87 1.87 1.86 1.87 1.87 1.86 1.87 1.87 1.87 1.86 1.87 1.87 1.87 1.86 1.87 1.8	f = 1 (f SE 1.94 0.89 1.8 0.52 0.69 0.84 0.3 9 0.84 0.3 9 0.64 1.29 0.2 0.66 0.42 0.69 0.2 0.66 0.42 0.69 1.2 1.69 0.2 0.69 0.42 0.69 0.42 0.69 0.42 0.69 0.42 1.29 1.29 0.2 0.69 0.42 0.59 1.2 1.29 0.2 0.69 0.44 0.39 0.54 0.52 0.69 0.84 0.52 0.69 0.69 0.84 0.52 0.69 0.64 0.52 0.69 0.64 0.52 0.69 0.64 0.52 0.69 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.64 0.52 0.69 0.64 0.52 0.69 0.64 0.52 0.69 0.64 0.52 0.69 0.64 0.52 0.69 0.64 0.52 0.69 0.64 0.52 0.69 0.69 0.69 0.69 0.69 0.64 0.52 0.69 0.69 0.64 0.52 0.69 0.69 0.69 0.69 0.69 0.69 0.69 0.69	T0 Total 14 20 14 18 19 26 24 22 167 <0.000 24 22 20 22 20 22 20 22 20 22 20 22 21 20 20 22 21 167 16 23 30 20 20 20 21 18 (20) 20 20 21 20 20 21 20 20 20 21 20 20 20 21 20 20 20 20 20 20 20 20 20 20 20 20 20	T1 Total 14 20 14 18 19 26 24 22 167 7001); ² 20 24 22 20 22 20 22 20 22 20 22 20 22 21 16 23 30 20 20 20 21 20 20 21 12 20 20 20 21 21 20 20 21 21 20 20 21 21 20 20 21 21 20 20 21 21 20 20 21 21 20 20 21 21 20 20 21 21 20 20 21 21 20 20 21 20 20 21 20 20 20 20 21 20 20 20 20 20 20 20 20 20 20 20 20 20	Weight 1.6% 3.9% 1.8% 4.6% 4.6% 4.7% 5.2% 4.7% 32.0% 2.7% 6.1% 4.7% 5.5% 3.9% 2.5% 5.5% 3.9% 2.5% 1.9% 5.5% 5.5% 4.4% 4.7% 5.5% 6.1% 4.7% 6.1% 6.1% 6.1% 6.2% 6.1% 6.1% 6.2% 6.1% 6.1% 6.2% 6.1% 6.1% 6.1% 6.1% 6.2% 6.2	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.54] 2013 9.00 [5.47, 12.53] 2013 2.80 [1.78, 3.82] 2014 3.20 [1.85, 4.55] 2015 0.00 [5.47, 12.53] 2013 3.00 [2.41, 3.59] 2016 0.10 [-7.58, 7.78] 2019 0.10 [-1.15, 1.35] 2022 2.37 [1.26, 3.49] 2014 1.53 [1.14, 1.92] 2015 3.85 [2.56, 5.14] 2017 2.93 [2.11, 3.76] 2018 3.68 [1.33, 6.03] 2018 3.68 [1.33, 6.03] 2018 3.68 [1.33, 6.03] 2018 3.69 [.03, 5.94] 2019 1.86 [1.04, 2.68] 2020 1.86 [1.44, 4.40] 2021 2.85 [-0.49, 5.94] 2021 2.48 [-1.44, 4.40] 2021 0.28 [-1.13, 1.69] 2021 2.48 [-0.46, 9.18] 2021 3.00 [2.75, 3.85] 2022 3.00 [3.56, 6.60] 2022 0.80 [3.58, 6.60] 2022	Mean Difference IV, Random, 95% CI
b Study or Subgroup 2 TAD2 Sar et al. 2013a Suzuki et al. 2013 Sar et al. 2013a Suzuki et al. 2014 Caprioglio et al. 2015 Miresmaelli et al. 2016 Cozzani et al. 2016 Cozzani et al. 2017 Miresmaelli et al. 2017 Subtotal (95% CI) Heterogeneily: Tau² = 1. Test for overall effect: Z D'ADD Altieri et al. 2017 Sade et al 2018 Lee et al 2018 Dark et al 2019 Alfaifi et al 2020 Chou et al 2021 Jung et al 2021b Park et al 2021b Park et al 2021b Park et al 2021b Dark	nces: Chi ² = 0.03. d Mean Difference 1.65 1.8 9 2.8 3.2 0.6 3.3 0.1 0.1 85; Chi ² = 37.54, df = 4.16 (P < 0.0001) 3.42 1.53 3.85 2.93 2.93 2.93 3.68 3.07 2.35 0.93 1.86 1.48 0.94 4.36 3.3 5.09 0.8 2.1; Chi ² = 101.58, d = 7.09 (P < 0.00001) 27; Chi ² = 146.78, d = 8.40 (P < 0.00001)	f = 1 (f SE 1.94 0.89 1.8 0.69 0.84 0.69 0.84 0.69 0.84 0.69 0.64 = 8 (P 1.29 0.2 0.66 0.42 0.89 1.4 0.42 0.42 0.42 0.42 1.69 0.42 0.42 0.42 1.69 0.42 0.42 0.42 1.69 0.42 0.42 0.49 0.42 0.42 0.49 1.49 0.72 0.63 0.77 0.2 f = 17) f = 26)	T0 Total 14 20 14 18 19 26 24 22 167 < 0.000 20 22 20 22 20 22 20 22 20 22 21 16 23 30 20 20 21 20 20 21 20 20 20 21 20 20 20 21 20 20 20 20 20 20 20 20 20 20 20 20 20	T1 Total 14 20 14 18 19 26 24 22 167 7001); l ² 20 24 22 20 22 20 22 20 22 20 22 20 22 21 16 23 30 20 20 20 22 17 16 24 32 30 20 20 20 20 20 22 20 20 20 20 20 20 20	Weight 1.6% 3.9% 1.8% 4.6% 4.6% 4.6% 4.7% 32.0% 5.5% 32.0% 2.7% 6.1% 5.5% 3.9% 1.9% 2.5% 4.4% 4.8% 1.7% 5.5% 4.4% 1.7% 5.5% 4.4% 1.7% 5.5% 1.7% 5.5% 1.7% 5.5% 1.7% 5.5% 1.7% 5.7% 1.7% 5.5% 1.7% 1.7% 5.5% 1.7% 1.7% 5.5% 1.7% 1.	IV, Random, 95% CI Year 1.65 [-2.15, 5.45] 2013 1.80 [0.06, 3.54] 2013 9.00 [5.47, 12.53] 2013 2.80 [1.78, 3.82] 2014 3.20 [1.85, 4.55] 2015 0.00 [5.47, 12.53] 2013 3.00 [2.41, 3.59] 2016 0.10 [-7.58, 7.78] 2019 0.10 [-1.15, 1.35] 2022 2.37 [1.26, 3.49] 2014 1.53 [1.14, 1.92] 2015 3.85 [2.56, 5.14] 2017 2.93 [2.11, 3.76] 2018 3.68 [1.33, 6.03] 2018 3.68 [1.33, 6.03] 2018 3.68 [1.33, 6.03] 2018 3.69 [.03, 5.94] 2019 1.86 [1.04, 2.68] 2020 1.86 [1.44, 4.40] 2021 2.85 [-0.49, 5.94] 2021 2.48 [-1.44, 4.40] 2021 0.28 [-1.13, 1.69] 2021 2.48 [-0.46, 9.18] 2021 3.00 [2.75, 3.85] 2022 3.00 [3.56, 6.60] 2022 0.80 [3.58, 6.60] 2022	Mean Difference IV, Random, 95% CI

Figure 3. Forest plot of U6 distalization (a), tipping (b), and vertical movement (c) of the 2-TAD and 3-TAD subgroups.

			то	T1		Mean Difference		Mean Difference
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
2 TADs								
Suzuki et al. 2013	-1	0.18	20	20	4.1%	-1.00 [-1.35, -0.65]	2013	-
Cozzani et al. 2014	0.7	0.45	18	18	3.3%	0.70 [-0.18, 1.58]	2014	+
Miresmaelli et al. 2015	-0.53	0.11	26	26	4.2%	-0.53 [-0.75, -0.31]	2015	-
Caprioglio et al. 2015	0.3	0.18	19	19	4.1%	0.30 [-0.05, 0.65]	2015	
Cozzani et al. 2016b	0.2	0.06	24	24	4.3%	0.20 [0.08, 0.32]	2016	-
Duran et al. 2016	-0.59	0.11	21	21	4.2%	-0.59 [-0.81, -0.37]	2016	-
Cambiano et al. 2017	-0.74	0.16	18	18	4.1%	-0.74 [-1.05, -0.43]	2017	-
Kircali et al. 2018	-0.6	0.22	20	20	4.0%	-0.60 [-1.03, -0.17]	2018	
Cassetta et al. 2019	-0.9	0.06	10	10	4.3%	-0.90 [-1.02, -0.78]	2019	-
Altieri et al. 2022	0.6	0.13	22	22	4.2%	0.60 [0.35, 0.85]	2022	-
Subtotal (95% CI)			198	198	40.6%	-0.29 [-0.68, 0.10]		•
Heterogeneity: Tau ² = 0.	36; Chi ² = 267.61, d	f = 9 (F	> < 0.00	0001); I	² = 97%			
Test for overall effect: Z	= 1.44 (P = 0.15)							
3 TADs								
Kook et al 2014	-1.75	0.3	20	20	3.8%	-1.75 [-2.34, -1.16]	2014	
Sa'aed et al 2015	-1.66		24	24	4.2%	-1.66 [-1.88, -1.44]		-
Park et al 2017	-2.53	0.3	22	22	3.8%	-2.53 [-3.12, -1.94]		
Jo et al 2018	-1.31	0.3	20	20	3.8%	-1.31 [-1.90, -0.72]		
Lee et al 2018a	-1.64		22	22	3.3%	-1.64 [-2.50, -0.78]		
Park et al 2018a	-1.02	0.4	17	17	3.4%	-1.02 [-1.80, -0.24]		
Park et al 2018b	-1.41		16	16	3.1%	-1.41 [-2.41, -0.41]		
Lee et al 2019	-0.35		20	20	3.2%	-0.35 [-1.27, 0.57]		
Shoaib et al 2019	1.42		23	23	4.0%	1.42 [0.97, 1.87]		
Alfaifi et al 2020		0.31	21	21	3.7%	1.60 [0.99, 2.21]		
Chou et al 2021	-0.25		20	20	2.2%	-0.25 [-1.78, 1.28]		
Jung et al 2021a	-0.57		20	20	3.4%	-0.57 [-1.39, 0.25]		
Jung et al 2021b	-0.15		20	20	3.5%	-0.15 [-0.91, 0.61]		
Park et al 2021b	-0.04		15	15	2.6%	-0.04 [-1.31, 1.23]		
Park et al 2021c	-0.95		12	12	2.3%	-0.95 [-2.40, 0.50]		
Lim et al. 2022		0.74	24	24	2.4%	-2.60 [-4.03, -1.17]		
Kim et al. 2022	-2.53		30	30	3.3%	-2.53 [-3.39, -1.67]		
Alfawaz et al 2022		0.36	25	25	3.6%	-1.30 [-2.01, -0.59]		
Subtotal (95% CI)	-1.5	0.00	371	371	59.4%	-0.94 [-1.57, -0.31]	LULL	•
Heterogeneity: Tau ² = 1.	67: Chi ² = 280.54, d	f = 17	(P < 0.0	00001):				
Test for overall effect: Z								
Total (95% CI)			569	569	100.0%	-0.66 [-0.99, -0.34]		•
Heterogeneity: Tau ² = 0.	65; Chi ² = 634.38, d	f = 27	(P < 0.0	00001):	l ² = 96%			
Test for overall effect: Z								-4 -2 0 2
Test for subgroup differe		f = 1/F	P = 0.09	(a) $l^2 = 6$	56.3%			intrusion extrusion

Figure 3. (Continued)

 $(l^2 = 96\%)$; no significant difference in intrusion (*P* = .09) was found between devices with 2 TADs (-0.29 mm; 95% CI, [-0.68, 0.10]; *P* < .0001; $l^2 = 97\%$) and those with 3 TADs (-0.94 mm; 95% CI, [-1.57, -0.31]; *P* < .0001; $l^2 = 94\%$).

Treatment comparison between rigid and nonrigid TAD-supported appliances. Figure 4 shows the comparison between rigid and nonrigid appliances in terms of distalization, tipping, and vertical movement. High heterogeneity ($I^2 = 87\%$) and no significant differences (P = .63) between the nonrigid (3.61 mm; 95% Cl, [2.85, 4.38]; P < .0001; $I^2 = 77\%$) and rigid (3.85 mm; 95% Cl, [3.27, 4.44]; P < .0001; $I^2 = 89\%$) appliances were found regarding distalization amount.

Distal tipping was significantly higher (P < .0001) in nonrigid (9.84°; 95% CI, [8.08, 11.60]; P < .0001; $I^2 = 60\%$) than in rigid (1.97°; 95% CI, [1.01, 2.92]; P < .0001; $I^2 = 71\%$) appliances, with high heterogeneity within subgroups ($I^2 = 95\%$); one study with mean values outside the mean of the group was excluded.²⁹

Finally, for vertical movements, there was considerable heterogeneity ($I^2 = 97\%$) and no significant difference (P = .06) within the nonrigid (-0.69 mm; 95% CI, [-0.95, -0.44]; P < .61; $I^2 = 0\%$) and rigid (-0.19 mm; 95% CI, [-0.64, 0.26]; P < .0001; $I^2 = 97\%$) subgroups.

DISCUSSION

TADs may reduce the need for tooth extraction for orthodontic purposes and orthognathic surgery. Maxillary molar distalization may be able to correct Class II malocclusion using different TAD-supported appliances. This review assessed the effectiveness of molar distalization based on TAD number, TAD position, and device design.

Distalization Movement

Data analysis revealed nonsignificant differences in the magnitude of distalization for the subgroup using palatal TADs (3.74 mm) compared to buccal (3.23 mm) and zygomatic (3.68 mm) TADs. Therefore, no significant clinical differences were observed among the different device positions. These results were similar to those of a 2021 review that found distalization values of 2.75 mm for buccal TADs, 4.07 mm for palatal TADs, and 4.17 mm for zygomatic anchorage.¹⁷ A 2022 systematic review also reported similar values for the distalization of molars by buccal TADs (2.44 mm) and palatal appliances (modified C-palatal plates [MCPPs]) in adults (4.00 mm) and adolescents (3.54 mm).¹⁸

One possible explanation for any differences would be that buccal TAD root proximity may be a factor limiting distalization, in contrast to extra-alveolar anchorage, which could allow greater movement. Also, palatal appliances allow force application closer to the center

	а			-						
$ \begin{array}{c} \text{Surt et al. 2015} \\ \text{Garchain out is 1.2017} & 2.46 0.38 & 16 & 16 & 4.64 & 3.572, 4.41 & 2017 \\ \text{Garchain out is 1.2017} & 4.26 0.18 & 20 & 20 & 9.87 \\ \text{Garchain ot is 1.2017} & 4.26 0.18 & 20 & 20 & 9.87 \\ \text{Machand (BYC, C)} & 4.2 & 0.18 & 20 & 20 & 9.87 \\ \text{Machand (BYC, C)} & 4.2 & 0.18 & 20 & 20 & 9.87 \\ \text{Machand (BYC, C)} & 4.2 & 0.21 & 20 & 20 & 9.87 \\ \text{Machand (BYC, C)} & 4.2 & 0.21 & 20 & 20 & 20 & 9.87 \\ \text{Sund et al. 2015} & 4.2 & 0.22 & 20 & 20 & 9.87 \\ \text{Sund et al. 2015} & 2.23 & 0.7 & 14 & 14 & 5.57 \\ \text{Sund et al. 2015} & 2.23 & 0.7 & 14 & 14 & 5.57 \\ \text{Cargonization (C)} & 4.2 & 0.22 & 20 & 9.67 \\ \text{Cargonization (C)} & 4.2 & 0.22 & 20 & 9.67 \\ \text{Cargonization (C)} & 4.2 & 0.22 & 20 & 9.67 \\ \text{Cargonization (C)} & 4.2 & 0.22 & 20 & 9.67 \\ \text{Cargonization (C)} & 4.2 & 0.22 & 20 & 9.67 \\ \text{Cargonization (C)} & 4.2 & 0.22 & 20 & 9.67 \\ \text{Cargonization (C)} & 4.2 & 0.22 & 22 & 9.66 \\ \text{Cargonization (C)} & 4.2 & 0.22 & 2.2 & 9.66 \\ \text{Cargonization (C)} & 4.2 & 0.22 & 2.2 & 9.66 \\ \text{Cargonization (C)} & 4.2 & 0.22 & 2.2 & 9.66 \\ \text{Cargonization (C)} & 4.2 & 0.23 & 0.65 & 10 & 0.05 & 1.6 & 3.2 & 0.01 \\ \text{Cargonization (C)} & 4.2 & 0.23 & 0.65 & 10 & 0.05 & 1.6 & 3.2 & 0.01 \\ \text{Cargonization (C)} & 4.2 & 0.23 & 0.65 & 10 & 0.05 & 1.6 & 3.2 & 0.01 \\ \text{Cargonization (C)} & 4.2 & 0.23 & 0.65 & 10 & 0.05 & 1.6 & 3.2 & 0.01 \\ Heterogeneity: Tual = 0.65 & 0.16 & 2.7 & 0.00001 \\ \text{Text for orwall differct 2 = 1.03 & 1.6 & 0.00001 \\ \text{Text for orwall differct 2 = 1.03 & 1.6 & 0.00001 \\ \text{Text for orwall differct 2 = 1.03 & 0.6 & 1.6 & 1.7 & 1.7 & 1.0 & 0.00001 \\ \text{Text for orwall differct 2 = 1.03 & 1.6 & 0.6 & 0.6 & 2.2 & 2.27 & 1.6 & 0.0001 \\ \text{Text for orwall differct 2 = 1.03 & 0.6 & 1.6 & 1.6 & 0.0001 \\ \text{Text for orwall differct 2 = 1.03 & 0.6 & 1.6 & 1.6 & 0.0001 \\ \text{Text for orwall differct 2 = 1.03 & 0.6 & 1.6 & 1.6 & 0.0001 \\ \text{Text for orwall differct 2 = 1.03 & 0.6 & 1.6 & 1.6 & 0.0001 \\ \text{Text for orwall differct 2 = 1.03 & 0.6 & 1.6 & 1.6 & 1.6 & 0.0001 \\ \text{Text for orwall diff$	Study or Subgroup	Mean Difference	SE	T0 Total	T1 Total	Weight	Mean Difference IV, Random, 95% Cl	l Year	Mean Difference IV, Random, 95% Cl	
Combined at 2017 3.45 0.28 19 19 4.45 $(342, 124, 464, 129)$ 2017 Studied (25% C) 4.24 0.18 2.05 0.29 8.64 3.20 (2.0.85, 4.53) 2018 Studied (25% C) 4.24 0.25, df = 2 (P = 0.01); P = 77%. Test for correll difference at 2.013 4.25 0.25 2.25 0.00 0.00 (2.0.87, 4.55) 2013 Subject at 2.013 4.25 0.27 2.26 0.07 (4.14 4.55) 2.26 11.62, 4.27] 2.015 Concar at at 2.014 4.25 0.22 0.2 0.87%. 4.50 (1.85, 5.15) 2.013 Subject at 2.013 2.0 0.2 0.87%. 4.50 (1.85, 5.15) 2.013 Subject at 2.015 4.2 0.00001) Figure 3.2 0.016 4.1 0.34 2.27 2.48 0.013, 4.471 2.016 Concar at at 2.016 4.1 0.34 2.27 2.48 0.013, 4.471 2.016 4.27 Concar at at 2.016 4.1 0.34 2.27 2.48 0.013, 4.471 2.016 4.27 Concar at at 2.016 4.1 0.34 2.27 2.48 0.013, 4.471 2.016 4.27 Concar at at 2.016 4.1 0.34 2.27 2.49.5%. Subject at 2.016 4.1 0.34 2.27 2.49.5%. Subject at 2.016 4.1 0.34 2.27 2.49.5%. Subject at 2.016 4.20 0.22 4.27.5%. Test for coverall direct 2.7 15.24 (P = 0.00001); F = 0%. Test for subgroup Main Difference 5.7 174 (P = 0.630); F = 0%. Test for subgroup Main Difference 5.7 12.24 (d = 8 (P = 0.00001); F = 0%. Test for subgroup Main Difference 5.7 12.24 (d = 10.05); F = 0%. Test for subgroup Main Difference 5.7 12.24 (d = 10.05); F = 0%. Test for subgroup Main Difference 5.7 12.24 (d = 10.05); F = 0%. Test for subgroup Main Difference 5.7 12.24 (d = 10.05); F = 0%. Test for subgroup Main Difference 5.7 12.24 (d = 10.05); F = 0%. Test for subgroup Main Difference 5.7 12.24 (d = 10.05); F = 0%. Test for subgroup Main Difference 5.7 12.20 (d = 10.05); F = 0%. Test for subgroup Main Difference 5.7 12.20 (d = 10.05); F = 0%. Test for subgroup Main Difference 5.7 12.20 (d = 10.05); F = 0%. Test for subgroup Main Difference 5.7 12.20 (d = 10.05); F = 0%. Test for subgroup Main Difference 5.7 12.20 (d = 10.05); F = 0%. Test for subgroup Main Difference 5.7 12.20 (d = 10.05); F = 0%. Test for subgroup Main Difference 5.7 12.20 (d = 10.05); F = 0%. Test for subgroup Main Difference 5.7 12.20 (d = 10.05); F = 0%. Test for subg		2.93	0.47	14	14	7 4%	2 93 [2 01 3 85]	2013		
Subted (95% C) $52 ext{ s2 } 25 ext{ s2 } 25 ext{ s5 } 3.56 ext{ s2 } 25 ext{ s5 } 3.56 ext{ s2 } 3.56 $									-	
Heinogravity: $T_{mat}^{m} = 0.35, df = 2 (P = 0.01); P = 77\%$ Test for overal effect 24 = 0.20 (P < 0.0001) Figid Sucus tel al. 2013 Sucus tel al. 2013 Sucus tel al. 2013 Gased al. 2013 Correct et al. 2016 Correct et al. 2016 Cor		4.2	0.18					2018	-	
Test for overall effect $Z = 9.26 (P < 0.0001)$ Figid Suxual et al. 2013 C accent et al. 2014 C accent et al. 2014 C accent et al. 2014 C accent et al. 2015 C accent et al. 2016 C accent et al. 2017 C accent et al. 2016 C accent et al. 2016 C accent et al. 2017 C accent et al. 2016 C accent et al. 2017 C accent et al. 2018 1 al. 165 194 1 41 41 756% 1 al. 216, 215, 5, 45[2013 C accent et al. 2017 C accent et al. 2017 C accent et al. 2017 C accent et al. 2018 C acc		04: Chi2 = 0 EE df =	2 (D -				3.61 [2.85, 4.38]			
Success of al. 2013 4:5 0.33 20 20 6.7% 4:50 (35.5 15) 2015 Sare tal. 2014 4:7 0.38 18 18 2.2% 4:70 (34.5 5.40) 2014 Mineremedii et al. 2014 4:7 0.38 18 18 2.2% 4:70 (34.5 5.40) 2014 Corzari et al. 2016 4:2 0.32 22 6:8 6.6% 4:20 (35.7 4.83) 2015 Corzari et al. 2016 4:1 0.34 2:1 2:1 8.6% 4:10 (34.4, 47.7 2016 Duran et al. 2016 4:1 0.34 2:1 2:1 8.6% 4:10 (34.4, 47.7 2016 Duran et al. 2016 4:1 0.34 2:1 2:1 8.6% 4:10 (34.4, 47.7 2016 Duran et al. 2016 4:1 0.34 2:1 2:1 8.6% 4:10 (34.4, 47.7 2016 Duran et al. 2016 4:1 0.34 2:1 2:1 8.6% 4:10 (34.4, 47.7 2016 Duran et al. 2016 4:1 0.34 2:1 2:1 8.6% 4:10 (34.4, 47.7 2016 Duran et al. 2016 4:1 0.34 2:1 2:1 8.6% 4:10 (34.4, 47.7 2016 Duran et al. 2016 4:1 0.34 2:1 2:1 8.6% 4:10 (34.4, 47.7 2016 Duran et al. 2016 4:1 0.34 2:1 2:2 5:2 5:0 (35.9, 41.4) Heterogeneity: Tau" = 0.54; Ch ² = 87.13, df = 11 ($P < 0.00001$); $P = 80%$. Test for subcroue difference: Ch ² = 87.13, df = 11 ($P < 0.0000$); $P = 80%$. Test for subcroue difference: Ch ² = 0.50, $P = 0.6$. Description of al. 2017 1:2.40 0.81 18 18 19.9% 11.24 (96.1; 2.33) 2013 Correspondence at al. 2016 9:0 0.0001) $P = 77\%$. Test for subcroue difference: Ch ² = 0.00, $P = 60\%$. Test for subcroue difference: Ch ² = 5.66, df = 2 ($P = 0.00$); $P = 60\%$. Test for subcroue difference: Ch ² = 5.66, df = 2 ($P = 0.00$); $P = 7\%$. Test for subcroue difference: Ch ² = 5.66, df = 2 ($P = 0.000$); $P = 7\%$. Test for subcroue difference: Ch ² = 5.66, df = 2 ($P = 0.00001$); $P = 7\%$. Test for subcroue difference: Ch ² = 5.66, df = 2 ($P = 0.00001$); $P = 7\%$. Test for coveral effect Z = 1.05 ($P < 0.00001$); $P = 7\%$. Test for coveral effect Z = 1.05 ($P < 0.00001$); $P = 7\%$. Test for coveral effect Z = 1.05 ($P < 0.00001$); $P = 7\%$. Test for coveral effect Z = 1.05 ($P < 0.00001$); $P = 7\%$. Test for coveral effect Z = 1.05 ($P < 0.00001$); $P = 7\%$. Test for coveral effect Z = 1.05 ($P < 0.00001$); $P = 7\%$. Test for coveral effect Z = 1.05 ($P < 0.00001$); $P = 7\%$. Test for coveral eff				0.01),		/0				
Sar et al. 2013a 2.81 0.7 14 14 5.5% 2.81 [1.44, 4.19] 2013 Cozzari et al. 2015 2.3 0.27 2.6 2.6 9.6% 2.30 [1.47, 2.73] 2015 Cozzari et al. 2015 2.3 0.22 2.6 2.6 9.6% 2.30 [1.47, 2.73] 2015 Cozzari et al. 2015 3.2 0.14 2.4 2.4 10.1% 3.20 [2.33, 3.47] 2016 Cozzari et al. 2015 3.2 0.14 2.4 2.4 10.1% 3.20 [2.33, 3.47] 2016 Cozzari et al. 2016 3.2 0.14 2.4 2.4 10.1% 3.20 [2.33, 3.47] 2016 Cozzari et al. 2017 3.0 0.26 2.2 2.2 0.3% 3.30 [3.30, 4.1] 2022 Subtotal (95% CI) 174 7 4.74, 4.4 Hetrogeneity: Tat' = 0.25, Ch' = 27.14, d' = 0 (P < 0.0001); P = 09% Test for output field: $Z = 12.7 (P < 0.00001);$ P = 09% Test for output field: $Z = 12.7 (P < 0.00001);$ P = 09% Test for output field: $Z = 12.7 (P < 0.00001);$ P = 00% Test for output field: $Z = 12.7 (P < 0.00001);$ P = 00% Test for output field: $Z = 12.7 (P < 0.00001);$ P = 00% Test for output field: $Z = 12.7 (P < 0.00001);$ P = 00% Test for output field: $Z = 12.7 (P < 0.00001);$ P = 00% Test for output field: $Z = 12.7 (P < 0.00001);$ P = 00% Test for output field: $Z = 12.7 (P < 0.00001);$ P = 00% Test for output field: $Z = 12.0 (P = 0.03);$ P = 0.0% Test for output field: $Z = 12.0 (P = 0.03);$ P = 0.0% Test for output field: $Z = 12.0 (P = 0.03);$ P = 0.0% Test for output field: $Z = 10.5 (P < 0.00001);$ P = 0.0% Test for output field: $Z = 10.5 (P < 0.00001);$ P = 0.0% Test for output field: $Z = 10.5 (P < 0.00001);$ P = 0.0% Test for output field: $Z = 10.5 (P < 0.00001);$ P = 0.0% Test for output field: $Z = 10.5 (P < 0.00001);$ P = 0.0% Test for output field: $Z = 10.5 (P < 0.00001);$ P = 0.0% Test for output field: $Z = 10.5 (P < 0.00001);$ P = 0.0% Test for output field: $Z = 10.5 (P < 0.00001);$ P = 0.0% Test for output field: $Z = 1.0 (P < 0.0001);$ P = 0.0% Test for output field: $Z = 1.0 (P < 0.0001);$ P = 0.0% Test for output field: $Z = 1.0 (P < 0.0001);$ P = 0.0% Test for output field: $Z = 1.0 (P < 0.0001);$ P = 0.0% Test for output field: $Z = 2.0 (P < 0.0001);$ P = 0.0% Test for output field: $Z = 0.000;$										
$ \begin{array}{c} \text{Cozzari et al. 2014} & 4.7 & 0.38 & 18 & 18 & 2% & 4.70 [3.86, 5.4] 2014 \\ \text{Meramalii et al. 2015} & 4.2 & 0.32 & 12 & 2.30 [1.87, 7.37] 2015 \\ \text{Capricigio et al. 2015} & 4.2 & 0.32 & 12 & 12 & 8.6\% & 4.20 [3.87, 4.83] 2015 \\ \text{Capricigio et al. 2016} & 4.1 & 0.34 & 2.1 & 21 & 8.6\% & 4.20 [3.83, 4.77] 2016 \\ \text{Carsenta et al. 2016} & 4.1 & 0.34 & 2.1 & 21 & 8.6\% & 4.10 [3.43, 4.77] 2016 \\ \text{Carsenta et al. 2016} & 3.3 & 0.26 & 1.20 & 2.5 & 5.30 [4.01, 6.50] 2029 \\ \text{Subbotal (95% C)} & 3.5 & 0.26 & 1.20 & 2.5 & 5.30 [4.01, 6.50] 2029 \\ Test for overall effect: 2 = 12.87 (P < 0.00001); P = 0.0001; P = 0.0000; P = 0.0000;$										
$ \begin{array}{c} \text{Mean Difference} \\ \hline \text{Corporality of al. 2015} & 2.3 & 0.22 & 2.6 & 2.6 & 96\% \\ \text{Capriciple of al. 2015} & 3.2 & 0.14 & 2.4 & 2.0 & 1.14 & 3.23 & 2.015 \\ \hline \text{Corporality of al. 2016} & 3.2 & 0.14 & 2.4 & 2.4 & 10.1\% & 3.20 & 2.23 & 3.47 & 2016 \\ \hline \text{Corporality of al. 2016} & 3.2 & 0.14 & 2.4 & 2.4 & 10.1\% & 3.20 & 2.23 & 3.47 & 2016 \\ \hline \text{Cassetta et al. 2019} & 5.3 & 0.66 & 10 & 10 & 5.8\% & 5.30 & (4.01, 5.69) & 2019 \\ \hline \text{Alterin et al. 2016} & 3.2 & 0.14 & 2.4 & 2.4 & 10.1\% & 3.20 & 2.23 & 3.47 & 2016 \\ \hline \text{Cassetta et al. 2019} & 5.3 & 0.66 & 10 & 10 & 5.8\% & 5.30 & (4.01, 5.69) & 2019 \\ \hline \text{Mean contrast (5C)} & 2.26 & 2.26 & 100.0\% & 3.03 & [3.27, 4.41] & 1222 & 2.6 & 3.5\% \\ \hline \text{Test for overall effect.} Z = 1.257 (P < 0.00001) \\ \hline \text{Test for overall effect.} Z = 1.247 (P < 0.00001) \\ \hline \text{Test for overall effect.} Z = 1.54 (P < 0.00001) \\ \hline \text{Test for overall effect.} Z = 1.54 (P < 0.00001) \\ \hline \text{Test for overall effect.} Z = 1.54 (P < 0.00001) \\ \hline \text{Test for overall effect.} Z = 1.54 (P < 0.00001) \\ \hline \text{Test for overall effect.} Z = 1.54 (P < 0.0001) \\ \hline \text{Test for overall effect.} Z = 1.54 (P < 0.00001) \\ \hline \text{Test for overall effect.} Z = 1.54 (P < 0.0001) \\ \hline \text{Test for overall effect.} Z = 1.54 (P < 0.0001) \\ \hline \text{Test for overall effect.} Z = 1.54 (P < 0.0001) \\ \hline \text{Test for overall effect.} Z = 1.00 & S (P < 0.0001) \\ \hline \text{Test for overall effect.} Z = 1.00 & S (P < 0.0001) \\ \hline \text{Test for overall effect.} Z = 1.00 & S (P < 0.0001) \\ \hline \text{Test for overall effect.} Z = 1.00 & S (P < 0.0001) \\ \hline \text{Test for overall effect.} Z = 1.00 & S (P < 0.0001) \\ \hline \text{Test for overall effect.} Z = 1.00 & S (P < 0.0001) \\ \hline \text{Test for overall effect.} Z = 3.02 & S & 2.2 & 2.7 & 3.6\% \\ \hline \text{Corporality for all 2.015 & 3.2 & 0.65 & 1.14 & 14 & 7.6\% \\ \hline \text{Test for overall effect.} Z = 3.02 & C & 1.15 & 0.2 & 2.0 & 2.7 & 3.0\% \\ \hline \text{Test for overall effect.} Z = 1.00 & S & 0.001 & 0.2 & 7.7 & 3.015 \\ \hline Corporality for all 2.015 & 0.05 & 0.15 & 3.2 & 0.05 & 1.10 & 0.05 & 3.011 & 1.05 & 0.05 & 0.01 & 0.001 & 0.01$										
$ \begin{array}{c} \text{Cozzari et al. 2016b} & 3.2 \ 0.14 \ 24 \ 24 \ 10.1\% \ 3.20 \ [2.33, 3.47 \ 2016 \ \hline \\ \text{Caseatta et al. 2016} & 4.10 \ (3.4, 10, 24, 17, 2016 \ \hline \\ \text{Caseatta et al. 2019} & 5.3 \ 0.66 \ 10 \ 10 \ 5.6\% \ 5.30 \ (4.01, 5.59 \ 2019 \ 10.0\% \ 10.00001 \)^{\mu} = 83\% \ 10.000001 \)^{\mu} = 83\% \ 10.0000001 \)^{\mu} = 10.000001 \)^{\mu} = 10.000001 \)^{\mu} = 10.000001 \)^{\mu} = 10.0000001 \)^{\mu} = 10.000001 \)^{\mu} = 10.000001 \)^{\mu} = 10.0000001 \)^{\mu} = 10.0000000000000000000000000000000000$									-	
Duran et al. 2016 4.1 0.34 21 21 8.6% 4.10 [3.43, 4.77] 2016 Cassetta et al. 2019 5.0 6.6 $Ch^{2} = 27.14$, $d = 8 (P < 0.00001)$, $P = 85\%$ Test for evenil effect. 2 = 1.27 ($P < 0.00001$) Test for $P = 0.65$, $Ch^{2} = 27.14$, $d = 8 (P < 0.00001)$, $P = 85\%$ Test for $P = 0.65$, $Ch^{2} = 27.14$, $d = 8 (P < 0.00001)$, $P = 85\%$ Test for $P = 0.65$, $Ch^{2} = 27.14$, $d = 8 (P < 0.00001)$, $P = 85\%$ Test for $P = 0.65$, $Ch^{2} = 67.13$, $d = 11 (P = 0.030)$, $P = 0\%$ b b b c b c c c b c c c b c c c b c c c c d c d c d c c d c d c d c d c d c d c d c d c d c d c d c d c d c d d d d d d d d									-	
Casestia et al. 2019 5.3 0.66 10 10 5.8% 5.30 [4.01, 6.59] 2019 Alteri et al. 2022 39 0.26 22 29 0.3% 3.30 [3.38, 4.41] 2022 Subtotal [95% C] Heterogeneity: Tau" = 0.6; ChF = 72.14, df = 8 (F < 0.00001); F = 89% Test for overall effect: Z = 12.87 (P < 0.00001) = 87% Test for overall effect: Z = 13.84 (P < 0.00001) = 87% Test for overall effect: Z = 13.84 (P < 0.00001) = 87% Test for overall effect: Z = 13.84 (P < 0.00001) = 87% Test for overall effect: Z = 13.84 (P < 0.00001) = 87% Test for overall effect: Z = 10.9.6 (P < 0.0301) = 0.0001; J = 0.05, J = 0.000 Test for subcroup difference: ChF = 0.23, J = 1 (P = 0.63), P = 0% Test for subcroup difference: SChF = 0.23, J = 1 (P = 0.63), P = 0% Test for subcroup difference: SChF = 0.23, J = 1 (P = 0.63), P = 0% Test for subcroup difference: SChF = 0.26, J = 2 (P = 0.08); P = 0% Test for subcroup difference: SChF = 0.20, J = 1 (P = 0.63), P = 0% Test for subcroup difference: SChF = 0.20, J = 0 (D = 0.67, 12.53) 2013 Carrelia 12.018 50, Gf = 2 (P = 0.08); P = 0% Test for overall effect: Z = 10.95 (P < 0.00001); T = 95% Subcroup difference: SChF = 0.22, J = 1 (P = 0.08); P = 0% Test for overall effect: Z = 10.95 (P < 0.00001); P = 96% Test for overall effect: Z = 10.95 (P < 0.00001); T = 15, 22, 22, 21, 3% Suck i et al. 2013 1.8 0.89 20 20 9.7% 1.86 [5.2.15, 5.45] 2013 Suck i et al. 2013 0.8 4.24 10.4% 3.00 [2.41, 3.59] 2016 Cozzari et al. 2014 0.8 2.0 66, 14 2 (P < 0.0001); T = 15, 32 (2.016, 3.54] 2013 Cozzari et al. 2015 0.6 0.84 22 62 8.8% 0.00(-1.05, 2.25) 2015 Cozzari et al. 2014 0.1 3.20 16 0.1 3.22 0.06 1.9 10.000; J = 10, 10, 10, 11, 51, 152 2022 Meterogeneity: Tau" = 1.11; ChF = 2.43, af = 7 (P < 0.0001); T = 71% Test for overall effect: Z = 4.02 (P < 0.0001); T = 71% Test for overall effect: Z = 4.02 (P < 0.0001); T = 9.83; C C Carrenti et al. 2017 0.7 (A = 16 (P < 0.0001); P = 08; Test for overall effect: Z = 4.02 (P < 0.0001); T = 71% Test for overall effect: Z = 5.34 (P < 0.00001); T = 70% Test for overall effect: Z = 5.34 (P < 0.00001); T = 0.05%, 0.7									· · ·	
Alter et al. 2022 3.9 0.26 2.2 2.2 9.3% 3.30 (3.39, 4.41) 2022 3.36 (3.27, 4.44) Heterogeneity: Tau" = 0.36; Ch ² = 7.21.4, d = 8 ($P < 0.00001$); $P = 80\%$ Test for overall effect. Z = 1.287 ($P < 0.00001$); $P = 0.0\%$ Total (95% C) 2.267 ($P < 0.00001$); $P = 0.0\%$ Subtotal (95% C) 3.78 (3.31, 4.24) Heterogeneity: Tau" = 0.23, df = 1 ($P = 0.03$); $P = 0\%$ So T 1 Mean Difference Study or Subgroup Mean Difference S Ch ² = 0.23, df = 1 ($P = 0.03$); $P = 0\%$ Nonrigid Survei at al. 2018 9 1.8 14 14 7.9% 9.00 (5.47, 12.53) 2013 Cambian et al. 2017 11.24 0.81 18 18 9.9% 11.24 (9.65, 12.83) 2017 Kincal et al. 2018 9 0.66 2.2 0 10.0% 1.80 (1.60) Heterogeneity: Tau" = 0.30; Ch ² = 5.06, df = 2 ($P < 0.0001$); $P = 0\%$ Near Difference Nonrigid Survei at al. 2013 9 1.8 14 14 7.9% 9.00 (5.47, 12.53) 2013 Cambian et al. 2017 11.24 0.81 18 18 9.9% 11.24 (9.65, 12.83) 2017 Kincal et al. 2018 9 0.66 2.2 0 2.0 10.0% 8.80 (7.53, 12.25) 2018 Survei et al. 2013 16 0.69 4.2 2.0 0.00% 1.80 (0.63, 3.42) 2013 Corract et al. 2013 16 0.69 0.2 0.0 9.7% 1.80 (0.60, 3.42) 2013 Corract et al. 2015 0.2 0.46 (f $\approx 2 (P < 0.0001$); $P = 0\%$ Test for overall effect: Z = 1.04, C ($P < 0.0001$); $P = 0\%$ Test for overall effect: Z = 4.02 ($P < 0.0001$); $P = 0\%$ Test for overall effect: Z = 4.02 ($P < 0.0001$); $P = 0\%$ Test for overall effect: Z = 4.02 ($P < 0.0001$); $P = 0\%$ Test for overall effect: Z = 4.02 ($P < 0.0001$); $P = 0\%$ Test for overall effect: Z = 4.02 ($P < 0.0001$); $P = 0\%$ Test for overall effect: Z = 4.02 ($P < 0.0001$); $P = 0\%$ Test for overall effect: Z = 4.02 ($P < 0.0001$); $P = 0\%$ Test for overall effect: Z = 4.02 ($P < 0.0001$); $P = 0\%$ Test for overall effect: Z = 4.02 ($P < 0.0001$); $P = 0\%$ Test for overall effect: Z = 4.02 ($P < 0.0001$); $P = 0\%$ Test for overall effect: Z = 4.02 ($P < 0.0001$); $P = 0\%$ Test for overall effect: Z = 4.02 ($P < 0.0001$); $P = 0\%$ Test for overall effect: Z = 4.02 ($P < 0.0001$); $P = 0\%$ Test for overall effect: Z = 5.04 ($P < 0.0001$);										
Heiserogeneity: Tayl = 0.68; ChF = 72, 14, df = 6 ($P < 0.00001$); P = 89% Test for overall effect: Z = 12.87 ($P < 0.00001$); C = 80% Test for overall effect: Z = 12.87 ($P < 0.00001$); P = 80% Test for overall effect: Z = 12.87 ($P < 0.00001$); P = 0.03); P = 0.05 Test for overall effect: Z = 13.94 ($P < 0.00001$); P = 0.05 Test for overall effect: Z = 13.94 ($P < 0.00001$); P = 0.05 Test for overall effect: Z = 13.94 ($P < 0.00001$); P = 0.05 Test for overall effect: Z = 13.94 ($P < 0.00001$); P = 0.05 Test for overall effect: Z = 13.94 ($P < 0.0001$); P = 0.05 Subd or Subgroup Mean Difference SE Total Total Weight (V , Random, 95% CI Year Nonrigid Sar et al. 2018 0.9 ($A = 0.00001$); P = 0.05 Heiterogeneity: Tayl = 0.39; CP < 0.0001 Rigid Sar et al. 2013 1.9 1.8 144 14 7.6% Test for overall effect: Z = 10.95 ($P < 0.0001$); P = 0.06 Heiterogeneity: Tayl = 1.39; ChF = 5.06, df = 2 ($P < 0.0001$); P = 0.06 Heiterogeneity: Tayl = 1.39; ChF = 5.06, df = 2 ($P < 0.0001$); P = 0.06 Test for overall effect: Z = 10.95 ($P < 0.00001$); P = 0.06 Heiterogeneity: Tayl = 1.39; ChF = 24.38, df = 7 ($P = 0.0001$); P = 0.06 Test for overall effect: Z = 4.02 ($P < 0.0001$); P = 0.06 Test for overall effect: Z = 4.02 ($P < 0.0001$); P = 0.06 Test for overall effect: Z = 4.02 ($P < 0.0001$); P = 0.05 Test for overall effect: Z = 4.02 ($P < 0.0001$); P = 95.% Test for overall effect: Z = 4.02 ($P < 0.0001$); P = 95.% Test for overall effect: Z = 4.02 ($P < 0.0001$); P = 95.% Test for overall effect: Z = 4.02 ($P < 0.0001$); P = 95.% Test for overall effect: Z = 4.02 ($P < 0.0001$); P = 0.0000; P = 95.% Test for overall effect: Z = 4.02 ($P < 0.0001$); P = 95.% Test for overall effect: Z = 4.02 ($P < 0.0001$); P = 0.0000; P = 95.% Test for overall effect: Z = 4.02 ($P < 0.0001$); P = 0.0000; P =				22		9.3%	3.90 [3.39, 4.41]			
Test for overall effect: $Z = 12.87$ ($P < 0.0001$) Total (9% C) Test for overall effect: $Z = 12.87$ ($P < 0.00001$): $P = 67\%$ Test for overall effect: $Z = 15.94$ ($P < 0.00001$): $P = 67\%$ Test for overall effect: $Z = 15.94$ ($P < 0.00001$): $P = 0.63$); $P = 0\%$ b Test for overall effect: $Z = 15.94$ ($P < 0.00001$): $P = 0.63$); $P = 0\%$ b Test for overall effect: $Z = 15.94$ ($P < 0.00001$): $P = 0.63$); $P = 0\%$ b To T1 Mean Difference b Norrigid Sare it al. 2013b Subtotal (9% C) b c f f f f f f f f							3.85 [3.27, 4.44]		•	
Heterogeneity: Tau ² = 0.54: Ch ² = 87.3, df = 11 ($P < 0.00001$); $P = 87\%$ Test for overall effect: Z = 15.4 ($P < 0.00001$) Test for subgroup differences: Ch ² = 0.23, df = 1 ($P = 0.63$); $P = 0\%$ b b b b b c b c b c c c c c c c c				< 0.000	001); I²	= 89%				
Test for overall effect: $Z = 15.94 (P < 0.0001)$ Test for subgroup differences: $Ch^{2} = 0.23$, $df = 1 (P = 0.63)$, $P = 0\%$ b b c s b c s c s c s c s c s c s c s c s c s c s c s c s c s c s c s c s c s c s c s c s c s c s c s c s c s c c s c c s c c s c c s c c s c c c s c c c c s c c c c c c c c		54: Chi ² = 87 13 df	= 11 /6				3.78 [3.31, 4.24]		→	
	Test for overall effect: Z =	= 15.94 (P < 0.0000	1)							
Study or Subgroup Mean Difference SE Total Total Weight IV, Random, 95%, CI Year IV, Random, 95%, CI Nonrigid Sar et al. 2013b 9 1.8 14 14 7.9% 9.00 [5.47, 12.53] 2013 Cambiano et al. 2017 11.24 0.81 18 9.9% 11.24 [9.65, 12.83] 2017 Krcali et al. 2018 8.9 0.69 20 20 10.0% 8.90 (755, 10.29] 2018 Subtotal (65% CI) 1.85 1.94 1.4 7.6% 1.65 [-2.15, 5.45] 2013 Cozzari et al. 2013 1.85 1.94 1.4 7.6% 1.65 [-2.15, 5.45] 2013 Suzuki et al. 2013 1.85 1.94 1.4 7.6% 1.65 [-2.15, 5.45] 2013 Cozzari et al. 2016 0.6 0.84 26 9.8% 0.060 [-1.05, 2.25] 2015 Cozzari et al. 2016 3 0.68 19 19 10.07, 53, 7.78 2018 4.01 [7.58, 7.78] 2019 Atter et al. 2016 0.1 0.42	1	nces. Oni - 0.23, 0		- 0.83	,,,,·=(/0				
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	-	Maan D'4				Materia		V-		
Sar et al. 2013b P = 1.8 14 14 7,9% P = 0.05 (27, 12.53) 2013 P = 0.05 (27, 12.53) 2017 P = 0.05 (75, 10.25) 2018 P = 0.08 (755, 10.25) 2015 C = 0.01015 P = 0.01016 P = 0.00101; P = 0.0101; P = 0.010; P = 0.001; P = 0.0101; P = 0.010; P = 0.001; P = 0.010; P = 0.0001; P = 0.010; P = 0.001; P = 0.000; P = 0.001; P = 0.000; P = 0.000; P = 0.000; P = 0.000; P =		wean Difference	SE	Iotal	rotal	weight	iv, Random, 95% C	rear	IV, Kandom, 95% Cl	
Cambiano et al. 2017 tircait et al. 2018 Subtotal (95% CI) Rigid Sar et al. 2013 Suzuki et al. 2013 Suzuki et al. 2013 Suzuki et al. 2013 Suzuki et al. 2013 Cozzani et al. 2014 Cozzani et al. 2015 Cozzani et al. 2015 Cozzani et al. 2016 Suzuki et al. 2017 Cozzani et al. 2017 Suzuki et al. 2017 Cozzani et al. 2018 Suzuki et al. 2017 Cozzani et al. 2019 Total (95% CI) Total (9		9	1.8	14	14	7.9%	9.00 [5.47, 12.53]	2013		
Subtotal (95% CI) 52 52 27.8% 9.84 (\$0.8, 11.60) Heterogeneity: Tau ² = 1.39; Ch ² = 5.06, df = 2 (P = 0.08); P = 60% Test for overall effect: Z = 10.95 (P < 0.00001) Rigid Surval: et al. 2013 1.8 0.9 20 20 9.7%, 1.65 [2.15, 5.45] 2013 Capricipito et al. 2014 2.8 0.52 18 18 10.2% 2.80 (1.78, 3.82) 2014 Miresmaelli et al. 2015 0.6 0.44 26 9.8%, 0.60 [1-105, 2.55] 2015 Caparoglio et al. 2015 3.2 0.69 19 19 10.0%, 3.20 [1.85, 4.55] 2015 Caparoglio et al. 2015 3.2 0.69 19 19 10.0%, 3.20 [1.85, 4.55] 2015 Caparoglio et al. 2015 3.2 0.69 19 19 10.0%, 3.20 [1.85, 4.55] 2015 Caparoglio et al. 2016 3 0.3 24 24 10.4% 3.00 [2.41, 3.59] 2016 Cassette at al. 2019 0.1 3.82 10 10 4.1% 0.10 [7.58, 7.78] 2019 Altieri et al. 2022 0.1 0.64 22 22 10.1% 0.10 [7.15, 7.38] 2019 Altieri et al. 2022 0.1 0.64 122 22 21 10.1% 0.10 [7.15, 7.38] 2019 Heterogeneity: Tau ² = 9.96; Ch ² = 212.10, df = 10 (P < 0.00001); P = 71% Test for overall effect: Z = 3.32 (P < 0.0001) Total (95% CI) 205 205 100.0% Heterogeneity: Tau ² = 9.96; Ch ² = 212.10, df = 10 (P < 0.00001); P = 95% Test for overall effect: Z = 3.32 (P < 0.00001) Total (95% CI) 205 205 df = 1 (P < 0.00001); P = 95% Test for overall effect: Z = 3.32 (P < 0.00001) Total (95% CI) 0.026 38 38 19.8% 0.69 [-0.95, 0.44] Heterogeneity: Tau ² = 0.05; Ch ² = 0.28, df = 1 (P < 0.61); P = 0% Test for overall effect: Z = 5.34 (P < 0.00001) Rigid Suzuki et al. 2013 -1 0.18 20 20 10.0% -1.00 [-1.35, -0.65] 2013 Cozari et al. 2015 0.3 0.18 19 19 10.0% 0.30 [-0.05, 0.65] 2013 Cozari et al. 2015 0.3 0.18 19 19 10.0% 0.30 [-0.05, 0.65] 2013 Cozari et al. 2015 0.53 0.11 26 26 10.6% -0.59 [-0.13, 2.07] 2016 Altier i et al. 2015 0.53 0.11 26 20 10.0% -1.00 [-1.35, -0.65] 2013 Cozari et al. 2015 0.53 0.11 26 20 10.0% -0.59 [-0.13, 2.07] 2016 Altier i et al. 2015 0.53 0.11 26 20 10.0% -0.59 [-0.13, 2.07] 2016 Cassetta et al. 2015 0.50 0.50 0.11 22 (2 10.68, 0.59 [-0.28, 2.01] 2015 Cassetta et al. 2016 0.02 0.06 24 4 10.8% 0.02 [0.06, 0.55] 2012 Subtotal (95% CI)									-	
$ \begin{array}{c} \mbox{Heterogeneity: Tau^2 = 1.39; Ch^2 = 5.06, df = 2 (P = 0.08); P = 60\%\\ \mbox{Test for overall effect: Z = 10.95 (P < 0.00001) \\ \hline \mbox{Rigid} \\ \mbox{Sar et al. 2013} & 1.65 & 1.94 & 14 & 14 & 7.6\% & 1.65 [-2.15, 5.45] & 2013\\ \mbox{Suzuki et al. 2013} & 1.8 & 0.89 & 20 & 20 & 9.7\% & 1.80 [0.06, 3.54] & 2013\\ \mbox{Suzuki et al. 2014} & 2.8 & 0.52 & 18 & 10.2\% & 2.80 [1.78, 3.82] & 2014\\ \mbox{Miresmaelli et al. 2015} & 0.6 & 0.84 & 26 & 26 & 9.8\% & 0.60 [-1.05, 2.25] & 2015\\ \mbox{Carpriciptic et al. 2015} & 3.2 & 0.69 & 19 & 10.0\% & 3.20 [1.85, 4.55] & 2015\\ \mbox{Carpriciptic et al. 2015} & 0.6 & 0.84 & 22 & 22 & 10.1\% & 0.10 [-7.58, 7.78] & 2019\\ \mbox{Carsent et al. 2019} & 0.1 & 3.92 & 10 & 0.4 & 1% & 0.10 [-7.58, 7.78] & 2012\\ \mbox{Subtral (95\% Cl)} & 2.05 & 205 & 205 & 100.0\% & 4.01 [2.01, 6.02]\\ \mbox{Heterogeneity: Tau^2 = 1.11; Chi^2 = 24.38, df = 7 (P = 0.0010); P = 71\% & Test for overall effect: Z = 3.92 (P < 0.0001)\\ \mbox{Test for overall effect: Z = 3.92 (P < 0.0001) & 205 & 205 & 205 & 100.0\% & 4.01 [2.01, 6.02]\\ \mbox{Heterogeneity: Tau^2 = 9.6; Chi^2 = 59.26, df = 1 (P < 0.00001); P = 9.3\% & \hline \mbox{Cl} & \mbox{Mean Difference} & \mbox{Mean Difference} & \mbox{Mean Difference} & \mbox{Norrigid} & \mbox{Mean Difference} & SE Total Total Weight & V, Random, 95\% Cl Year & V, Random, 95\% Cl Year$		8.9	0.69					2018		
Sar et al. 2013a 1.65 1.94 14 14 7.6% 1.65 [-2.15, 5.45] 2013 Suzuki et al. 2013 1.8 0.89 20 20 9.7% 1.60 [-2.15, 5.45] 2013 Suzuki et al. 2014 2.8 0.52 18 18 10.2% 2.80 [1.78, 3.82] 2014 Miresmaelli et al. 2015 0.6 0.84 26 26 9.8% 0.60 [-1.05, 2.25] 2015 Caproiglic et al. 2015 3.2 0.69 19 19 10.0% 3.20 [1.85, 4.55] 2015 Cassetta et al. 2019 0.1 3.92 10 10 4.1% 0.10 [-7.58, 7.78] 2019 Altieri et al. 2022 0.1 0.64 22 22 10.1% 0.10 [-7.58, 7.78] 2019 Altieri et al. 2022 0.1 0.64 22 22 21 0.1% 0.10 [-7.58, 7.78] 2019 Heterogeneity: Tau ² = 9.96; Chi ² = 212.10, df = 10 ($P < 0.00001$); $P = 95\%$ Test for overall effect: Z = 4.02 ($P < 0.0001$) Test for overall effect: Z = 4.02 ($P < 0.0001$) Test for subaroup differences: Chi ² = 59.26, df = 1 ($P < 0.00001$); $P = 98.3\%$ C Study or Subgroup Mean Difference SE Total Total Weight IV, Random, 95% CI Year Norrigid Cambiano et al. 2017 - 0.74 0.16 18 18 10.2% -0.64 [-0.3, 0.17] 2017 Test for overall effect: Z = 5.34 ($P < 0.0001$) Test for overall effect: Z = 5.34 ($P < 0.0001$) Test for overall effect: Z = 5.34 ($P < 0.0001$) Test for overall effect: Z = 5.34 ($P < 0.0001$) Test for overall effect: Z = 5.34 ($P < 0.0001$) Test for overall effect: Z = 5.34 ($P < 0.0001$) Test for overall effect: Z = 5.34 ($P < 0.0001$) Test for overall effect: Z = 5.34 ($P < 0.00001$) Test for overall effect: Z = 5.34 ($P < 0.00001$) Test for overall effect: Z = 5.34 ($P < 0.00001$) Test for overall effect: Z = 5.34 ($P < 0.00001$) Test for overall effect: Z = 5.34 ($P < 0.00001$) Heterogeneity: Tau ² = 0.00; Chi ² = 0.26, df = 1 ($P = 0.61$); $P = 0\%$ Test for overall effect: Z = 5.34 ($P < 0.00001$) Explore tal. 2015 0.3 0.11 26 26 10.6% -0.53 [-0.75, -0.31] 2015 Cazasetta et al. 2015 0.3 0.11 26 22 10.6% -0.53 [-0.75, -0.31] 2015 Cazasetta et al. 2015 0.03 0.11 21 21 10.6\% 0.05 [0.81, -0.37] 2016 Casestta et al. 2015 0.03 0.18 19 19 19 10.0% 0.30 [0.05, 0.65] 2022 Subtotal (65% CI) 0.06 0.13 22 22 10.4\% 0.60 [0.35, 0.85] 2022 Subtotal (65% C	Heterogeneity: Tau ² = 1.3						0.04 [0.00, 11.00]			
Suzuki et al. 2013 Cozzani et al. 2014 Cozzani et al. 2014 Cozzani et al. 2015 Cozzani et al. 2016 Cozzani et al. 2016 Cozzani et al. 2016 Cozzani et al. 2019 Altier et al. 2020 Subtotal (95% Cl) Total (95% Cl) Total (95% Cl) Total (95% Cl) Cozzani et al. 2017 Cozzani et al. 2015 Cozzani et al. 2015 Cozzan	Rigid									
$\begin{array}{c} \text{Cozzani et al. 2014} & 2.8 \ 0.52 \ 18 \ 18 \ 10.2\% \ 2.80 \ 17.76, 3.82 \ 2014 \\ \text{Miresmaelli et al. 2015} & 0.6 \ 0.44 \ 26 \ 0.80 \ -1.05, 2.25 \ 2015 \\ \text{Caproiglo et al. 2015} & 3.2 \ 0.69 \ 19 \ 19 \ 19 \ 10.0\% \ 3.20 \ 1.28, 4.55 \ 2015 \\ \text{Cozzani et al. 2019} & 0.1 \ 3.22 \ 10 \ 10 \ 4.1\% \ 0.10 \ [-7.58, 7.78] \ 2019 \\ \text{Alteri et al. 2022} & 0.1 \ 0.64 \ 22 \ 22 \ 10.1\% \ 0.10 \ [-7.58, 7.78] \ 2019 \\ \text{Alteri et al. 2022} & 0.1 \ 0.64 \ 22 \ 22 \ 10.1\% \ 0.10 \ [-7.58, 7.78] \ 2019 \\ \text{Heterogeneity: Tau2 = 1.11; \ Ch2 = 2.4.38, df = 7 \ (P = 0.0010); P = 71\% \\ \text{Test for overall effect: } Z = 4.02 \ (P < 0.0001) \\ \text{Test for overall effect: } Z = 4.02 \ (P < 0.0001) \\ \text{Test for subgroup} \ Mean \ Difference \ SE \ Total \ 10 \ (P < 0.00001); P = 98.3\% \\ \hline \begin{array}{c} \textbf{C} \\ \textbf{C} \\ \textbf{C} \\ \textbf{C} \\ \textbf{C} \\ \textbf{C} \\ \textbf{Morigid} \\ \text{C} \\ \textbf{C} \\ \textbf{Nonrigid} \\ \text{C} \\ \textbf{C} \\ \textbf{Nonrigid} \\ \text{C} \\ \textbf{Moreal effect: } Z = 3.92 \ (P < 0.0001) \\ \text{Monson ot al. 2017} \ -0.74 \ 0.16 \ 18 \ 18 \ 10.2\% \ -0.74 \ [-1.05, -0.43] \ 2017 \\ \textbf{Miresmaelli effect: } Z = 3.34 \ (P < 0.00001) \\ \textbf{Mean Difference} \\ \textbf{SE \ Total \ 10 \ P = 0.61); P = 0.63 \ .060 \ [-1.03, -0.17] \ 2018 \\ \textbf{Morigid} \\ \textbf{Subtotal (95\% CI) \\ \textbf{Mean Difference} \ SE \ Total \ 10 \ P = 0.61); P = 0.66 \ .069 \ [-0.95, -0.44] \\ \textbf{Heterogeneity: Tau2 = 0.00; Ch2 = 0.26, df = 1 \ (P = 0.61); P = 0\% \\ \textbf{Tist or overall effect: } Z = 5.34 \ (P < 0.00001) \\ \textbf{Miresmaelli tal. 2018} \ -0.69 \ [-0.95, -0.44] \\ \textbf{Heterogeneity: Tau2 = 0.00; Ch2 = 0.26, df = 1 \ (P = 0.61); P = 0\% \\ \textbf{Tist or overall effect: } Z = 5.34 \ (P < 0.00001) \\ \textbf{Miresmaelli et al. 2015} \ -0.53 \ 0.11 \ 20 \ 20 \ 10.0\% \ 0.30 \ 0.20 \ [-0.95, -0.44] \\ \textbf{Miresmaelli et al. 2015} \ -0.53 \ 0.11 \ 20 \ 20 \ 10.0\% \ 0.30 \ 0.20 \ [-0.95, 0.55] \ 2013 \ \textbf{Miresmaelli et al. 2016} \ -0.55 \ 0.11 \ 21 \ 21 \ 10.6\% \ 0.25 \ 0.55 \ [-0.75, -0.78] \ 2019 \ \textbf{Miresmaelli et al. 2016} \ -0.55 \ 0.11 \ 21 \ 21 \ 10.6\% \ 0.25 \ 0.55 \ 0.55 \ 2021 \ \textbf{Miresmaelli et al. 2016} \ -0.55$	Sar et al. 2013a	1.65	1.94	14	14	7.6%	1.65 [-2.15, 5.45]	2013		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $										
$\begin{array}{c} Capringlio et al. 2015 & 3.2 \ 0.69 \ 19 \ 19 \ 10.0\% & 3.20 \ 11.85, 65 \ 2015 \\ Cozzari et al. 2016b & 3 \ 0.3 \ 24 \ 24 \ 10.4\% & 3.00 \ [2.41, 3.59] \ 2016 \\ Cassette et al. 2019 & 0.1 \ 3.92 \ 10 \ 10 \ 4.1\% & 0.10 \ [-7.58, 7.78] \ 2019 \\ Altieri et al. 2022 & 0.1 \ 0.64 \ 22 \ 22 \ 10.1\% & 0.10 \ [-7.58, 7.78] \ 2019 \\ Altieri et al. 2022 & 0.1 \ 0.64 \ 22 \ 22 \ 10.1\% & 0.10 \ [-7.58, 7.78] \ 2019 \\ Heterogeneity: Tau2 = 1.11; Chi2 = 24.38, df = 7 (P = 0.0010); I2 = 71% \\ Test for overall effect: Z = 4.02 (P < 0.0001) \\ Total (95\% Cl) & 205 \ 205 \ 100.0\% & 4.01 \ [2.01, 6.02] \\ Heterogeneity: Tau2 = 9.96; Chi2 = 212.10, df = 10 (P < 0.00001); I2 = 95\% \\ Test for overall effect: Z = 3.92 (P < 0.0001) \\ Test for subgroup Mean Difference SE \ Total \ Total Weight V, Random, 95% Cl Year \\ Nonrigid \\ Cambiano et al. 2017 & -0.74 \ 0.16 \ 18 \ 18 \ 10.2\% & -0.74 \ [-1.05, -0.43] \ 2017 \\ Kircali et al. 2018 & -0.6 \ 0.22 \ 20 \ 20 \ 9.6\% & -0.66 \ [-1.03, -0.17] \ 2018 \\ Subutotal (95\% Cl) & 38 \ 38 \ 38 \ 38 \ 38 \ 38 \ 38 \ 38$										
$\begin{array}{c} \begin{array}{c} \begin{array}{c} \text{Cozzari et al. 2016b} \\ \text{Cassentia et al. 2019} \\ \text{Cassentia et al. 2019} \\ \text{Cassentia et al. 2022} \\ \text{Subtotal (95\% CI)} \\ \begin{array}{c} 1 & 0.64 \\ 22 \\ \text{Z2} \\ \text{Subtotal (95\% CI)} \\ \text{Heterogeneity: Tau^2 = 0.42 (P < 0.0010); P = 71\% \\ \text{Test for overall effect: Z = 4.02 (P < 0.0001); P = 71\% \\ \text{Test for overall effect: Z = 4.02 (P < 0.00001); P = 95\% \\ \text{Test for overall effect: Z = 3.92 (P < 0.0001) \\ \text{Total (95\% CI)} \\ \text{Test for overall effect: Z = 3.92 (P < 0.0001) \\ \text{Test for overall effect: Z = 3.92 (P < 0.0001) \\ \text{Test for overall effect: Z = 3.92 (P < 0.0001) \\ \text{Test for overall effect: Z = 3.92 (P < 0.0001) \\ \text{Test for overall effect: Z = 3.92 (P < 0.0001) \\ \text{Test for overall effect: Z = 3.92 (P < 0.0001) \\ \text{Test for overall effect: Z = 3.92 (P < 0.0001) \\ \text{Test for overall effect: Z = 3.92 (P < 0.00001) \\ \text{Test for overall effect: Z = 3.92 (P < 0.00001) \\ \text{Test for overall effect: Z = 3.92 (P < 0.00001) \\ \text{Test for overall effect: Z = 3.92 (P < 0.00001) \\ \text{Test for overall effect: Z = 3.92 (P < 0.00001) \\ \text{Test for overall effect: Z = 5.34 (f = 1 (P < 0.00001), P = 98.3\% \\ \end{array} } \end{array}$									-	
Altieri et al. 2022 0.1 0.64 22 22 10.1% 0.10 [-1.15, 1.35] 2022 Subtotal (95% CI) 153 153 72.2% 1.97 [1.01, 2.92] Heterogeneity: Tau ² = 1.11; Chi ² = 24.38, df = 7 ($P = 0.0010$); $P = 71\%$ Test for overall effect: Z = 4.02 ($P < 0.0001$) Total (95% CI) 205 205 100.0% 4.01 [2.01, 6.02] Heterogeneity: Tau ² = 9.96; Chi ² = 212.10, df = 10 ($P < 0.00001$); $P = 95\%$ Test for overall effect: Z = 3.92 ($P < 0.0001$) Test for subgroup Mean Difference SE Total Total Weight V, Random, 95% CI Year Y, Random, 95% CI Year V, Random, 95% CI Year Y, Yaar Y,							3.00 [2.41, 3.59]	2016	-	
Subtotal (95% CI) 153 10 10 10 10 -10 -5 10 -10 -5 5 10 11 Mean Difference Mean Difference <th colsp<="" td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th>	<td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>									
Heterogeneity: Tau ² = 1.11; Chi ² = 24.38, df = 7 (P = 0.0010); I ² = 71% Test for overall effect: Z = 4.02 (P < 0.0001) Total (95% CI) 205 205 100.0% 4.01 [2.01, 6.02] Heterogeneity: Tau ² = 9.96; Chi ² = 212.10, df = 10 (P < 0.00001); I ² = 95% Test for overall effect: Z = 3.92 (P < 0.0001) To T1 Mean Difference Study or Subgroup Mean Difference Mean Difference Norrigid C Mean Difference Mean Difference Notal (95% CI) Mean Difference Study or Subgroup Mean Difference Notal (95% CI)		0.1	0.64					2022	•	
Heterogeneity: Tau ² = 9.96; Chi ² = 212.10, df = 10 (P < 0.00001); I ² = 95% Test for overall effect: Z = 3.92 (P < 0.0001) Test for subgroup differences: Chi ² = 59.26, df = 1 (P < 0.00001), I ² = 98.3% C Mean Difference T0 T1 Mean Difference Nonrigid C Mean Difference SE Total Weight IV, Random, 95% CI Year Nonrigid Cambiano et al. 2017 -0.74 0.16 18 Mean Difference Nonrigid Cambiano et al. 2017 -0.74 0.16 10 To T1 Mean Difference Mean Difference Nonrigid Mean Difference Mean Difference Nonrigid Mean Difference Notal Mean Difference Nonrigid Mean Difference Subtotal (95% CI) Mean Difference Nonrigid Mean Difference	Heterogeneity: Tau ² = 1.		= 7 (P	= 0.001	10); I ² =	71%				
Test for overall effect: $Z = 3.92$ ($P < 0.0001$) -10 -5 10 Test for overall effect: $Z = 3.92$ ($P < 0.0001$) Test for subgroup differences: Chi ² = 59.26, df = 1 ($P < 0.00001$), $P = 98.3\%$ C Mean Difference SE Total Total Weight Mean Difference	Total (95% CI)			205	205	100.0%	4.01 [2.01, 6.02]		◆	
Test for subgroup differences: Chi² = 59.26, df = 1 (P < 0.00001), I² = 98.3% Mean Difference To T1 Mean Difference Mean Difference Study or Subgroup Mean Difference SE Total Total Weight Numerical Nonrigid Nonrigid Mean Difference Mean Difference Mean Difference Mean Difference Mean Difference Numerical Nonrigid Cambiano et al. 2017 -0.74 0.16 18 10.05, -0.43] 2017 Kircali et al. 2018 -0.60 0.22 0.60 0.66 10.0% O.074 [-1.05, -0.43] 2017 Kircali et al. 2018 -0.60 0.22 0.66 0.66 0.66 No Subtotal (95% Cl) -0.6 0.20 0.66 0.20 No Mean Difference Mean Difference No <th< td=""><td></td><td></td><td>f = 10</td><td>(P < 0.0</td><td>00001);</td><td>l² = 95%</td><td></td><td></td><td></td></th<>			f = 10	(P < 0.0	00001);	l² = 95%				
Study or Subgroup Mean Difference SE Total Total Weight IV, Random, 95% CI Year IV, Random, 95% CI Nonrigid Cambiano et al. 2017 -0.74 0.16 18 18 10.2% -0.74 [-1.05, -0.43] 2017 - Kircali et al. 2018 -0.60 0.22 20 20 9.6% -0.60 [-1.03, -0.17] 2018 - Subtotal (95% CI) 38 38 19.8% -0.69 [-0.95, -0.44] - - - - Heterogeneity: Tau ² = 0.00; Chi ² = 0.26, df = 1 (P = 0.61); I ² = 0% 38 19.8% -0.69 [-0.95, -0.44] - <			df = 1	(P < 0.0	00001),	l² = 98.39	%		mesial tipping distal tipping	
Study or Subgroup Mean Difference SE Total Weight IV, Random, 95% CI Year IV, Random, 95% CI Nonrigid	С			то	T1		Mean Difference		Mean Difference	
Cambiano et al. 2017 -0.74 0.16 18 18 10.2% -0.74 $1-05$ -0.43 2017 Kircali et al. 2018 -0.6 0.22 20 20 9.6% -0.60 $[-1.03, -0.17]$ 2018 Subtotal (95% CI) 38 38 19.8% -0.69 $[-0.95, -0.43]$ 0.66 $[-1.03, -0.17]$ 2018 Heterogeneity: Tau ² = 0.00; Chi ² = 0.26, df = 1 (P = 0.61); P = 0% Test for overall effect: Z = 5.34 (P < 0.00001) -0.69 $[-0.95, -0.43]$ 0.70 Rigid Suzuki et al. 2013 -1 0.18 20 20 10.0% -1.00 [$-1.35, -0.65]$ 2013 Miresmaelli et al. 2015 -0.53 0.11 26 26 10.6% 0.51 [-0.55 2015 Caprioglio et al. 2015 0.3 0.18 19 19 10.0% 0.30 [$-0.05, 0.65$] 2015 Caprioglio et al. 2016 0.2 0.06 10 10.8% 0.20 [$0.08, 0.32$] 2016 Duran et al. 2016 0.29 0.66 10 10 10.8% 0.59 [$0.13, 0.3$		Mean Difference	SE			Weight		l Year		
Kircali et al. 2018 -0.6 0.22 20 9.6% -0.60 $[1.03, -0.17]$ 2018 Subtotal (95% Cl) 38 38 19.8% -0.60 $[1.03, -0.17]$ 2018 Heterogeneity: Tau ² = 0.00; Chi ² = 0.26, df = 1 (P = 0.61); l ² = 0% Test for overall effect: Z = 5.34 (P < 0.00001) -0.60 -1.00 $-1.35, -0.65$ 2013 Rigid Suzuki et al. 2013 -1 0.18 20 20 10.0% -1.00 $[-1.35, -0.65]$ 2013 Cozzani et al. 2014 0.7 0.45 18 18 7.0% 0.70 $[-0.5, 6.51]$ 2013 Cozzani et al. 2015 0.53 0.11 26 26 10.6% 0.25 10.05 0.32 2016 Duran et al. 2016 0.25 0.06 10 10.8% 0.90 $[-1.02, -0.78]$ 2019 Alteri et al. 2022 0.6 0.13 22 22 10.4% 0.60 0.35 0.25 2022 0.64 0.70 0.90 10 10 10.8% 0.90 10.2		-0.74	0.16	19	19	10.2%	-0 74 [-1 05 -0 42]	2017	-	
Heterogeneity: Tau ² = 0.00; Chi ² = 0.26, df = 1 (P = 0.61); l ² = 0% Test for overall effect: Z = 5.34 (P < 0.00001)										
Test for overall effect: Z = 5.34 (P < 0.00001)							-0.69 [-0.95, -0.44]		•	
Suzuki et al. 2013 -1 0.18 20 20 10.0% $-1.00 [-1.35, -0.65]$ 2013 Cozzani et al. 2014 0.7 0.45 18 18 7.0% $0.70 [-0.18, 1.58]$ 2014 Miresmaelli et al. 2015 -0.53 0.11 26 26 10.6% $-0.53 [-0.75, -0.31]$ 2015 Caprioglio et al. 2015 0.3 0.18 19 19 0.0% $0.30 [-0.05, 0.65]$ 2015 Cozzani et al. 2016b 0.2 0.6 24 24 10.8% $0.20 [0.08, 0.32]$ 2016 Duran et al. 2016 -0.59 0.11 21 21 10.6% $-0.59 [-0.81, -0.37]$ 2016 Altieri et al. 2022 0.6 0.13 22 22 10.4% $0.60 [0.35, 0.85]$ 2022 Subtotal (95% CI) 160 160 60 0.2% $0.21 [0.46, 0.26]$ Heterogeneity: Tau ² = 0.39; Chi ² = 259.58, df = 7 (P < 0.00001); $l2 = 97\%$ $-0.19 [-0.64, 0.26]$ $-0.19 [-0.64, 0.26]$				0.61);	l² = 0%					
Cozzani et al. 2014 0.7 0.45 18 18 7.0% 0.70 [-0.18, 1.56] 2014 Miresmaelli et al. 2015 -0.53 0.11 26 26 10.6% -0.53 [-0.75, -0.31] 2015 Caprioglio et al. 2015 0.3 0.18 19 19 10.0% 0.30 [-0.05, 0.65] 2015 Cozzani et al. 2016b 0.2 0.6 24 24 10.8% 0.20 [0.08, 0.32] 2016 Duran et al. 2016 -0.59 0.11 21 21 10.6% -0.59 [-0.81, -0.37] 2016 Cassetta et al. 2019 -0.9 0.06 10 10 10.8% -0.90 [-1.02, -0.78] 2019 Altieri et al. 2022 0.6 0.13 22 22 10.4% 0.60 [0.35, 0.85] 2022 Subtotal (95% CI) 160 160 80.2% -0.19 [-0.64, 0.26] -0.19 [-0.64, 0.26] Heterogeneity: Tau ² = 0.39; Chi ² = 259.58, df = 7 (P < 0.00001); l ² = 97% -0.19 [-0.64, 0.26] -0.19 [-0.64, 0.26] -0.19 [-0.64, 0.26] -0.19 [-0.64, 0.26] -0.19 [-0.64, 0.26] -0.19 [-0.64, 0.26] -0.19 [-0.64, 0.26] -0.19 [-0.64, 0.26] -0.19 [-0.64, 0.	Rigid									
Miresmaelli et al. 2015 -0.53 0.11 26 26 10.6% -0.53 [0.75, -0.31] 2015 Caprioglio et al. 2015 0.3 0.18 19 19 10.0% 0.30 [-0.5, 0.65] 2015 Cozzani et al. 2016b 0.2 0.06 24 4 10.8% 0.20 [0.08, 0.32] 2016 Duran et al. 2016 -0.59 0.11 21 21 10.6% -0.59 [-0.81, -0.37] 2016 Cassetta et al. 2019 -0.9 0.06 10 10 10.8% -0.90 [-1.02, -0.78] 2019 Attieri et al. 2022 0.6 0.13 22 22 10.4% 0.60 [0.35, 0.85] 2022 Subtotal (95% CI) 160 160 80.2% -0.19 [-0.64, 0.26] -0.19 [-0.64, 0.26] Heterogeneity: Tau ² = 0.39; Chi ² = 259.58, df = 7 (P < 0.00001); l ² = 97% -0.19 [-0.64, 0.26] -0.19 [-0.64, 0.26] -0.19 [-0.64, 0.26]									-	
Caprioglio et al. 2015 0.3 0.18 19 19 10.0% 0.30 [-0.05, 0.65] 2015 Cozzani et al. 2016b 0.2 0.06 24 24 10.8% 0.20 [0.08, 0.32] 2016 Duran et al. 2016 -0.59 0.11 21 10.6% -0.59 [-0.81, -0.37] 2016 Cassetta et al. 2019 -0.9 0.06 10 10 10.8% -0.90 [-1.02, -0.78] 2019 Atieri et al. 2022 0.6 0.13 22 22 10.4% 0.60 [0.35, 0.85] 2022 Subtotal (95% C1) 160 160 80.2% -0.19 [-0.64, 0.26] -0.19 [-0.64, 0.26]									+	
Cozzani et al. 2016b 0.2 0.06 24 24 10.8% 0.20 [0.08, 0.32] 2016 Duran et al. 2016 -0.59 0.11 21 21 10.6% -0.59 [-0.81, -0.37] 2016 Cassetta et al. 2019 -0.9 0.06 10 10 10.8% -0.90 [-0.81, -0.37] 2016 Altieri et al. 2022 0.6 0.13 22 22 10.4% 0.60 [0.35, 0.85] 2022 Subtotal (95% CI) 160 160 80.2% -0.19 [-0.64, 0.26] - Heterogeneity: Tau ² = 0.39; Chi ² = 259.58, df = 7 (P < 0.00001); l ² = 97% > > >										
Cassetta et al. 2019 -0.9 0.06 10 10.8% -0.90 [-1.02, -0.78] 2019 Altieri et al. 2022 0.6 0.13 22 22 10.4% 0.60 [0.35, 0.85] 2022 Subtotal (95% CI) 160 160 80.2% -0.19 [-0.64, 0.26] Heterogeneity: Tau ² = 0.39; Chi ² = 259.58, df = 7 (P < 0.00001); l ² = 97%							0.20 [0.08, 0.32]	2016	-	
Altieri et al. 2022 0.6 0.13 22 22 10.4% 0.60 [0.35, 0.85] 2022 Subtotal (95% Cl) 160 160 80.2% -0.19 [-0.64, 0.26] Heterogeneity: Tau ² = 0.39; Chi ² = 259.58, df = 7 (P < 0.00001); l ² = 97%									-	
Subtotal (95% Cl) 160 160 80.2% -0.19 [-0.64, 0.26] Heterogeneity: Tau² = 0.39; Chi² = 259.58, df = 7 (P < 0.00001); l² = 97%									· -	
Heterogeneity: Tau ² = 0.39; Chi ² = 259.58, df = 7 (P < 0.00001); l ² = 97%		0.6	0.15					2022	•	
	Heterogeneity: Tau ² = 0.3		f = 7 (F	P < 0.00						
Total (95% CI) 198 198 100.0% -0.29 [-0.68, 0.10]	Total (95% CI)			198	198	100.0%	-0.29 [-0.68, 0.10]		•	
Heterogeneity: $Tau^2 = 0.36$; $Chi^2 = 267.61$, $df = 9.(P < 0.00001)$; $l^2 = 97\%$		36; Chi² = 267.61, d	f = 9 (F				0.20 [0.00, 0.10]			
Test for overall effect: Z = 1.44 (P = 0.15) -4 -2 0 2 4 Test for subaroup differences: Chi ² = 3.62, df = 1 (P = 0.06), l ² = 72.4% -4 -2 0 2 4	Test for overall effect: Z =	= 1.44 (P = 0.15)								

Figure 4. Forest plot of U6 distalization (a), tipping (b), and vertical movement (c) of the rigid and nonrigid subgroups.

of resistance, leading to more distalization. No differences were found between 2-TAD-supported and 3-TAD-supported appliances as well as when comparing nonrigid and rigid devices.

Tipping Movement

Distal tipping is a common effect of molar distalization. There were no significant differences in distal tipping when comparing by position and number of TADs, but the difference was statistically and clinically significant when rigid (1.97°) and nonrigid (9.84°) appliances were compared. These results were consistent with the specific biomechanical properties involved. Palatal devices with pendulum arms result in distal tipping because the force is applied to the clinical crown, far from the center of resistance.⁶⁰

Among all rigid palatal devices, the tipping values were generally low, as expected. The least tipping was shown by 3-TAD-supported devices (MCPPs) that used a controlled force vector that passed through the center of resistance of the U6, increasing distal movement while reducing distal tipping simultaneously.⁶¹ Therefore, the direction of the force vector applied to the distalization system can certainly alter the tipping of teeth during distalization.

Vertical Movement

In this meta-analysis, no significant differences were found for vertical movements among the buccal, palatal, and zygomatic TADs, but zygomatic TADs showed the greatest degree of intrusion (-1.16 mm). These findings contradicted those reported in two previous reviews.^{17,18} It was expected that rigid appliances would provide better vertical control of maxillary molars due to their nonelastic nature, ensuring complete control over vertical movements. However, in a few cases, there was slight extrusive movement (ranging from 0.2 mm²⁸ to 0.70 mm²³), observed exclusively with rigid palatal appliances. As discussed above, the direction of the resultant force vector plays a role in the effectiveness of the intrusion of teeth connected to the appliance.

Zygomatic anchorage should allow better vertical control and intrusion since the resulting vector force is above the center of resistance of the U6 and maxilla, therefore enabling intrusion of the upper arch simultaneously with a clockwise rotation of the occlusal plane.

Limitations

Only 4 RCTs were eligible to be reviewed. To enhance our understanding of distalization effects, prospective and retrospective cohort studies were included. Bias and study design differences may The methods used to assess U6 movement varied among the studies reviewed. Most commonly, measurements were made on lateral cephalograms, cone beam computed tomography (CBCT) images, and three-dimensional (3D) dental models using different landmarks. Although each method was validated and accurate, variations among studies may limit generalizations and comparisons.

Additionally, the limited information provided on the severity of the Class II molar relationships within the studies could confound the meta-analysis.

CONCLUSIONS

- There were no significant differences in the magnitude of molar distalization, molar distal tipping, or molar intrusion among distalization appliances using palatal, zygomatic, or buccal TAD anchorages.
- The use of 3-TAD-supported appliances compared to 2-TAD-supported appliances for appliance anchorage did not improve the molar distalization magnitude or modify the extent of tipping and intrusion observed.
- Nonrigid palatal appliances resulted in significantly greater distal tipping than rigid appliances, although rigid and nonrigid appliances showed similar magnitudes of molar distalization and molar intrusion.
- Further well-designed, high-quality RCTs or prospective cohort studies are needed to provide clinical evidence of the efficacy of molar distalization with TADs.

REFERENCES

- Fontana M, Cozzani M, Caprioglio A. Non-compliance maxillary molar distalizing appliances: an overview of the last decade. *Prog Orthod*. 2012;13(2):173–184.
- 2. Yin Y, Wang Z, Huang L, et al. Orthodontic maximum anchorages in malocclusion treatment: a systematic review and network meta-analysis. *J Evid Based Med.* 2021;14(4): 295–302.
- Feldmann I, Bondemark L. Orthodontic anchorage: a systematic review. Angle Orthod. 2006;76(3):493–501.
- Jambi S, Thiruvenkatachari B, O'Brien KD, Walsh T. Orthodontic treatment for distalising upper first molars in children and adolescents. *Cochrane Database Syst Rev.* 2013; 2013(10):CD008375.
- Odman J, Lekholm U, Jemt T, Brånemark PI, Thilander B. Osseointegrated titanium implants—a new approach in orthodontic treatment. *Eur J Orthod.* 1988;10(2):98–105.
- Huang LH, Shotwell JL, Wang HL. Dental implants for orthodontic anchorage. *Am J Orthod Dentofacial Orthop.* 2005; 127(6):713–722.
- Wehrbein H, Feifel H, Diedrich P. Palatal implant anchorage reinforcement of posterior teeth: a prospective study. *Am J Orthod Dentofacial Orthop.* 1999;116(6):678–686.

- Costa A, Raffainl M, Melsen B. Miniscrews as orthodontic anchorage: a preliminary report. *Int J Adult Orthodon Orthognath Surg.* 1998;13(3):201–209.
- 9. Serafin M, Maspero C, Bocchieri S, Fastuca R, Caprioglio A. Subperiosteal anchorage in orthodontics: a narrative review. *Appl Sci.* 2021;11:8376.
- Mariani L, Maino G, Caprioglio A. Skeletal versus conventional intraoral anchorage for the treatment of class II malocclusion: dentoalveolar and skeletal effects. *Prog Orthod.* 2014;15(1):43.
- 11. Lee JS, Kim DH, Park YC, Kyung SH, Kim TK. The efficient use of midpalatal miniscrew implants. *Angle Orthod.* 2004;74(5):711–714.
- Ye C, Zhihe Z, Zhao Q, Ye J. Treatment effects of distal movement of lower arch with miniscrews in the retromolar area compared with miniscrews in the posterior area of the maxillary. *J Craniofac Surg.* 2013;24(6):1974–1979.
- Seres L, Kocsis A. Closure of severe skeletal anterior open bite with zygomatic anchorage. *J Craniofac Surg.* 2009;20(2): 478–482.
- 14. Afrashtehfar KI. Patient and miniscrew implant factors influence the success of orthodontic miniscrew implants. *Evid Based Dent.* 2016;17(4):109–110.
- Mohamed RN, Basha S, Al-Thomali Y. Maxillary molar distalization with miniscrew-supported appliances in Class II malocclusion: a systematic review. *Angle Orthod.* 2018;88(4): 494–502.
- Soheilifar S, Mohebi S, Ameli N. Maxillary molar distalization using conventional versus skeletal anchorage devices: a systematic review and meta-analysis. *Int Orthod.* 2019;17(3): 415–424.
- 17. Bayome M, Park JH, Bay C, Kook YA. Distalization of maxillary molars using temporary skeletal anchorage devices: a systematic review and meta-analysis. *Orthod Craniofac Res.* 2021;24(suppl 1):103–112.
- Raghis TR, Alsulaiman TMA, Mahmoud G, Youssef M. Efficiency of maxillary total arch distalization using temporary anchorage devices (TADs) for treatment of Class II-malocclusions: a systematic review and meta-analysis. *Int Orthod.* 2022;20(3):100666.
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med.* 2009;151(4):264–269, w264.
- 20. Lockwood C, Oh EG. Systematic reviews: guidelines, tools and checklists for authors. *Nurs Health Sci.* 2017;19(3):273–277.
- Sar C, Kaya B, Ozsoy O, Özcirpici AA. Comparison of two implant-supported molar distalization systems. *Angle Orthod.* 2013;83(3):460–467.
- Suzuki EY, Suzuki B. Maxillary molar distalization with the indirect palatal miniscrew for anchorage and distalization appliance (iPANDA). *Orthodontics (Chic).* 2013;14(1):e228–e241.
- 23. Cozzani M, Pasini M, Zallio F, et al. Comparison of maxillary molar distalization with an implant-supported distal jet and a traditional tooth-supported distal jet appliance. *Int J Dent.* 2014;2014:937059.
- 24. Kook YA, Bayome M, Trang VT, et al. Treatment effects of a modified palatal anchorage plate for distalization evaluated with cone-beam computed tomography. *Am J Orthod Dentofacial Orthop.* 2014;146(1):47–54.
- 25. Caprioglio A, Cafagna A, Fontana M, Cozzani M. Comparative evaluation of molar distalization therapy using pendulum

and distal screw appliances. *Korean J Orthod.* 2015;45(4): 171–179.

- 26. Miresmaeili A, Sajedi A, Moghimbeigi A, Farhadian N. Threedimensional analysis of the distal movement of maxillary 1st molars in patients fitted with mini-implant-aided trans-palatal arches. *Korean J Orthod.* 2015;45(5):236–244.
- Sa'aed NL, Park CO, Bayome M, Park JH, Kim Y, Kook YA. Skeletal and dental effects of molar distalization using a modified palatal anchorage plate in adolescents. *Angle Orthod.* 2015;85(4):657–664.
- Cozzani M, Fontana M, Maino G, Maino G, Palpacelli L, Caprioglio A. Comparison between direct vs indirect anchorage in two miniscrew-supported distalizing devices. *Angle Orthod.* 2016;86(3):399–406.
- 29. Duran GS, Görgülü S, Dindaroğlu F. Three-dimensional analysis of tooth movements after palatal miniscrew-supported molar distalization. *Am J Orthod Dentofacial Orthop.* 2016;150(1):188–197.
- Cambiano AO, Janson G, Fuziy A, Garib DG, Lorenzoni DC. Changes consequent to maxillary molar distalization with the bone-anchored pendulum appliance. *J Orthod Sci.* 2017;6(4):141–146.
- 31. Park CO, Sa'aed NL, Bayome M, et al. Comparison of treatment effects between the modified C-palatal plate and cervical pull headgear for total arch distalization in adults. *Korean J Orthod.* 2017;47(6):375–383.
- Lee SK, Abbas NH, Bayome M, et al. A comparison of treatment effects of total arch distalization using modified C-palatal plate vs buccal miniscrews. *Angle Orthod.* 2018;88(1):45–51.
- Jo SY, Bayome M, Park J, Lim HJ, Kook YA, Han SH. Comparison of treatment effects between four premolar extraction and total arch distalization using the modified C-palatal plate. *Korean J Orthod.* 2018;48(4):224–235.
- Park JH, Kim S, Lee YJ, et al. Three-dimensional evaluation of maxillary dentoalveolar changes and airway space after distalization in adults. *Angle Orthod.* 2018;88(2):187–194.
- Kırcalı M, Yüksel AS. Evaluation of dentoalveolar and dentofacial effects of a mini-screw-anchored pendulum appliance in maxillary molar distalization. *Turk J Orthod.* 2018;31(4): 103–109.
- Lee YJ, Kook YA, Park JH, et al. Short-term cone-beam computed tomography evaluation of maxillary third molar changes after total arch distalization in adolescents. *Am J Orthod Dentofacial Orthop.* 2019;155(2):191–197.
- Shoaib AM, Park JH, Bayome M, Abbas NH, Alfaifi M, Kook YA. Treatment stability after total maxillary arch distalization with modified C-palatal plates in adults. *Am J Orthod Dentofacial Orthop.* 2019;156(6):832–839.
- Cassetta M, Brandetti G, Altieri F. Miniscrew-supported distal jet versus conventional distal jet appliance: a pilot study. *J Clin Exp Dent.* 2019;11(7):e650–e658.
- Alfaifi M, Park JH, Tai K, et al. Comparison of treatment effects with modified C-palatal plates vs Greenfield molar distalizer appliances in adolescents. *J Clin Pediatr Dent.* 2020;44(3): 202–208.
- Chou AHK, Park JH, Shoaib AM, et al. Total maxillary arch distalization with modified C-palatal plates in adolescents: a long-term study using cone-beam computed tomography. *Am J Orthod Dentofacial Orthop.* 2021;159(4):470–479.
- Jung CY, Park JH, Ku JH, Lee NK, Kim Y, Kook YA. Dental and skeletal effects after total arch distalization using modified C-palatal plate on hypo- and hyperdivergent Class II

malocclusions in adolescents. Angle Orthod. 2021;91(1): 22-29.

- 42. Park JH, Kim Y-J, Kim J, et al. Use of artificial intelligence to predict outcomes of nonextraction treatment of Class II malocclusions. *Semin Orthod.* 2021;27(2):87–95.
- Park JH, Kim Y, Park JH, Lee NK, Kim SH, Kook YA. Longterm evaluation of maxillary molar position after distalization using modified C-palatal plates in patients with and without second molar eruption. *Am J Orthod Dentofacial Orthop.* 2021;160(6):853–861.
- 44. Alfawaz F, Park JH, Lee NK, et al. Comparison of treatment effects from total arch distalization using modified C-palatal plates versus maxillary premolar extraction in Class II patients with severe overjet. Orthod Craniofac Res. 2022;25(1):119–127.
- 45. Kim S, Lee NK, Park JH, et al. Treatment effects after maxillary total arch distalization using a modified C-palatal plate in patients with Class II malocclusion with sinus pneumatization. Am J Orthod Dentofacial Orthop. 2022;162(4):469–476.
- Lim HJ, Kim Y, Park JH, Lee NK, Kim KB, Kook YA. Cephalometric and model evaluations after molar distalization using modified C-palatal plates in patients with severe arch length discrepancy. *Am J Orthod Dentofacial Orthop.* 2022; 162(6):870–880.
- Altieri F, Mezio M, Guarnieri R, Cassetta M. Comparing distal-jet with dental anchorage to distal-jet with skeletal anchorage: a prospective parallel cohort study. *Dent J (Basel).* 2022; 10(10):179.
- Bechtold TE, Kim JW, Choi TH, Park YC, Lee KJ. Distalization pattern of the maxillary arch depending on the number of orthodontic miniscrews. *Angle Orthod.* 2013;83(2):266–273.
- Ali D, Mohammed H, Koo SH, Kang KH, Kim SC. Three-dimensional evaluation of tooth movement in Class II malocclusions treated without extraction by orthodontic mini-implant anchorage. *Korean J Orthod.* 2016;46(5):280–289.
- Abdelhady NA, Tawfik MA, Hammad SM. Maxillary molar distalization in treatment of angle class II malocclusion growing patients: uncontrolled clinical trial. *Int Orthod.* 2020; 18(1):96–104.
- 51. Bechtold TE, Park YC, Kim KH, Jung H, Kang JY, Choi YJ. Long-term stability of miniscrew anchored maxillary molar

distalization in Class II treatment. *Angle Orthod.* 2020;90(3): 362–368.

- Song B-J, Lee K-J, Cha J-Y, Lee J-S, Mo S-S, Yu H-S. Stability of the maxillary and mandibular total arch distalization using temporary anchorage devices (TADs) in adults. *Appl Sci.* 2022;12:2898.
- 53. Nur M, Bayram M, Celikoglu M, Kilkis D, Pampu AA. Effects of maxillary molar distalization with zygoma-gear appliance. *Angle Orthod.* 2012;82(4):596–602.
- EI-Dawlatly MM, Abou-EI-Ezz AM, EI-Sharaby FA, Mostafa YA. Zygomatic mini-implant for Class II correction in growing patients. *J Orofac Orthop.* 2014;75(3):213–225.
- 55. Kilkis D, Celikoglu M, Nur M, Bayram M, Candirli C. Effects of zygoma-gear appliance for unilateral maxillary molar distalization: a prospective clinical study. *Am J Orthod Dentofacial Orthop.* 2016;150(6):989–996.
- Wu X, Liu H, Luo C, Li Y, Ding Y. Three-dimensional evaluation on the effect of maxillary dentition distalization with miniscrews implanted in the infrazygomatic crest. *Implant Dent.* 2018;27(1):22–27.
- Shahani M, Singh G, Gupta N, et al. En masse distalisation of maxillary arch using TADs (IZC); passive self-ligating appliance v/s clear aligner—a comparative cephalometric study. *J Contemp Orthod.* 2019;3(3):11–17.
- Shaikh A, Jamdar AF, Galgali SA, Patil S, Patel I, Hemagiriyappa MS. Efficacy of infrazygomatic crest implants for full-arch distalization of maxilla and reduction of gummy smile in Class II malocclusion. *J Contemp Dent Pract.* 2021; 22(10):1135–1143.
- Rosa WGN, de Almeida-Pedrin RR, Oltramari PVP, et al. Total arch maxillary distalization using infrazygomatic crest miniscrews in the treatment of Class II malocclusion: a prospective study. *Angle Orthod*. 2023;93(1):41–48.
- Kinzinger GS, Diedrich PR. Biomechanics of a modified pendulum appliance—theoretical considerations and in vitro analysis of the force systems. *Eur J Orthod.* 2007; 29(1):1–7.
- Bayome M, Park JH, Kook Y-A. Clinical applications and treatment outcomes with modified C-palatal plates. *Semin Orthod.* 2018;24(1):45–51.